

**INFORME DE BÚSQUEDA SISTEMÁTICA DE EVIDENCIA
DE LOS EFECTOS DESEABLES E INDESEABLES
Guía de Práctica Clínica Cáncer de Ovario**

2018



ÍNDICE

TABLA RESUMEN	2
ESTRATEGIA DE BÚSQUEDA	3
CRITERIOS DE INCLUSIÓN	3
RECOLECCIÓN, ANÁLISIS Y SÍNTESIS DE DATOS	4
Selección de las revisiones	4
Extracción de datos	4
Mapeo de la evidencia	4
Apéndice 1. Estrategias de búsqueda:	5
Apéndice 2. Diagrama de flujo PRISMA	7
Apéndice 3. Referencias seleccionadas	8



TABLA RESUMEN

Problema de salud	Cáncer de Ovario
ICD10	C56
Fecha de entrega	01/12/2018
Investigador responsable	Gabriel Rada Giacaman
Número de revisiones sistemáticas	738
Número de preguntas	924
L·OVE	<i>Ovarian cancer</i>
L·OVE URL	https://love.epistemonikos.org/loves/5a30379565dee0049e89c757

ESTRATEGIA DE BÚSQUEDA

Se realizaron búsquedas en Epistemonikos, una base de datos exhaustiva de revisiones sistemáticas relevantes para la toma de decisiones en salud. La búsqueda de evidencia fue realizada en las siguientes bases de datos¹ con las estrategias descritas en el Apéndice 1.

1. Cochrane database of systematic reviews (CDSR)
2. Database of Abstracts of Reviews of Effectiveness (DARE)
3. HTA Database
4. PubMed
5. LILACS
6. CINAHL.
7. PsychINFO.
8. EMBASE.
9. EPPI-Centre Evidence Library
10. 3ie Systematic Reviews and Policy Briefs Campbell Library
11. Clinical Evidence.
12. SUPPORT Summaries
13. WHO Institutional Repository for Information Sharing
14. NICE public health guidelines and systematic reviews
15. ACP Journal Club.
16. Evidencias en Pediatría
17. The JBI Database of Systematic Reviews and Implementation Reports

CRITERIOS DE INCLUSIÓN

Consideramos todas las revisiones sistemáticas que están sintetizando estudios primarios (tanto experimentales como observacionales) de acuerdo a la definición empleada por la Colaboración Cochrane y la declaración PRISMA.²

Una revisión elegible debe cumplir con los siguientes criterios operacionales:

1. Reporta una búsqueda en al menos una base de datos electrónica.
2. Reporta al menos uno de los siguientes criterios inclusión de los estudios:
 - **Tipo de participantes:** Se incluyen todas las revisiones sistemáticas que resuman estudios que respondan la pregunta acerca de intervenciones para Cáncer de Ovario.
 - **Tipo de desenlaces:** Se incluyen revisiones que presentan una síntesis (cuantitativa o cualitativa) de al menos un desenlace importante para el paciente u otra información

¹ La actualización se realiza de manera semanal. Se encuentra disponible en la plataforma digital un sistema de alerta que permite informar a través de correo electrónico la publicación de nuevos estudios que dan respuesta a las preguntas definidas, de manera de mantener continuamente actualizada la evidencia.

² “Una revisión sistemática intenta recopilar toda la evidencia empírica para responder a una pregunta de investigación específica, que cumple con criterios previamente definidos. Utiliza métodos explícitos y sistemáticos, que se eligen con miras a minimizar el sesgo, de manera de entregar hallazgos confiables que permitan sacar conclusiones y tomar decisiones”.

relevante para tomar decisiones poblacionales o individuales acerca de intervenciones para Cáncer de Ovario.

RECOLECCIÓN, ANÁLISIS Y SÍNTESIS DE DATOS

SELECCIÓN DE LAS REVISIONES

Al menos dos revisores, de manera independiente, realizaron el cribado de los títulos y resúmenes para identificar los artículos relevantes. El texto completo de las revisiones potencialmente elegibles fue recuperado y evaluado, de manera independiente, para su inclusión final. Un tercer investigador resolvió cualquier discrepancia que pudiera haberse provocado entre los distintos revisores.

MAPEO DE LA EVIDENCIA

Con el objetivo de generar un listado exhaustivo de todas las posibles preguntas relacionadas con el tópico del L-OVE: *Cáncer de ovarios*³, se realiza la agrupación de las revisiones resultantes en formato PICO, es decir: población, intervención, comparación y desenlace [*outcome*]) utilizamos las siguientes fuentes:

1. Guías y documentos
2. Criterios de inclusión de las revisiones sistemáticas identificadas
3. Consulta con expertos
4. Retroalimentación de los usuarios

Como resultado final la plataforma incluye toda la evidencia disponible en revisiones sistemáticas y sus estudios primarios incluidos, segregada por nodos de evidencia que representan cada una de las preguntas priorizadas para actualización de la guía (Ver “Diagrama de flujo PRISMA” en Apéndice 2 y “Referencia Seleccionada” en Apéndice 3).

ACTUALIZACIÓN – “LIVING”

Todas las búsquedas a través de esta plataforma se mantienen continuamente actualizada gracias a la tecnología implementada en el buscador de Epistemonikos y sus distintos colaboradores. Por lo cual, tanto la cantidad de revisiones, preguntas, entre otros datos cambian continuamente. Los datos presentados en este informe son los correspondientes a la fecha de entrega.

³Ver resultados de la búsqueda en: <https://love.epistemonikos.org/loves/5a30379565dee0049e89c757>

APÉNDICE 1. ESTRATEGIAS DE BÚSQUEDA:⁴

Cochrane Library - Cochrane database of systematic reviews (CDSR)

<http://www.thecochranelibrary.com>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*), in Title, Abstract, Keywords: Cochrane Reviews (Reviews NOT protocols)

Medline/PubMed - US National Library of Medicine

<http://www.ncbi.nlm.nih.gov/pubmed/>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*) AND (MEDLINE[Title/Abstract] OR (systematic[Title/Abstract] AND review[Title/Abstract]) OR meta analysis[Publication Type])

EMBASE (Excerpta Medica dataBASE)

<http://www.embase.com>

Frequency of search: weekly
ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*) AND (meta-analysis.tw. OR systematic review.tw)

CINAHL (Cumulative Index to Nursing and Allied Health Literature)

<https://www.ebscohost.com/nursing/products/cinahl-databases/the-cinahl-database>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*) AND ((TI meta analys* or AB meta analys*) or (TI systematic review or AB systematic review))

PsycINFO

<http://www.apa.org/pubs/databases/psycinfo>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*) AND (meta-analysis OR search*)

LILACS (Literatura Latinoamericana y del Caribe en Ciencias de la Salud)

<http://lilacs.bvsalud.org/en/>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*) AND (tw:"revision sistematica" or tw:"revisao sistematica" or tw:"systematic review") or ((MH:"Literatura de Revisión como asunto" OR MH:"Metanálisis como asunto" OR PT:Revision OR PT:Metanálisis)

⁴ No se aplican restricciones en base al idioma o estado de publicación.

and (TW:Metaanal\$ OR TW:"Meta-analysis" OR TW:"Meta-analise" OR TW:"Meta-analysis"
OR TI:overview\$ or TW:"estudio sistematico" OR TW:"systematic study" OR TW:"estudo
sistematico" OR TI:review OR TI:revisao OR TI:revision))

[DARE \(Database of Abstracts of Reviews of Effectiveness\) - Centre for Reviews and Dissemination, University of York](#)

<http://www.crd.york.ac.uk/CRDWeb/>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*), in Any field: CRD assessed review (bibliographic)/ CRD assessed review (full abstract)

HTA

Database

<http://www.crd.york.ac.uk/CRDWeb/>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*), in Any field

[The Campbell Collaboration Online Library](#)

<https://www.campbellcollaboration.org/library.html>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*) in Title: Review

[JBI Database of Systematic Reviews and Implementation Reports](#)

<http://journals.lww.com/jbisrir/pages>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*) AND (review OR meta*), in All fields


[EPPI-Centre Evidence Library](#)

<http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=56>

ovar* AND (cancer* OR neoplas* OR tumor* OR tumour* OR carcinoma* OR maligna* OR adenocar* OR metasta* OR mass OR masses OR nodul* OR oncolog*) All records in chronological list (<http://eppi.ioe.ac.uk/cms/Default.aspx?tabid=62>)



APÉNDICE 2. DIAGRAMA DE FLUJO PRISMA



APÉNDICE 3. REFERENCIAS SELECCIONADAS

1. Li X, Xu J. Meta-analysis of the association between dietary lycopene intake and ovarian cancer risk in postmenopausal women. *Scientific reports*. 2014;4:4885. www.epistemonikos.org/documents/0001e2ffacd528ee6b7b56edb89d32070d25e4ce
2. Guo J., Yu J., Song X., Mi H.. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis. *Open Medicine (Poland)*. 2017;12(1):131-137. www.epistemonikos.org/documents/00a0257f006044830ab1d8ed041dedaf8511bc3f
3. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. *Health technology assessment (Winchester, England)*. 1998;2(2):i-iv, 1-84. www.epistemonikos.org/documents/00b03ae58e4dad6bffd6cf740a3ac9fb344cbc064
4. Lan Z, Fu D, Xi M. Serum B7 homologous body 4 for the diagnosis of ovarian cancer in Chinese Han women: A meta-analysis. *Journal of cancer research and therapeutics*. 2018;14(Supplement):S433-S436. www.epistemonikos.org/documents/010c2aa8310073103bf7533c7b05887d584b5748
5. Ramaseshan AS, Felton J, Roque D, Rao G, Shipper AG, Sanses TVD. Pelvic floor disorders in women with gynecologic malignancies: a systematic review. *International urogynecology journal*. 2018;29(4):1-18. www.epistemonikos.org/documents/01a2b932df0e30b35415e5607a92837d317d5f8c
6. Li W, Liu Z, Liang B, Chen S, Zhang X, Tong X, Lou W, Le L, Tang X, Fu F. Identification of core genes in ovarian cancer by an integrative meta-analysis. *Journal of ovarian research*. 2018;11(1):94. www.epistemonikos.org/documents/01e9a14984a1b3749bb569173031414aaf496715
7. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. *Journal of clinical pathology*. 2013;66(4):273-81. www.epistemonikos.org/documents/02916d074e8051128c12bec3c3f8470f5496bd7f
8. Zapata LB, Whiteman MK, Marchbanks PA, Curtis KM. Intrauterine device use among women with ovarian cancer: a systematic review. *Contraception*. 2010;82(1):38-40. www.epistemonikos.org/documents/02e2d83b0ac94322acb02854d0a66e284f7f7b59
9. Lan Z., Fu D., Yu X., Xi M.. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. *Familial Cancer*. 2016;15(2):221-230. www.epistemonikos.org/documents/02e63f9c8e81cf479a5cc22135389d9e8993ba45
10. Yi S., Zeng L., Kuang Y., Cao Z., Zheng C., Zhang Y., Liao M., Yang L.. Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: A meta-analysis. *OncoTargets and Therapy*. 2017;10:973-984. www.epistemonikos.org/documents/02eb194f10134fad6926dd9b08026b079b612e1
11. Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010;20(5):704-16. www.epistemonikos.org/documents/0367341473a6ccef98eebf3d0cb348ae3e60eea7
12. Ye Y, Wang JJ, Li SL, Wang SY, Jing FH. Does B7-H4 expression correlate with clinicopathologic characteristics and survival in ovarian cancer?: A systematic review and PRISMA-compliant meta-analysis. *Medicine*. 2018;97(32):e11821. www.epistemonikos.org/documents/03b8e086ff30986fc78f5871fb0595cd70c77994
13. Kelly-Newton S.L., Tulp O.L., Einstein G.P.. The correlation between dairy product consumption and gastrointestinal bleed, ovarian cancer, and diabetes in infants: A meta-analysis approach. *FASEB Journal*. 2016; www.epistemonikos.org/documents/042c4b23f1e498f723bb60a4fcf94218ebf47028
14. Shi S, Qin L, Tian M, Xie M, Li X, Qi C, Yi X. The effect of RAD51 135 G>C and XRCC2 G>A (rs3218536) polymorphisms on ovarian cancer risk among Caucasians: a meta-analysis. *Tumour*

- biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35(6):5797-804.
www.epistemonikos.org/documents/04f08aed883b169b0236f89852040be11e709202
15. Mardas M, Stelmach-Mardas M, Zalewski K, Grabowski JP, Czapka-Matyasik M, Steffen A, Boeing H, Mądry R. Influence of body weight changes on survival in patients undergoing chemotherapy for epithelial ovarian cancer. *European review for medical and pharmacological sciences*. 2016;20(10):1986-92.
www.epistemonikos.org/documents/051620a2d037a554645ed5b0c9a4b38cae4f6e9e
 16. Cui Y, Jing Y, Sun Z. Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(4):3385-9.
www.epistemonikos.org/documents/06512ac4a6506ef6929ed6bd5f2be96bb3a8a8c7
 17. Zhang D, Zhao Y, Wang T, Xi Y, Li N, Huang H. Diabetes mellitus and long-term mortality of ovarian cancer patients. A systematic review and meta-analysis of 12 cohort studies. *Diabetes/metabolism research and reviews*. 2017;33(4).
www.epistemonikos.org/documents/0715b36e9b6bfda475158f681c3e7e192feae834
 18. Yeganeh L, Harrison C, Vincent AJ, Teede H, Boyle JA. Effects of lifestyle modification on cancer recurrence, overall survival and quality of life in gynaecological cancer survivors: A systematic review and meta-analysis. *Maturitas*. 2018;111:82-89.
www.epistemonikos.org/documents/0760aa39f0c1b335ceb21bbfad423f86da34f8eb
 19. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. *Gynecologic oncology*. 2006;103(3):1070-6.
www.epistemonikos.org/documents/080ab30acf8920f28c34c732368dd554ec460d53
 20. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. *European journal of obstetrics, gynecology, and reproductive biology*. 2013;167(1):81-5.
www.epistemonikos.org/documents/083d2fdbe4ab0e7af556eefb6e04e192ddda389d
 21. Bentivegna E, Gouy S, Maulard A, Pautier P, Leary A, Colombo N, Morice P. FERTILITY-SPARING SURGERY IN EPITHELIAL OVARIAN CANCER: A SYSTEMATIC REVIEW OF ONCOLOGICAL ISSUES. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2016;27(11):1994-2004.
www.epistemonikos.org/documents/08409ee9e79ef1812ba9406b2a2a34b3a40c96bd
 22. Einhorn N. Ovarian cancer. *Acta oncologica (Stockholm, Sweden)*. 1996;35 Suppl 7:86-92.
www.epistemonikos.org/documents/08ec995654609724faa54570eaf7aeb357e934a1
 23. Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. *Cochrane database of systematic reviews (Online)*. 2010;(3):CD001034.
www.epistemonikos.org/documents/0918ad8984519c36fec81d2062e1fb00eb2c39e5
 24. Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. *Gynecologic oncology*. 2004;92(3):827-32.
www.epistemonikos.org/documents/091cc8751490836bf17e2522b2f894f06eea86d9
 25. Yang L, Guo G, Sun L, Li C, Zhang H. Efficacy and safety of traditional chemotherapies for patients with ovarian neoplasm: a network meta-analysis. *Oncotarget*. 2017;8(35):59867-59877.
www.epistemonikos.org/documents/098aaf56bf194044e8942c0500c799430e0df990
 26. Olsen CM, Bain CJ, Jordan SJ, Nagle CM, Green AC, Whiteman DC, Webb PM, Australian Ovarian Cancer Study Group. Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2007;16(11):2321-30.
www.epistemonikos.org/documents/09992d2111806d188b9ec8f9b1fc01bbb476118b
 27. Zeng F, Wei H, Yeoh E, Zhang Z, Ren ZF, Colditz GA, Tworoger SS, Su X. Inflammatory markers of CRP, IL-6, TNF- α and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective
-

- studies. *Cancer epidemiology, biomarkers & prevention* : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016;25(8):1231-9.
www.epistemonikos.org/documents/09b5d944bfb999b8efc5a78af0efc1c9d0072e87
28. Al-Dakkak I., Borrill J., Murphy E., Posnett J., Zhang Y.. A systematic review of health state utility values for advanced ovarian cancer. *Value in Health*. 2014;17(7):A645.
www.epistemonikos.org/documents/0a13750999ea8988280ad736e245eda6ccb754c5
29. Wu YS, Shui L, Shen D, Chen X. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials. *Oncotarget*. 2017;8(6):10703-10713.
www.epistemonikos.org/documents/0aa4502dc15df7da6f1c266f73b2cf187fb1c749
30. Winter-Roach B, Hooper L, Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2003;13(4):395-404.
www.epistemonikos.org/documents/0b9a8b60c06829eb8e53e4c7518262324f28aa05
31. Jia N, Chen Y, Tao X, Ou E, Lu X, Feng W. A gestational choriocarcinoma of the ovary diagnosed by DNA polymorphic analysis: a case report and systematic review of the literature. *Journal of ovarian research*. 2017;10(1):46.
www.epistemonikos.org/documents/0bddd4b19d03e3c6da0799c8047732f5f7be04be
32. Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, Huybrechts KF. Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry. *PloS one*. 2011;6(4):e18210.
www.epistemonikos.org/documents/0c1680594ad492722f8fc8a631220c293eb6d7c0
33. Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. *Menopause (New York, N.Y.)*. 2016;23(3):335-42.
www.epistemonikos.org/documents/0c34a875b986ab4ceaf481a5aac37cc6a5c264c2
34. Mei L., Wei D.-M., Fang F.. A systematic review of maintenance radiotherapy for epithelial ovarian cancer. *Chinese Journal of Evidence-Based Medicine*. 2010;10(6):724-729.
www.epistemonikos.org/documents/0d49b1d89d059bb12443d21818c4f85943dc5292
35. Garg D, Mor GG, Silasi DA. Role of MyD88 expression in Epithelial Ovarian Cancer: A Literature Review [237]. *Obstetrics and gynecology*. 2015;125 Suppl 1:76S-77S.
www.epistemonikos.org/documents/0d6899da59b23602d548e3c361b39ace8ba73ede
36. Harter P., Reuss A., Pfisterer J., Pujade-Lauraine E., Ray-Coquard I.L., Du Bois A.. Prognostic role of lymph node status in primary advanced ovarian cancer after complete resection or residual disease less than 1 cm: Results of a meta-analysis of the AGO-OVAR meta-database. *Journal of Clinical Oncology*. 2010;
www.epistemonikos.org/documents/0dc9616e422ae2186209cc8fe1c4d4c3bb369295
37. Hui G, Meng M. Prognostic value of vascular endothelial growth factor expression in women with ovarian cancer: A meta-analysis. *Journal of B.U.ON. : official journal of the Balkan Union of Oncology*. 2015;20(3):870-8.
www.epistemonikos.org/documents/0df9c09ff71106cfd328307cabadebf53b6a84e3
38. Shazly SA, Laughlin-Tommaso SK, Dowdy SC, Famuyide AO. Staging for low malignant potential ovarian tumors: a global perspective. *American journal of obstetrics and gynecology*. 2016;215(2):153-168.e2.
www.epistemonikos.org/documents/0dfcac25f7e890661a502884e7830c8aecab6594
39. Zhou Q, Li W, Leng B, Zheng W, He Z, Zuo M, Chen A. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis. *PloS one*. 2016;11(6):e0155495.
www.epistemonikos.org/documents/0e161905fe400a7a253f21530fcabcc70b9a3609

40. Cormio G, Maneo A, Parma G, Pittelli MR, Miceli MD, Bonazzi C. Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and a literature review. *Annals of oncology : official journal of the European Society for Medical Oncology*. 1995;6(6):571-4. www.epistemonikos.org/documents/0e1f27725d665c50a42068542ff611154ba356a2
41. Dai-Yuan M, Bang-Xian T, Xian-Fu L, Ye-Qin Z, Hong-Wei C. A meta-analysis: neoadjuvant chemotherapy versus primary surgery in ovarian carcinoma FIGO stage III and IV. *World journal of surgical oncology*. 2013;11(1):267. www.epistemonikos.org/documents/0e507feb3dd6f1317ac5a5aa54919e02cf8db62a
42. He X, Yang K, Wang H, Chen X, Wu H, Yao L, Ma S. Expression and clinical significance of survivin in ovarian cancer: A meta-analysis. *PLoS one*. 2018;13(5):e0194463. www.epistemonikos.org/documents/0ea46767e77e9535b54a533e225241aeb7babd4a
43. Poorolajal J, Jenabi E, Masoumi SZ. Body mass index effects on risk of ovarian cancer: a meta-analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(18):7665-71. www.epistemonikos.org/documents/0ec60efb81c4b94e299942deb5aaf3ab0807c4d5
44. Wuntakal, Rekha, Seshadri, Srividya, Montes, Ana, Lane, Geoff. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2016;6(6):CD011322. www.epistemonikos.org/documents/0ed73d87b50cd7605b8ca0452aa7721a688887d5
45. Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J. Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients. *European journal of cancer (Oxford, England : 1990)*. 2015;51(7):825-32. www.epistemonikos.org/documents/0f18a8b119dd0a1513f107ad930ca1bf2768d0f3
46. Woopen, H., Inci, G., Richter, R., Chekerov, R., Ismaeel, F., Sehouli, J.. Elderly ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). *European Journal of Cancer*. 2016;60:101-106. www.epistemonikos.org/documents/0fe1faff22ad38c7c18fd6facba172ab99440fd2
47. Kim J., Oh I., Yoon S., Shim S., Lee S., Kim S., Kang S.. Prophylactic bilateral salpingectomy and ovarian cancer : A meta-analysis. *International Journal of Gynecological Cancer*. 2015;:606. www.epistemonikos.org/documents/1026638ca4f35d2c25bbe52dc9d065e1452cb3e1
48. Sung H.K., Ma S.H., Choi J.-Y., Hwang Y., Ahn C., Kim B.-G., Kim Y.-M., Kim J.W., Kang S., Kim J., Kim T.J., Yoo K.-Y., Kang D., Park S.. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: A systematic review and meta-analysis. *Journal of Preventive Medicine and Public Health*. 2016;49(6):349-366. www.epistemonikos.org/documents/1059d6126319f4a6b89d5bb72167dc4898deb3cf
49. Kireeva GS, Gafton GI, Guseynov KD, Senchik KY, Belyaeva OA, Bepalov VG, Panchenko AV, Maydin MA, Belyaev AM. HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes. *Surgical oncology*. 2018;27(2):251-258. www.epistemonikos.org/documents/10bd4b4de4231df65c12152c8e0e80afd0521f0a
50. Kamali M, Hamadani S, Neamatzadeh H, Mazaheri M, Zare Shehneh M, Modaress Gilani M, Haghighi F. Association of XRCC2 rs3218536 Polymorphism with Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2017;18(7):1743-1749. www.epistemonikos.org/documents/10cdacb70980357f25f56e7310a2f075ef0f5ccf
51. Cook LS, Neilson HK, Lorenzetti DL, Lee RC. A systematic literature review of vitamin D and ovarian cancer. *American journal of obstetrics and gynecology*. 2010;203(1):70.e1-8. www.epistemonikos.org/documents/1146a3807e0c443606ed2665fce32538f65dc31f
52. Yang F., Hu Z.-D., Chen Y., Hu C.-J.. Diagnostic value of KLK6 as an ovarian cancer biomarker: A meta-analysis. *Biomedical Reports*. 2016;4(6):681-686. www.epistemonikos.org/documents/119353b527ff899cdf21a09f8ddea676f55f6c41

53. Lesley Stewart, . Chemotherapy for advanced ovarian cancer. Cochrane Database of Systematic Reviews. 2000;(1):CD001418.www.epistemonikos.org/documents/128346ae74d018277ba7efee2e2dc14c3d57601
54. Zheng X, Zhu Y, Zhao Y, Feng S, Zheng C. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review. *International journal of clinical pharmacology and therapeutics*. 2017;55(9):753-760.
www.epistemonikos.org/documents/12eb299082b8e1a53bb616e5326806d1ce4090d8
55. Encinas G, Maistro S, Pasini FS, Katayama ML, Brentani MM, Bock GH, Folgueira MA. Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis. *Revista da Associação Médica Brasileira* (1992). 2015;61(5):474-83.www.epistemonikos.org/documents/13039a23fb3bf29c20264615976e13ed777e0cf8
56. He Y.-F., Xu C.-J., Feng L.-D.. HER-2/neu status and post-operative survival in epithelial ovarian carcinoma: A meta-analysis. *Chinese Journal of Evidence-Based Medicine*. 2007;7(6):420-432.
www.epistemonikos.org/documents/14bfe05d88551fdd3711463b615282c8967d4482
57. Swart AM, Burdett S, Ledermann J, Mook P, Parmar MK. Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2008;19(4):688-95.www.epistemonikos.org/documents/14ef6403de2fd2fc6cf2cf7f021d58e7394ca875
58. Gao, Ming, Ma, Wang, Chen, Xiao-Bing, Chang, Zhi-Wei, Zhang, Xu-Dong, Zhang, Ming-Zhi. Meta-analysis of green tea drinking and the prevalence of gynecological tumors in women. *Asia-Pacific Journal of Public Health*. 2013;25(4, Suppl).
www.epistemonikos.org/documents/1508d790c1f4f172bb26afcad3a9d1a0e93465bc
59. Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. *British journal of cancer*. 2011;104(9):1478-81.
www.epistemonikos.org/documents/155f7a83c6967f9e68834130d30b704324fba05a
60. Trudel D, Labbé DP, Bairati I, Fradet V, Bazinet L, Têtu B. Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies. *Gynecologic oncology*. 2012;126(3):491-8.
www.epistemonikos.org/documents/156b590150333d87bc8f77def52067e94bf3d533
61. West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. *European journal of gynaecological oncology*. 1997;18(5):343-8.
www.epistemonikos.org/documents/15755bade2b95e2a469783173a1fd53fc264f55e
62. Schwarz C, Pedraza-Flechas AM, Lope V, Pastor-Barriuso R, Pollan M, Perez-Gomez B. Gynaecological cancer and night shift work: A systematic review. *Maturitas*. 2018;110:21-28.
www.epistemonikos.org/documents/15834dacd214bda52c4c2635227a76b177030026
63. Dick ML, Siskind V, Purdie DM, Green AC, Australian Cancer Study Group (Ovarian Cancer), Australian Ovarian Cancer Study Group. Incomplete pregnancy and risk of ovarian cancer: results from two Australian case-control studies and systematic review. *Cancer causes & control : CCC*. 2009;20(9):1571-85.
www.epistemonikos.org/documents/158e3a39f0a83b0013d1e2c3167c14f670c6f370
64. Chua, T C, Robertson, G, Farrell, R, Liauw, W, Yan, T D, Morris, D L. Systematic review of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian peritoneal carcinomatosis: A more efficacious way of delivering intraperitoneal chemotherapy. *Journal of Clinical Oncology*. 2009;27:5524-5524.
www.epistemonikos.org/documents/16888c28190340c6608207871730ecb86741cf1e
65. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. *Annals of internal medicine*. 1994;121(2):124-32.
www.epistemonikos.org/documents/16c7d4279ec589e974a3fedb5ad5dc25bc777850

66. Li X., Zhu S., Hong C., Cai H.. Angiogenesis inhibitors for patients with ovarian cancer: A meta-analysis of 12 randomized controlled trials. *Current Medical Research and Opinion*. 2016;32(3):555-562.
www.epistemonikos.org/documents/170cc9ffda2f17379e49845a138746b36ce43b20
67. Wallin A, Orsini N, Wolk A. Red and processed meat consumption and risk of ovarian cancer: a dose-response meta-analysis of prospective studies. *British journal of cancer*. 2011;104(7):1196-201. www.epistemonikos.org/documents/1722705ce0f4640fc5908ed732fdecfa776d0925
68. Economopoulos KP, Sergentanis TN, Vlahos NF. Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010;20(5):732-7. www.epistemonikos.org/documents/18319cab6632b498b258407fa265b62b0aecc297
69. Ozga M, Aghajanian C, Myers-Virtue S, McDonnell G, Jhanwar S, Hichenberg S, Sulimanoff I. A systematic review of ovarian cancer and fear of recurrence. *Palliative & supportive care*. 2015;13(6):1-10.
www.epistemonikos.org/documents/1843ac726bf646e72baca162ff6c8212684cde0b
70. Chen H, Zhu J. Vitamin D receptor rs2228570 polymorphism and susceptibility to ovarian cancer: An updated meta-analysis. *The journal of obstetrics and gynaecology research*. 2018;44(3):556-565. www.epistemonikos.org/documents/19080ab9728e85a171b6412f43ed04763545a8ba
71. Penninkilampi R, Eslick GD. Perineal Talc Use and Ovarian Cancer: A Systematic Review and Meta-Analysis. *Epidemiology (Cambridge, Mass.)*. 2018;29(1):41-49. www.epistemonikos.org/documents/192da15946cd799464e07f3567ea8ded9d140537
72. Lee JY, Jeon I, Kim JW, Song YS, Yoon JM, Park SM. Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2013;23(3):402-412. www.epistemonikos.org/documents/1951bcfba15faef1775873f3b3af1132ad670407
73. Wiggins AJ, Cass GK, Bryant A, Lawrie TA, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. *Cochrane Database of Systematic Reviews*. 2015;5(5):CD007929.
www.epistemonikos.org/documents/199a116862b05d3ccd0913a6001a15f9275f48ba
74. Shi XY, Shen Q. MTHFR A1298C polymorphism and ovarian cancer risk: a meta-analysis. *Genetics and molecular research : GMR*. 2015;14(3):8211-8. www.epistemonikos.org/documents/1a630908e64d1eb919dc9ec85bd1daeda816114c
75. Shi Y.Y., Jiang H.. Prognostic role of the cancer stem cell marker CD44 in ovarian cancer: A meta-analysis. *Genetics and Molecular Research*. 2016;15(3). www.epistemonikos.org/documents/1a6a23f4b34a7fc7325d6e1f1b22e7d0a568d9eb
76. Strømsvik N, Råheim M, Oyen N, Gjengedal E. Men in the women's world of hereditary breast and ovarian cancer—a systematic review. *Familial cancer*. 2009;8(3):221-229. www.epistemonikos.org/documents/1b759a2c804487f9ce0b0d2de68271c0c53bb4f3
77. Dybro A, Blaakær J. [Treatment of epithelial ovarian cancer should be followed by lymphadenectomy—a systematic review]. *Ugeskrift for læger*. 2012;174(13):865-870. www.epistemonikos.org/documents/1bff974df0943723186d2954bccbd7aa0d2c2075
78. Cai J, Xu L, Tang H, Yang Q, Yi X, Fang Y, Zhu Y, Wang Z. The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis. *The oncologist*. 2014;19(5):528-35. www.epistemonikos.org/documents/1c147ed41f8e0c453e7703e012d1a0ca1c2c5dd3
79. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. *The Lancet. Oncology*. 2012;13(9):946-956. www.epistemonikos.org/documents/1c1cc35e2702adb24dfa96cd44aaa6f06af2c591

80. Ouyang W, Xu L, Huang Z, Guo J, Cai J, Gao X, Wang Z. Role of HER family members in predicting prognoses in epithelial ovarian cancer: a meta-analysis. *Tumori*. 2015;101(6):595-602. www.epistemonikos.org/documents/1c371b8c9412091e7377ae9d103cea74446944aa
81. Willis S, Villalobos VM, Gevaert O, Abramovitz M, Williams C, Sikic BI, Leyland-Jones B. Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. *PloS one*. 2016;11(2):e0149183. www.epistemonikos.org/documents/1cac71ee8ee073e78b354955add78fea48a286bd
82. Huncharek M, Kupelnick B. Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis of 6,689 subjects from 8 observational studies. *Nutrition and cancer*. 2001;40(2):87-91. www.epistemonikos.org/documents/1cd8498ee8e7d67bde5b55c0520320bcbfd6f777
83. Yuan X, Guo L, Du W, Mo F, Liu M. Diagnostic accuracy of DWI in patients with ovarian cancer: A meta-analysis. *Medicine*. 2017;96(19):e6659. www.epistemonikos.org/documents/1d3596951c24aaddf0114ef8c083ab57c7fb249a
84. Cardenas-Goicoechea J, Wang Y, McGorray S, Saleem MD, Carbajal Mamani SL, Pomputius AF, Markham MJ, Castagno JC. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis. *Journal of robotic surgery*. 2019;13(1):23-33. www.epistemonikos.org/documents/1da99e91850277402cdb16c01812643165f41747
85. Qin J.-C., Yang Z.-J., Xiong L., Li L.. Systematic lymphadenectomy for overall survival in epithelial ovarian cancer: A meta-analysis. *Chinese Journal of Evidence-Based Medicine*. 2012;12(2):224-230. www.epistemonikos.org/documents/1e459862733dd37d840ae97bd85e88562093212a
86. Marsoni S, Torri W, Taiana A, Gambino A, Grilli R, Liati P, Franzosi MG, Pistotti V, Parazzini F, Focarile F. Critical review of the quality and development of randomized clinical trials (RCTs) and their influence on the treatment of advanced epithelial ovarian cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 1990;1(5):343-50. www.epistemonikos.org/documents/1f684b16499ccb5f16a962934b750865ffdd9556
87. Komura N, Mabuchi S, Yokoi E, Kozasa K, Kuroda H, Sasano T, Matsumoto Y, Kimura T. Comparison of clinical utility between neutrophil count and neutrophil-lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review. *International journal of clinical oncology*. 2018;23(1):104-113. www.epistemonikos.org/documents/1ff855835c6f8491a11f13a477a82a3caeeb89d4
88. Li J., Li S., Chen R., Yu H., Lu X.. The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis. *Journal of Ovarian Research*. 2015;8(1):54. www.epistemonikos.org/documents/204e84cf2f751f1d0ed78a9c2a7213961654dff5
89. Bonovas S, Filioussi K, Sitaras NM. Paracetamol use and risk of ovarian cancer: a meta-analysis. *British journal of clinical pharmacology*. 2006;62(1):113-21. www.epistemonikos.org/documents/2090b5255e8901f34322b2ac940818b54f1f9f61
90. Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. *European journal of cancer (Oxford, England : 1990)*. 2016;61:137-45. www.epistemonikos.org/documents/20917a86c926d5732d165db5274c4fcd083b7c4a
91. Pajjens ST, Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ, de Bruyn M, Nijman HW. Antigen-specific active immunotherapy for ovarian cancer. *The Cochrane database of systematic reviews*. 2018;9:CD007287. www.epistemonikos.org/documents/20dbb99a52ee69d4141147b257e91d1dcfc3d0f6
92. Liu J., Tang W., Sang L., Dai X., Wei D., Luo Y., Zhang J.. Milk, yogurt, and lactose intake and ovarian cancer risk: A meta-analysis. *Nutrition and Cancer*. 2015;67(1):68-72. www.epistemonikos.org/documents/214900571175075304dec688ba5fb87286383515
93. Bogani G, Cromi A, Serati M, Di Naro E, Casarin J, Pinelli C, Ghezzi F. Laparoscopic and open abdominal staging for early-stage ovarian cancer: our experience, systematic review, and meta-analysis of comparative studies. *International journal of gynecological cancer : official journal of*

- the International Gynecological Cancer Society. 2014;24(7):1241-9.
www.epistemonikos.org/documents/21d2a81279327a6aef8595b79bc0f4458781bf10
94. Pu D, Jiang SW, Wu J. Association between MTHFR gene polymorphism and the risk of ovarian cancer: a meta-analysis of the literature. *Current pharmaceutical design*. 2014;20(11):1632-8.
www.epistemonikos.org/documents/224a14af416451f9997ea0ea25ea940ffe9a5700
95. Galazis N.G., Drymiotou S.D., Thoukididou S.N.T., Atiomo W.A., Docheva N.. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome (PCOS): A systematic review and biomarker database integration. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2013;233.
www.epistemonikos.org/documents/225c481546d49c34d7c65ccf51b6640d192aa94b
96. Cheng M., Xie C., Wang D.-Q., Yin R.-T., Kang D.-Y.. Systematic review of paclitaxel intensive therapy for ovarian epithelial cancer. *Chinese Journal of Evidence-Based Medicine*. 2009;9(12):1328-1335.
www.epistemonikos.org/documents/22acc5337c2521799c06babbc7cc8ac25b17625e
97. Ding XP, Feng L, Ma L. MTHFR C677T polymorphism and ovarian cancer risk: a meta-analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2012;13(8):3937-42.
www.epistemonikos.org/documents/22bca0d8cd6e5b35b96c21317cf99264407e8978
98. Omura G.A., Buyse M., Marsoni S., Bertelsen K., Conte P.F., Jakobsen A., Vermorken J.. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1991;9(9):1668-74.
www.epistemonikos.org/documents/22e948807a08c625a78be239ccd9c57ce28bf15d
99. Yang B, Yan X, Liu L, Jiang C, Hou S. Overexpression of the cancer stem cell marker CD117 predicts poor prognosis in epithelial ovarian cancer patients: evidence from meta-analysis. *OncoTargets and therapy*. 2017;10:2951-2961.
www.epistemonikos.org/documents/230959b48b6c55fde6fe4940a45db623140d188e
100. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2016;1(1):CD005340.
www.epistemonikos.org/documents/24459c0c078e1173aa4a84381af98c1c40e1a8cd
101. Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic review and meta-analysis. *Cancer prevention research (Philadelphia, Pa.)*. 2012;5(7):901-10.
www.epistemonikos.org/documents/24b148c0fb487956b7c588547d13fbf797e27481
102. Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S. Tolerability, Efficacy, and Safety of Pegylated Liposomal Doxorubicin in Combination with Carboplatin Versus Gemcitabine-Carboplatin for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review. *The oncologist*. 2010;15(10):1073-82.
www.epistemonikos.org/documents/24d732f88a99e2e4eae741d23570572bf34b326
103. Madeira K, Dondossola ER, Farias BF, Simon CS, Alexandre MC, Silva BR, Rosa MI. Mesothelin as a biomarker for ovarian carcinoma: a meta-analysis. *Anais da Academia Brasileira de Ciencias*. 2016;88(2):923-932.
www.epistemonikos.org/documents/24ed798a5e09b924103776f72f6ce0c3b7de78ce
104. Liu JX, Luo RC, Li R, Li X, Guo YW, Ding DP, Chen YZ. Lack of associations of the COMT Val158Met polymorphism with risk of endometrial and ovarian cancer: a pooled analysis of case-control studies. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(15):6181-6.
www.epistemonikos.org/documents/2590aa1b236c33df612704e0d2d99542f5220773
105. Edwards S.J., Barton S., Thurgar E., Trevor N.. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: A systematic review and economic evaluation. *Health Technology Assessment*. 2015;19(7):1-524.
www.epistemonikos.org/documents/264048c0102101462da35c4964ef7633f4c24b7b

106. Albiruni Ryan Abdul Razak, Louise Li, Andrew Bryant, Ivan Diaz-Padilla. Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease. *Cochrane Database of Systematic Reviews*. 2011;(3):CD007584.
www.epistemonikos.org/documents/2663a92280f17e2240bd7fcb6fb177e7fa1127f0
107. Yang Z, Gu JH, Guo CS, Li XH, Yang WC. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. *Oncotarget*. 2017;8(28):46414-46424.
www.epistemonikos.org/documents/268995ba2d309b7a4a0ec71c7583f2295f27b412
108. Lu Z, Chen Y, Hu Z, Hu C. Diagnostic Value of Total Plasma Lysophosphatidic Acid in Ovarian Cancer: A Meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2015;25(1):18-23.
www.epistemonikos.org/documents/26ab73d01fe7e5c85fa4600cd941e4b5249451d5
109. Roze JF, Hoogendam JP, van de Wetering FT, Spijker R, Verleye L, Vlayen J, Veldhuis WB, Scholten RJ, Zweemer RP. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer. *The Cochrane database of systematic reviews*. 2018;10:CD012567.
www.epistemonikos.org/documents/26b0acfaf39933ca3c127c5b3af2c26404a3c647
110. Li LN, Zhou X, Gu Y, Yan J. Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2013;14(7):4107-13.
www.epistemonikos.org/documents/26bf18ab5f7540a1fba147c2a5c8c55fb46da326
111. Wang HF, Yao AL, Sun YY, Zhang AH. Empirically derived dietary patterns and ovarian cancer risk: a meta-analysis. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. 2018;27(5):493-501.
www.epistemonikos.org/documents/26ebd9039081b391313b244d9ebbdd9dc94117dd
112. Long H, Li G, Wen X, Lv Y, Zhang M, Wei Y, Xie W, Zhong P, Pang L. Prognostic significance of β -catenin expression in patients with ovarian cancer: A meta-analysis. *Gene*. 2018;678:270-279.
www.epistemonikos.org/documents/273a44050507793f4c055f2433b7aac9dd210e8f
113. Pakneshan S, Safarpour D, Tavassoli F, Jabbari B. Brain metastasis from ovarian cancer: a systematic review. *Journal of neuro-oncology*. 2014;119(1):1-6.
www.epistemonikos.org/documents/27db400d5340c59a9120d00e89037de273cbabf0
114. Hu ZD, Wei TT, Yang M, Ma N, Tang QQ, Qin BD, Fu HT, Zhong RQ. Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. *PloS one*. 2015;10(5):e0126444.
www.epistemonikos.org/documents/281c86bdceb4e5e82b08e6eab87c2ecb8f7acdc0
115. Pergialiotis V, Karampetsou N, Bellos I, Thomakos N, Daskalakis G. The Diagnostic Accuracy of Human Epididymis Factor 4 for the Prediction of Optimal Debulking in Patients With Ovarian Cancer: A Meta-Analysis of Observational Studies. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2018;28(8):1471-1477.
www.epistemonikos.org/documents/28e034cdb5330a8346505dd2137466cab15794a3
116. Hess LM, Rong N, Monahan PO, Gupta P, Thomaskutty C, Matei D. Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. *Cancer*. 2010;116(22):5251-60.
www.epistemonikos.org/documents/2a1385afdb2e2769e560423d631ee1573c678e1e
117. Clark RM, Rice LW, Del Carmen MG. Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review. *Gynecologic oncology*. 2018;150(2):370-377.
www.epistemonikos.org/documents/2a518cd74b3cc4821d39c21b7e6c5ed223236b30
118. Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Musty MD, Lallinger KR, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use for the primary prevention of ovarian cancer. *Evidence report/technology assessment*. 2013;(212):1-514.
www.epistemonikos.org/documents/2a6e3ef9a5f2232d026b32719ee0f6f3e0056887

119. Leviton A. Methylxanthine consumption and the risk of ovarian malignancy. *Cancer letters*. 1990;51(2):91-101.
www.epistemonikos.org/documents/2ac9dfc29deb95ecdf3d5dba5cb901d0f413f24a
120. Du Bois A., Luck H.-J., Bauknecht T., Pfisterer J., Meier W.. Second-line chemotherapie after platinum or platinum and paclitaxel- based chemotherapy for ovarian cancer: A systematic review. *Geburtshilfe und Frauenheilkunde*. 2000;60(1):41-58.
www.epistemonikos.org/documents/2b4d6762ef0d2f994e887a8b73236216980d3159
121. Ning Tang, Dan Lyu, Yan Zhang, Haiping Liu, Tang, Ning, Lyu, Dan, Zhang, Yan, Liu, Haiping. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis. *BMC Women's Health*. 2017;17(1):1-8.
www.epistemonikos.org/documents/2b5295f8195f1cd6421041bd9ceb119d8050d572
122. Hua X, Yu L, You R, Yang Y, Liao J, Chen D, Yu L. Association among Dietary Flavonoids, Flavonoid Subclasses and Ovarian Cancer Risk: A Meta-Analysis. *PloS one*. 2016;11(3):e0151134.
www.epistemonikos.org/documents/2b8b1afd5f3d3b4be7a6e92f11f83f84c11df686
123. Shanmughapriya S, Nachiappan V, Natarajaseenivasan K. BRCA1 and BRCA2 mutations in the ovarian cancer population across race and ethnicity: special reference to Asia. *Oncology*. 2013;84(4):226-32.
www.epistemonikos.org/documents/2c5e74169e5b5d749e6e5ce3d12a77dfafe6e46f
124. Kim J.W., Kim H.S., Chung H.H., Kim Y.-B., Park N.H., Song Y.S., Kang S.-B., Lee H.P.. Endometriosis-associated ovarian cancer risk and prognosis: A meta-analysis. *International Journal of Gynecological Cancer*. 2011;:S663.
www.epistemonikos.org/documents/2c708298cadd8436d356de4b030694df31f0c8f2
125. Deng Y, Wang J, Wang L, Du Y. Androgen receptor gene CAG repeat polymorphism and ovarian cancer risk: A meta-analysis. *Bioscience trends*. 2017;11(2):193-201.
www.epistemonikos.org/documents/2c81eadd32a304fb2338d203b9ca090ac7d5c45a
126. Weihua LIU, Qing GUO, Jian YANG. Systematic review summary - Perioperative nutrition interventions for women with ovarian cancer. *Singapore Nursing Journal*. 2015;42(1):41-42.
www.epistemonikos.org/documents/2cf70658a89850cb9348a1041ff65cba20db9736
127. Bang H.. Human epididymis protein 4 test. *Value in Health*. 2014;17(7):A662.
www.epistemonikos.org/documents/2d104f1d976a47a37aadd91ce03046730bbde806
128. Yu X., Wei Z., Li Y., Wang B., Mi C., Xing A., Hu C.. Association between ERCC2 rs13181 and XRCC2 rs3218536 polymorphisms and the risk of ovarian cancer: A meta-analysis. *International Journal of Clinical and Experimental Medicine*. 2016;9(2):1558-1566.
www.epistemonikos.org/documents/2d3e8e755616607ce8e558d065b605d9f5dbcd5
129. Wang Y.-D., Chen H., Liu H.-Q., Hao M.. Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(12):11799-11808.
www.epistemonikos.org/documents/2dec9c452ffeb2619e885c0507f423faa69b9f54
130. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, Wang B. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. *Gynecologic oncology*. 2008;108(3):641-51.
www.epistemonikos.org/documents/2e4572224a9b7f8b42faa0b8e7b0ace6f90d433d
131. Chen H., Rao Y., Qu P.. Combination of docetaxel-carboplatin for adjuvant chemotherapy of epithelial ovarian, primary peritoneal and fallopian tube cancers: A meta-analysis. *Chinese-German Journal of Clinical Oncology*. 2010;9(8):475-481.
www.epistemonikos.org/documents/2e55c1aeca73423282759095f9614cd9f6cf5bc0
132. Zhang J, Zhang Y, Zhang Z. Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer: A meta-analysis of case-control studies. *Medicine*. 2018;97(2):e9554.
www.epistemonikos.org/documents/2e580534c0bc2d654c2ffb4d692349926a20e2ee
133. Reade C.J., Riva J.J., Busse J.W., Goldsmith C.H., Elit L.. Risks and benefits of screening asymptomatic women for ovarian cancer: A systematic review and meta-analysis. *International*

- Journal of Gynecological Cancer. 2012;;E221.
www.epistemonikos.org/documents/2e9faeab4321d2d3dd3d88c9853c77ae9139c70d
134. Ahmed-Lecheheb D, Joly F. Ovarian cancer survivors' quality of life: a systematic review. *Journal of cancer survivorship : research and practice*. 2016;10(5):789-801. www.epistemonikos.org/documents/2edadce35dbe5a656d30fd7c62a8e9409760f18b
135. Jin M, Cai J, Wang X, Zhang T, Zhao Y. Successful maintenance therapy with apatinib in platinum-resistant advanced ovarian cancer and literature review. *Cancer biology & therapy*. 2018;19(12):1-5.
www.epistemonikos.org/documents/2efe48524f7c14a4c42398ecb07447f6a9f28b66
136. Qin LQ, Xu JY, Wang PY, Hashi A, Hoshi K, Sato A. Milk/dairy products consumption, galactose metabolism and ovarian cancer: meta-analysis of epidemiological studies. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. 2005;14(1):13-9. www.epistemonikos.org/documents/2f33a5de8223c924078305bbd8dcb4cddf654e08
137. Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum, Jo Morrison. Angiogenesis inhibitors for the treatment of ovarian cancer. *Cochrane database of systematic reviews (Online)*. 2011;9(9):CD007930.
www.epistemonikos.org/documents/30adb8d97dd5340cba43e3691662017af9a6e731
138. Aravantinos G, Pectasides D. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. *Journal of ovarian research*. 2014;7(1):57.
www.epistemonikos.org/documents/30d9d7fb12300291a7f51ef9069b9fc433f536d6
139. Ma YY, Guan TP, Yao HB, Yu S, Chen LG, Xia YJ, He XJ, Wang HJ, Jiang XT, Tao HQ. The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls. *PloS one*. 2013;8(1):e55019.
www.epistemonikos.org/documents/315469ffd75a1c1b7757af5f4db7a9af8b307cb6
140. Marchetti C, De Felice F, Di Pinto A, D'Oria O, Aleksa N, Musella A, Palaia I, Muzii L, Tombolini V, Benedetti Panici P. Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. *Critical reviews in oncology/hematology*. 2018;125:30-34. www.epistemonikos.org/documents/31846ea96168084c0c8b2cc86abc80314514cfbb
141. Raouf S, Bertelli G, Ograbek A, Field P, Tran I. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review. *Future oncology (London, England)*. 2019;15(5):543-561.
www.epistemonikos.org/documents/319497e185e64cf94f4a446166a736a5f6f5c5d6
142. Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. *Obstetrics and gynecology*. 2004;103(4):785-94.
www.epistemonikos.org/documents/31ea8d647f560e2d1cd12aafadd79b23e694313e
143. Wu Y, Lu M, Zhou Q. Kallikrein expression as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. *Journal of B.U.ON. : official journal of the Balkan Union of Oncology*. 2015;20(3):855-61.
www.epistemonikos.org/documents/3262ec057a67084270b7475cf8e0feb62082fd26
144. Zheng B, Shen H, Han H, Han T, Qin Y. Dietary fiber intake and reduced risk of ovarian cancer: a meta-analysis. *Nutrition journal*. 2018;17(1):99. www.epistemonikos.org/documents/32e5146ffae1cec99d23eef8d74d45665063a959
145. Parvaresh A., Razavi R., Rafie N., Ghiasvand R., Pourmasoumi M., Miraghajani M.. Quercetin and ovarian cancer: An evaluation based on a systematic review. *Journal of Research in Medical Sciences*. 2016;21(2).
www.epistemonikos.org/documents/331dee482abffbf0112e50ef145607bb108d8f7d
146. Luo H, Xu X, Ye M, Sheng B, Zhu X. The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies. *PloS one*.

- 2018;13(1):e0191972. www.epistemonikos.org/documents/335946d0a7af3e16b4a744676c2d3d1e64ff76f4
147. Troiano, Gianmarco, Nantea, Nicola, Cozzolino, Mauro. The Angelina Jolie effect -- Impact on breast and ovarian cancer prevention. *ovarian cancer prevention: A systematic review of effects after the public announcement in May 2013. Health Education Journal.* 2017;76(6):707-715. www.epistemonikos.org/documents/3363925fffd5e1ed05154df1c78d9935a74f85b
148. Smits A, Lopes A, Das N, Kumar A, Cliby W, Smits E, Bekkers R, Massuger L, Galaal K. Surgical morbidity and clinical outcomes in ovarian cancer - the role of obesity. *BJOG : an international journal of obstetrics and gynaecology.* 2016;123(2):300-8. www.epistemonikos.org/documents/33ac0749acae1ff9f767aa375e82ccfdc6b34734
149. Murphy MA, Wentzensen N. Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America. *International journal of cancer. Journal international du cancer.* 2011;129(8):1914-22. www.epistemonikos.org/documents/33b8ca7a99bf79b450021c341dbc176895463e57
150. Zagouri F, Sergentanis TN, Chrysikos D, Dimopoulos MA, Bamias A. Epitheliones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review. *OncoTargets and therapy.* 2015;8:2187-98. www.epistemonikos.org/documents/344fc677051d48dbb96ba6ebee1841c168c4ce1
151. Buyse M, Parmar MK. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival. *European journal of cancer & clinical oncology.* 1989;25(12):1901. www.epistemonikos.org/documents/3476ac91822914dc0d46f6625f2e91331bc248f7
152. Gianuzzi X., Palma-Ardiles G., Hernandez-Fernandez W., Pasupuleti V., Hernandez A.V., Perez-Lopez F.R.. Insulin growth factor (IGF) 1, IGF-binding proteins and ovarian cancer risk: A systematic review and meta-analysis. *Maturitas.* 2016;94:22-29. www.epistemonikos.org/documents/35ace6b21696cc5f9ea80c527cde756ffee41b15
153. Colloca G, Venturino A, Governato I. CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.* 2016;18(8):813-824. www.epistemonikos.org/documents/35b170ae91cd449a0a5991fd38d02b5e86745ebb
154. Mohammadi V, Dehghani S, Larijani B, Azadbakht L. Ovarian cancer risk and nonisoflavone flavonoids intake: A systematic review of epidemiological studies. *Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.* 2016;21:123. www.epistemonikos.org/documents/35b4a814e00f93390d8893ee143edc7deca18c93
155. Reviews of effectiveness. Screening for ovarian cancer: a systematic review... R. Bell, M. Petticrew, S. Luengo, and T.A. Sheldon. *Health Technology Assessment Vol 2 No. 2 1998 pp. 1-84. British Journal of Clinical Governance.* 1999;4(3):117-118. www.epistemonikos.org/documents/36005cb23487c6e12ec87d130cf7c42521f2791a
156. Zhou M, Yu P, Qu X, Liu Y, Zhang J. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. *PloS one.* 2013;8(12):e81858. www.epistemonikos.org/documents/364947054dce42c1d9b5a19179a333883d196fa9
157. Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* 2013;23(1):25-33. www.epistemonikos.org/documents/36e4c0ef3ab41c3954b74dbafd36f6fbcd58bc07
158. Chittenden B., Fullerton G., Maheshwari A., Bhattacharya S.. Polycystic ovarian syndrome and the risk of gynaecological cancer: A systematic review. *International Journal of Gynecology*

- and Obstetrics. 2009;:S142.
www.epistemonikos.org/documents/372836131fde50c4be163baf0b86c43888ccad4a
159. Safarpour D., Tavassoli F., Jabbari B.. Intramedullary metastasis from ovarian cancer: A systematic review of the literature. *Neurology*. 2015;
www.epistemonikos.org/documents/375e9cf51571e6c6f5c1c2b81e0263cf5ba55482
160. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta-analysis. *Human reproduction update*. 2013;19(2):105-23.
www.epistemonikos.org/documents/3794b3a3b7f2702c9465944feef7acdf3bf4ee2b
161. Shi JX, Qin JJ, Ye H, Wang P, Wang KJ, Zhang JY. Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis. *Expert review of molecular diagnostics*. 2015;15(6):829-52.
www.epistemonikos.org/documents/387b131d53c8218f650987bfb4cdf640bbd7a203
162. Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, Sherman ME, Hollenbeck A, Wentzensen N. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review. *Cancer causes & control : CCC*. 2012;23(11):1839-52.
www.epistemonikos.org/documents/38960b3a66e5034aa0c28daf4e5c8fb7f8fc1954
163. Cui L, Kwong J, Wang CC. Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis. *Journal of ovarian research*. 2015;8(1):38.
www.epistemonikos.org/documents/38d5937d619e90bfb1582ac97c75d95d38e01e2e
164. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. *Cancer*. 2009;115(3):531-9.
www.epistemonikos.org/documents/390495cb1314808f848670866c015bd1f5c9123d
165. Hu J, Hu Y, Hu Y, Zheng S. Intake of cruciferous vegetables is associated with reduced risk of ovarian cancer: a meta-analysis. *Asia Pacific journal of clinical nutrition*. 2015;24(1):101-9.
www.epistemonikos.org/documents/39a60bf3195332687195070aeec83e9b61fbb2e1
166. Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: A meta-analysis (*Onco Targets Ther*, (2013), 6, (957-966)). *OncoTargets and Therapy*. 2014;7:135. www.epistemonikos.org/documents/39b795b37333cb1e4420639c0c5df6e2b0f15aaf
167. Yuan C, Wang C, Liu X, Kong B. Analyze association of the progesterone receptor gene polymorphism PROGINS with ovarian cancer risk. *Molecular biology reports*. 2013;40(10):6001-10.
www.epistemonikos.org/documents/39cf112f4aa8356296199f562781f62ee3025a15
168. Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, Lu Z. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. *BMC cancer*. 2018;18(1):288.
www.epistemonikos.org/documents/39dcac050e0c9d403b84502a2be081a3559275e7
169. Dai C, Cao J, Zeng Y, Xu S, Jia X, Xu P. E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis. *Oncotarget*. 2017;8(46):81052-81061.
www.epistemonikos.org/documents/39f58a39161db41d773506975428d511adffcda1
170. Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. *Gynecologic oncology*. 2011;123(3):610-4.
www.epistemonikos.org/documents/3a7545a46952a66a881bd689a1bdf2cbe5d2da0
171. Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer. *Health technology assessment (Winchester, England)*. 2001;5(28):1-110.
www.epistemonikos.org/documents/3af88bf578f76364f8616e4a89e3b4e0abf99fe1
172. Wu J, Fu Z, Liu G, Xu P, Xu J, Jia X. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. *Medicine*. 2017;96(25):e7062.
www.epistemonikos.org/documents/3b259ff89d98cad0bd251b452e88f1ca6242a66b

173. Zhou Y, Bian B, Yuan X, Xie G, Ma Y, Shen L. Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis. *PloS one*. 2015;10(6):e0130873. www.epistemonikos.org/documents/3c3a05faf71b167dc2ab932f2e1ca443431eaf39
174. Zhang Z, Xiang Q, Mu G, Xie Q, Chen S, Zhou S, Hu K, Cui YM. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy: A systematic review and MOOSE-compliant meta-analysis. *Medicine*. 2018;97(45):e12996. www.epistemonikos.org/documents/3c85921ba559e55983c2591e68ca08eb97a6f84d
175. Heatley MK. Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma from gastric carcinoma: a systematic review with statistical meta-analysis. *Histopathology*. 2008;52(3):267-76. www.epistemonikos.org/documents/3c8d12a64104bb5256f702709be48dcdb9292ab2
176. Wang Y, Wang D, Ren M. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: a meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(1):33-8. www.epistemonikos.org/documents/3cacede40db74bd53966796e6ac5b65b74d44567
177. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. *Gynecologic oncology*. 2002;84(2):201-9. www.epistemonikos.org/documents/3ccd10886c62d18b40c6b3a377a826bfc9ec2cfc
178. Darelus A, Lycke M, Kindblom JM, Kristjansdottir B, Sundfeldt K, Strandell A. Efficacy of salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer: a systematic review. *BJOG : an international journal of obstetrics and gynaecology*. 2017;124(6):880-889. www.epistemonikos.org/documents/3e375dca35b6014b65e15c9d455efbfd3325a79e
179. Buhling KJ, Lezon S, Eulenburg C, Schmalfeldt B. The role of transvaginal ultrasonography for detecting ovarian cancer in an asymptomatic screening population: a systematic review. *Archives of gynecology and obstetrics*. 2017;295(5):1259-1268. www.epistemonikos.org/documents/3e853a4e89a31f6fe1e4785edae5be37002ca0af
180. Sjoquist K.M., Lord S.J., Friedlander M.L., John Simes R., Marschner I.C., Lee C.K.. Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. *Therapeutic Advances in Medical Oncology*. 2018;10(no pagination). www.epistemonikos.org/documents/3eaace0003119111d4dcd9475bba7b08ef11b4f4
181. Pignata S, Vermorken JB. Ovarian cancer in the elderly. *Critical reviews in oncology/hematology*. 2004;49(1):77-86. www.epistemonikos.org/documents/3fbb404956d4288cfd2af481fbf7493a010d644d
182. Liu C.. Pathological and prognostic significance of matrix metalloproteinase-2 expression in ovarian cancer: a meta-analysis. *Clinical and Experimental Medicine*. 2016;16(3):375-382. www.epistemonikos.org/documents/3fc2bd13402981212cf54c16ed18fa9507c05ec9
183. Aune D., Navarro Rosenblatt D., Chan D., Abar L., Vingeliene S., Vieira A., Greenwood D., Norat T.. Anthropometric factors and ovarian cancer risk: A systematic review and meta-analysis of prospective studies in the WCRF/AICR continuous update project. *Obesity Reviews*. 2014;86. www.epistemonikos.org/documents/3fdd515bce44db399504af41c440966c49aa9a94
184. Jiang PY, Jiang ZB, Shen KX, Yue Y. Fish intake and ovarian cancer risk: a meta-analysis of 15 case-control and cohort studies. *PloS one*. 2014;9(4):e94601. www.epistemonikos.org/documents/40a3731c5f5f406adf43344c13ca2e572b522d77
185. Hoogendam JP, Vlek CA, Witteveen PO, Verheijen R, Zweemer RP. Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta-analysis. *BJOG : an international journal of obstetrics and gynaecology*. 2017;124(3):370-378. www.epistemonikos.org/documents/4146ea4f38b2474c866c37816e7a90c7f8ff52bd

186. Helder-Woolderink JM, Blok EA, Vasen HF, Hollema H, Mourits MJ, De Bock GH. Ovarian cancer in Lynch syndrome; a systematic review. *European journal of cancer (Oxford, England : 1990)*. 2016;55:65-73.
www.epistemonikos.org/documents/414ee4083c21a88ba5bf8ab797fc51132b467b99
187. Zhang D, Kaushiva A, Xi Y, Wang T, Li N. Non-Herbal Tea Consumption and Ovarian Cancer Risk. A Systematic Review and Meta-Analysis of Observational Epidemiologic Studies with Indirect Comparison and Dose-Response Analysis. *Carcinogenesis*. 2018;39(6):808-818.
www.epistemonikos.org/documents/414ef16341de0b08e6fb474d9461cfe25b0e6681
188. Hu T, Zhao H, Wang K, Sun W, Li L, Wang W. Association of IL-27 polymorphisms and cancer risk in Chinese population. *Journal of receptor and signal transduction research*. 2015;35(2):180-3.
www.epistemonikos.org/documents/415051d62d752d988e4455282d8a0f55c61aab55
189. Zhan X, Wang J, Pan S, Lu C. Tea consumption and the risk of ovarian cancer: A meta-analysis of epidemiological studies. *Oncotarget*. 2017;8(23):37796-37806.
www.epistemonikos.org/documents/4166464d4cb60ffe282914a0f8156a890aa3d183
190. Krok-Schoen JL, Oliveri JM, Paskett ED. Cancer Care Delivery and Women's Health: The Role of Patient Navigation. *Frontiers in oncology*. 2016;6:2.
www.epistemonikos.org/documents/41e0a0dd8c447a1efe59a1e2c48e8be1bb2f10b4
191. Chen Y, Zhang L, Hao Q. Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. *Cancer cell international*. 2013;13(1):86.
www.epistemonikos.org/documents/41f4df465707d292598a4b39d68d89ccfd0ef8dd
192. Lago V, Minig L, Fotopoulou C. Incidence of Lymph Node Metastases in Apparent Early-Stage Low-Grade Epithelial Ovarian Cancer: A Comprehensive Review. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2016;26(8):1407-1414.
www.epistemonikos.org/documents/4201dcf95beba2ca921509d0145533952e99dc78
193. Schüller S, Ponnath M, Engel J, Ortman O. Ovarian epithelial tumors and reproductive factors: a systematic review. *Archives of gynecology and obstetrics*. 2013;287(6):1187-204.
www.epistemonikos.org/documents/42e0c96714e13da4928285e82658c557f6acc1c3
194. Fang J, Guo X, Zheng B, Han W, Chen X, Zhu J, Xie B, Liu J, Luan X, Yan Y, He Z, Li H, Qiao C, Yu J. Correlation between NM23 protein overexpression and prognostic value and clinicopathologic features of ovarian cancer: a meta-analysis. *Archives of gynecology and obstetrics*. 2018;297(2):449-458.
www.epistemonikos.org/documents/42eb5bdc7d4b4bf59ac30fff2995518a8db2cf06
195. Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: Individual participant meta-analysis of 52 epidemiological studies. *The Lancet*. 2015;385(9980):1835-1842.
www.epistemonikos.org/documents/433d5e4477d7b845a7e5abf828eec0acdc70a3b8
196. Falchetta, Frederico S, Lawrie, Theresa A, Medeiros, Lídia RF, da Rosa, Maria Ines, Edelweiss, Maria I, Stein, Airtton T, Zelmanowicz, Alice, Moraes, Anaelena B, Zanini, Roselaine R, Rosa, Daniela D. Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. *Cochrane Database of Systematic Reviews*. 2016;10:CD005344.
www.epistemonikos.org/documents/43417b974faebc3427fa14dfdca81240a7b6e4ad
197. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, Bernard L, Maisonneuve P, Gandini S. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. *European journal of cancer (Oxford, England : 1990)*. 2010;46(12):2275-2284.
www.epistemonikos.org/documents/43b8c8856d585595c68a9c4b2ae5b12a3f265d52
198. Mousavi A., Karimi-Zarchi M., Behtash N., Modares-Gilani M., Mokhtari-Gorgani M., Mehrdad N., Rouhi M., Anari P.Y.. The role of intraperitoneal carboplatin as consolidation

- chemotherapy in women with ovarian carcinoma: Report of our experience and systematic review. *International Journal of Biomedical Science*. 2016;12(4):120-124. www.epistemonikos.org/documents/4418e9c4484d4a59787c86c9b270653f5e976543
199. Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjær SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N, Ovarian Cancer Association Consortium. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. *Journal of the National Cancer Institute*. 2014;106(2):djt431. www.epistemonikos.org/documents/450f1486f3dcf591626384d50972292ed136827c
200. Foster T, Brown TM, Chang J, Menssen HD, Blieden MB, Herzog T.J. A review of the current evidence for maintenance therapy in ovarian cancer. *Gynecologic oncology*. 2009;115(2):290-301. www.epistemonikos.org/documents/455be5edf8b0f873a96f79f830358bf267337a37
201. Tang L., Li J., Bao M., Xiang J., Chen Y., Wang Y.. Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: A meta-analysis. *OncoTargets and Therapy*. 2018;11:1055-1066. www.epistemonikos.org/documents/45e1b844951788e264eebec89c01009bffb9c73a
202. Wang H., Cui M., Zhang S., He J., Song L., Chen Y.. Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis. *Gynecologic and Obstetric Investigation*. 2018;83(4):349-357. www.epistemonikos.org/documents/46668f5bdacd7241df0be08438ef036deec22508
203. Xu H, Li S, Qiu JQ, Gao XL, Zhang P, Yang YX. The VDR gene FokI polymorphism and ovarian cancer risk. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2013;34(6):3309-16. www.epistemonikos.org/documents/471511c4c2482fdee1a8da779852637b27fc47fd
204. Bamia C., Turati F., Guercio V., Guha N., Loomis D., Tavani A.. Coffee intake and risk of breast and ovarian cancer: Updated systematic review and meta-analysis. *Annals of Nutrition and Metabolism*. 2017;;950-951. www.epistemonikos.org/documents/4794906ccb0862ce84d91cb6913ac883f636b6cb
205. Fan S.-Y., Wang J., Liu Y., Zhou H.-P., Dong X.-P., Qian H.-L.. Efficacy and safety of paclitaxel and carboplatin for ovarian cancer: A meta-analysis. *Medical Journal of Chinese People's Liberation Army*. 2016;41(7):589-597. www.epistemonikos.org/documents/47db41fd5d31f4170d6d5c00c313b1ae9ef712bf
206. Sharma V, Sundar SS, Breheny K, Monahan M, Sutton AJ. Methods Used in Economic Evaluations of Testing and Diagnosis for Ovarian Cancer: A Systematic Review. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2016;26(5):865-72. www.epistemonikos.org/documents/47ddc81723fd74b8ce1db3b58f5459872417c303
207. du Bois A, Lück HJ, Pfisterer J, Meier W, Bauknecht T. [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum]. *Zentralblatt für Gynäkologie*. 2000;122(5):255-67. www.epistemonikos.org/documents/481d450307672f3503192db94cac157ec01eee92
208. Zhou J, Shan G, Chen Y. The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis. *Japanese journal of clinical oncology*. 2016;46(8):718-726. www.epistemonikos.org/documents/482f2da66e93538c00b3b19917cc40aba44c2e67
-

209. Fung MF, Bryson P, Johnston M, Chambers A, Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Screening postmenopausal women for ovarian cancer: a systematic review. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC*. 2004;26(8):717-28. www.epistemonikos.org/documents/48aac33a66d17601d140f2361ee971413e11a21f
210. Pharoah P.D.P., Tsai Y.-Y., Ramus S.J., Phelan C.M., Goode E.L., Lawrenson K., Buckley M., Fridley B.L., Tyrer J.P., Weber R., Karevan R., Larson M.C., Song H., Tessier D.C., Bacot F., Vincent D., Cunningham J.M., Dennis J., Dicks E., Aben K.K., Anton-Culver H., Antonenkova N., Armasu S.M., Baglietto L., Bandera E.V., Beckmann M.W., Birrer M.J., Bloom G., Bogdanova N., Brenton J.D., Brinton L.A., Brooks-Wilson A., Brown R., Butzow R., Campbell I., Carney M.E., Carvalho R.S., Chang-Claude J., Chen Y.A., Chen Z., Chow W.-H., Cicek M.S., Coetzee G., Cook L.S., Cramer D.W., Cybulski C., Dansonka-Mieszkowska A., Despierre E., Doherty J.A., Dork T., Du Bois A., Durst M., Eccles D., Edwards R., Ekici A.B., Fasching P.A., Fenstermacher D., Flanagan J., Gao Y.-T., Garcia-Closas M., Gentry-Maharaj A., Giles G., Gjysli A., Gore M., Gronwald J., Guo Q., Halle M.K., Harter P., Hein A., Heitz F., Hillemanns P., Hoatlin M., Hogdall E., Hogdall C.K., Hosono S., Jakubowska A., Jensen A., Kalli K.R., Karlan B.Y., Kelemen L.E., Kiemenev L.A., Kjaer S.K., Konecny G.E., Krakstad C., Kupryjanczyk J., Lambrechts D., Lambrechts S., Le N.D., Lee N., Lee J., Leminen A., Lim B.K., Lissowska J., Lubinski J., Lundvall L., Lurie G., Massuger L.F.A.G., Matsuo K., McGuire V., McLaughlin J.R., Menon U., Modugno F., Moysich K.B., Nakanishi T., Narod S.A., Ness R.B., Nevanlinna H., Nickels S., Noushmehr H., Odunsi K., Olson S., Orlow I., Paul J., Pejovic T., Pelttari L.M., Permut-Wey J., Pike M.C., Poole E.M., Qu X., Risch H.A., Rodriguez-Rodriguez L., Rossing M.A., Rudolph A., Runnebaum I., Rzepecka I.K., Salvesen H.B., Schwaab I., Severi G., Shen H., Shridhar V., Shu X.-O., Sieh W., Southey M.C., Spellman P., Tajima K., Teo S.-H., Terry K.L., Thompson P.J., Timorek A., Tworoger S.S., Van Altena A.M., Van Den Berg D., Vergote I., Vierkant R.A., Vitonis A.F., Wang-Gohrke S., Wentzensen N., Whittemore A.S., Wik E., Winterhoff B., Woo Y.L., Wu A.H., Yang H.P., Zheng W., Ziogas A., Zulkifli F., Goodman M.T., Hall P., Easton D.F., Pearce C.L., Berchuck A., Chenevix-Trench G., Iversen E., Monteiro A.N.A., Gayther S.A., Schildkraut J.M., Sellers T.A.. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*. 2013;45(4):362-370. www.epistemonikos.org/documents/48b2655ee12ba5976131dc9f3d5c1f7a4097d8bd
211. Elit L, Chambers A, Fyles A, Covens A, Carey M, Fung MF. Systematic review of adjuvant care for women with Stage I ovarian carcinoma. *Cancer*. 2004;101(9):1926-35. www.epistemonikos.org/documents/48b2920f093c5a0d91ff3bf021a314e808990c58
212. Tang L, Li J, Bao M, Xiang J, Chen Y, Wang Y. Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis. *Oncotargets and therapy*. 2018;11:1055-1066. www.epistemonikos.org/documents/49069c070205e0dc8d911dbd1907f26d990b9260
213. Bristow R.E., Chi D.S.. Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer: A meta-analysis. *Gynecologic Oncology*. 2007;106(1):274-275. www.epistemonikos.org/documents/491d04dfb0c67ea82d1284b00e3d768b84c2b9a6
214. Geomini P, Kruitwagen R, Bremer GL, Clossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. *Obstetrics and gynecology*. 2009;113(2 Pt 1):384-94. www.epistemonikos.org/documents/491f5e1cca1e1486744ba23ae4943bddb5938eab
215. Cheng D, Shi H, Zhang K, Yi L, Zhen G. RAD51 Gene 135G/C polymorphism and the risk of four types of common cancers: a meta-analysis. *Diagnostic pathology*. 2014;9:18. www.epistemonikos.org/documents/493541c34ddac7ed25e03899865c71fcc43e0649
216. Messori A, Trippoli S, Becagli P, Tendi E. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation. *Anti-cancer drugs*. 1998;9(6):491-502. www.epistemonikos.org/documents/496fd845450afdd989eb9c79b795f867e2a2e788
217. Scaletta G, Plotti F, Luvero D, Capriglione S, Montera R, Miranda A, Lopez S, Terranova C, De Cicco Nardone C, Angioli R. The role of novel biomarker HE4 in the diagnosis, prognosis and

- follow-up of ovarian cancer: a systematic review. Expert review of anticancer therapy. 2017;17(9):1-13.
www.epistemonikos.org/documents/49869275e54e6b79c6b3f3b79649e3f8aba43f61
218. Wang H, Li Z, Sun Y, Xu Z, Han J, Song B, Song W, Qin C, Yin L. Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: a meta-analysis. *OncoTargets and therapy*. 2015;8:3523-31.
www.epistemonikos.org/documents/4a00aba5aab2bc7e506320bd1411afd8ef5bd079
219. Thuria Al Rawahi, Alberto D Lopes, Robert E Bristow, Andrew Bryant, Ahmed Elattar, Supratik Chattopadhyay, Khadra Galaal. Surgical cytoreduction for recurrent epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2013;2(2):CD008765.
www.epistemonikos.org/documents/4a1cfdd07ea45c360a3e812b9ac6a99bf4f50291
220. Alipour S, Zoghi S, Khalili N, Hirbod-Mobarakeh A, Emens LA, Rezaei N. Specific immunotherapy in ovarian cancer: a systematic review. *Immunotherapy*. 2016;8(10):1193-204.
www.epistemonikos.org/documents/4a53c58ce91d92dd4c0a338d56c74a187ae56a52
221. Byrne T, Coleman HG, Cooper JA, McCluggage WG, McCann A, Furlong F. The association between MAD2 and prognosis in cancer: a systematic review and meta-analyses. *Oncotarget*. 2017;8(60):102223-102234.
www.epistemonikos.org/documents/4b23c85d6f6a94821d49860593ec580051e89bd8
222. Uson P.L.S., Bugano D.D.G., Franca M.S., Antunes Y.P.P.V., Taranto P., Kaliks R.A., Del Giglio A.. Does Time-to-Chemotherapy Impact the Outcomes of Resected Ovarian Cancer? Meta-analysis of Randomized and Observational Data. *International Journal of Gynecological Cancer*. 2017;27(2):274-280.
www.epistemonikos.org/documents/4b26e90a06add0807c06ce929a8c200306bb2eb4
223. Ning L, Hu YC, Wang S, Lang JH. Altered long noncoding RNAs and survival outcomes in ovarian cancer: A systematic review and meta-analysis (PRISMA Compliant). *Medicine*. 2018;97(32):e11481.
www.epistemonikos.org/documents/4b5f97273452118312645fdb059dd03e8922f
224. Hotouras A, Desai D, Bhan C, Murphy J, Lampe B, Sugarbaker PH. Heated IntraPeritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2016;26(4):661-70.
www.epistemonikos.org/documents/4bb604b2d0c66541d6a6178cb0457c0ba4fd43db
225. Brilhante AV, Augusto KL, Portela MC, Sucupira LC, Oliveira LA, Pouchaim AJ, Nóbrega LR, Magalhães TF, Sobreira LR. Endometriosis and Ovarian Cancer: an Integrative Review (Endometriosis and Ovarian Cancer). *Asian Pacific journal of cancer prevention : APJCP*. 2017;18(1):11-16.
www.epistemonikos.org/documents/4c121ea9ce4dbf4a8ac264a1ea45710d45b8d3dd
226. Ma XM, Sun X, Yang GW, Yu MW, Zhang GL, Yu J, Zhang Y, Wang XM. The platelet-to-lymphocyte ratio as a predictor of patient outcomes in ovarian cancer: a meta-analysis. *Climacteric : the journal of the International Menopause Society*. 2017;20(5):1-8.
www.epistemonikos.org/documents/4c411ee0c3b95c952c64c33922b1d19e6d7cc87a
227. Madhuri TK, Tailor A, Haagsma B, Coley H, Butler-Manuel S. Relevance of immunohistochemical expression of p57kip2 in epithelial ovarian carcinoma- A systematic literature review. *Journal of ovarian research*. 2012;5(1):46.
www.epistemonikos.org/documents/4c4acd004f5f091a6d8c1a7b3b5f751aa42dd2c5
228. Muscat JE, Huncharek MS. Perineal talc use and ovarian cancer: a critical review. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. 2008;17(2):139-46.
www.epistemonikos.org/documents/4c62b009df3511287bd848d956e59c7f228658f1
229. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. *Gynecologic*

- oncology. 2009;112(1):257-64.
www.epistemonikos.org/documents/4d5db3e7a391323f0fb70c1ac6c2380ba33fb2fc
230. Bankhead CR, Kehoe ST, Austoker J, Cancer Research UK Primary Care Education Research Group, University of Oxford, Old Road Campus, Old Road, Headington, Oxford, UK. Symptoms associated with diagnosis of ovarian cancer: a systematic review. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2005;112(7):857-865.
www.epistemonikos.org/documents/4f0c0e0ed95fe69c43ce7e0d859c39901f935305
231. Li X, Zhou J. Impact of post-diagnostic statin use on ovarian cancer mortality: a systematic review and meta-analysis of observational studies. *British journal of clinical pharmacology*. 2018;84(6):1109-1120.
www.epistemonikos.org/documents/4f2792d8ae1e8611d8606d25fe3df870cd9c2226
232. Pearce CL, Wu AH, Gayther SA, Bale AE, Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjaer SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb PM, Whitman DC, Whittemore AS, Zheng W, Pharoah PD, Chenevix-Trench G, Pike MC, Schildkraut J, Berchuck A, Ovarian Cancer Association Consortium. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. *British journal of cancer*. 2008;98(2):282-8.
www.epistemonikos.org/documents/4fa27dcd7e50351dbbbee58e85bc263040292bc4
233. Rutten MJ, van de Vrie R, Bruining A, Spijkerboer AM, Mol BW, Kenter GG, Buist MR. Predicting Surgical Outcome in Patients With International Federation of Gynecology and Obstetrics Stage III or IV Ovarian Cancer Using Computed Tomography: A Systematic Review of Prediction Models. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2015;25(3):407-15.
www.epistemonikos.org/documents/4fc976d93755599ef754fa0b204af696071b2f2a
234. Gu HF, Zhou Y, Li YX, Ou YL, Liu JH. [Prognostic significance of systematic retroperitoneal lymphadenectomy in patients with epithelial ovarian cancer: a Meta-analysis]. *Zhonghua yi xue za zhi*. 2016;96(37):3020-3025.
www.epistemonikos.org/documents/506f356f70b4f83e570831416138b902308953b4
235. Jia MM, Deng J, Cheng XL, Yan Z, Li QC, Xing YY, Fan DM, Tian XY. Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis. *Oncotarget*. 2017;8(6):9660-9671.
www.epistemonikos.org/documents/5082b5341a813f4959bd80e632a4fdc9b72fd4a
236. Sweet ES, Standish LJ, Goff BA, Andersen MR. Adverse events associated with complementary and alternative medicine use in ovarian cancer patients. *Integrative cancer therapies*. 2013;12(6):508-16.
www.epistemonikos.org/documents/50af1db849f756addb9ab3e05d972a72ca2e66af
237. Sun C, Li N, Ding D, Weng D, Meng L, Chen G, Ma D. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. *PloS one*. 2014;9(5):e95285.
www.epistemonikos.org/documents/51b08b66ebda5f8d9eef94984ec4894fcfa1ddc0
238. Feng D., Liu J.-L., Xu C.-A.. Meta-analysis of case-control trials on risk factors of ovarian neoplasm. *Chinese Journal of Cancer Prevention and Treatment*. 2010;17(22):1805-1807+1827.
www.epistemonikos.org/documents/520b1b08cc5dd246fb6113acd6c2c894add74b7a
239. Iavazzo C., Papakiritsis M., Gkegkes I.D.. A systematic review of the correlation of hypodontia with ovarian cancer. *International Journal of Gynecological Cancer*. 2016;:729.
www.epistemonikos.org/documents/52489a9c32bf1636864e653aa988678d8fcd6c62
240. Borley J, Wilhelm-Benartzi C, Brown R, Ghaem-Maghami S. Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review. *British journal of cancer*. 2012;107(7):1069-74.
www.epistemonikos.org/documents/525cc1f8dd04a5a54a813a071146017c9ef99e41

241. Howard AF, Balneaves LG, Botorff JL. Women's decision making about risk-reducing strategies in the context of hereditary breast and ovarian cancer: a systematic review. *Journal of genetic counseling*. 2009;18(6):578-97.
www.epistemonikos.org/documents/53cf28b5057ae9b2b8d77f632953c42e6323d320
242. Luan NN, Wu QJ, Gong TT, Vogtmann E, Wang YL, Lin B. Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. *The American journal of clinical nutrition*. 2013;98(4):1020-31.
www.epistemonikos.org/documents/5438bd4c71ade83fb77ee55ecbb10d2bfc96311d
243. CHAI Cheng-liang, WANG Xiao-hui, CUI Yan, SHI Xiao-fang. Effectiveness and Safety of Intraperitoneal Hyperthermic Perfusion Chemotherapy for Ovarian Cancer: A Systematic Review. *中国循证医学杂志 (Chinese Journal of Evidence-Based Medicine)*. 2014;10(2014):1247-1253.
www.epistemonikos.org/documents/5464082b14a9381aecf46cbfb1321f9e3d8dfb39
244. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. *Expert review of anticancer therapy*. 2011;11(8):1197-207.
www.epistemonikos.org/documents/54c1338202322374f4a3f38849adedc2ba399b15
245. Jo Morrison, Krishnayan Haldar, Sean Kehoe, Theresa A Lawrie. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. *Cochrane Database of Systematic Reviews*. 2012;8(8):CD005343.
www.epistemonikos.org/documents/54cb8cbf7bb50e1ad094451dc4de72691016971d
246. Zeff N.. Role of laparoscopy in initial tumour staging in advanced epithelial ovarian cancer: A systematic review. *Pleura and Peritoneum*. 2018;3(1):20180106.
www.epistemonikos.org/documents/554f6b76aa85b2c823b3f5e600d8bf38139a2c3d
247. Zhang D., Li N., Xi Y., Zhao Y., Wang T.. Diabetes mellitus and risk of ovarian cancer. A systematic review and meta-analysis of 15 cohort studies. *Diabetes Research and Clinical Practice*. 2017;130:43-52.
www.epistemonikos.org/documents/5584cfd3b5f1cac2bda0d519e285b67f4322f0c4
248. Du JZ, Dong YL, Wan GX, Tao L, Lu LX, Li F, Pang LJ, Jia W. Lack of association between the COMT rs4680 polymorphism and ovarian cancer risk: evidence from a meta-analysis of 3,940 individuals. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(18):7941-5.
www.epistemonikos.org/documents/5585b6c395d8aa072bf4bdb158093e69bd6d4b81
249. Dovern E, de Hingh IH, Verwaal VJ, van Driel WJ, Nienhuijs SW. Hyperthermic intraperitoneal chemotherapy added to the treatment of ovarian cancer. A review of achieved results and complications. *European journal of gynaecological oncology*. 2010;31(3):256-61.
www.epistemonikos.org/documents/55fd3e7d839fe962e05b0615c371ae5c7c5f0c13
250. Jiang X.-P., Rui X.-H., Guo C.-X., Huang Y.-Q., Li Q., Xu Y.. A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer. *Oncotarget*. 2017;8(12):19125-19136.
www.epistemonikos.org/documents/562e646d60e3e717afc800bb5c1372a1c278eb77
251. Gerestein CG, Damhuis RA, Burger CW, Kooi GS. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. *Gynecologic oncology*. 2009;114(3):523-7.
www.epistemonikos.org/documents/564ad416d7eabcf244c2ba866644ccfa4b646ac8
252. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. *Obstetrics and gynecology*. 1998;92(3):472-9.
www.epistemonikos.org/documents/5664e8c38fdb7f2f33158ba35b0389f1ef60969
253. Qiao JJ, Yu J, Yu Z, Li N, Song C, Li M. Contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors. *PloS one*. 2015;10(3):e0118872.
www.epistemonikos.org/documents/567933e19a2bc3dc4ba2be6b58812a4e36605f5a

254. Prodromidou A, Andreakos P, Kazakos C, Vlachos DE, Perrea D, Pergialiotis V. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. *Inflammation research : official journal of the European Histamine Research Society ... [et al.]*. 2017;66(6):1-9. www.epistemonikos.org/documents/5699c7b7a682ffc47c01b38dea18beb2b09dbf88
255. Song JL, Chen C, Yuan JP, Sun SR. The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis. *Familial cancer*. 2017;16(3):1-11. www.epistemonikos.org/documents/56e1c369a12c54935267da4e1d3669e8cfd7df7
256. Vitale SG, Marilli I, Lodato M, Tropea A, Cianci A. The role of cytoreductive surgery in advanced-stage ovarian cancer: a systematic review. *Updates in surgery*. 2013;65(4):265-70. www.epistemonikos.org/documents/56fc44fa9e030fd1dd1b9e990463b494011a91a0
257. Ahmed Elattar, Andrew Bryant, Brett A Winter-Roach, Mohamed Hatem, Raj Naik. Optimal primary surgical treatment for advanced epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2011;(8):CD007565. www.epistemonikos.org/documents/577154c78e6fa575596a23bce7d08d7aa87b4181
258. du Bois A, Heitz F, Harter P. Fertility-sparing surgery in ovarian cancer: a systematic review. *Onkologie*. 2013;36(7-8):436-43. www.epistemonikos.org/documents/5793c74f72c71f11c0094b5074d97e610967a008
259. Huang QT, Zhou L, Zeng WJ, Ma QQ, Wang W, Zhong M, Yu YH. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*. 2017;41(6):2411-2418. www.epistemonikos.org/documents/5875fe044ae20c4b598d411534b4cd0dd7d5bc0a
260. Reade C., Tsoi B., Tanvejsilp P., Hanson M., Marcotte M., Goeree R.. A systematic review of economic evaluations on the treatment of ovarian cancer: What have we learned in the past 10 years?. *Gynecologic Oncology*. 2013;;e41. www.epistemonikos.org/documents/58b6771c28a9d574025c5c7ead84c1ea7007a3c5
261. Williams, Christopher J.. Tamoxifen in relapsed ovarian cancer: A systematic review. *International Journal of Gynecological Cancer*. 1998;8(2):89-94. www.epistemonikos.org/documents/58c0860fb567ea4307f5e6bc6b1e6370deac386f
262. Pei H.-Y., Fang F., Wu T.-X.. Topotecan for recurrent ovarian cancer: A systemic review. *Chinese Journal of Evidence-Based Medicine*. 2006;6(10):733-742. www.epistemonikos.org/documents/5a4bf01ddd8cfce2fcb5b7f57692a7b45a3ce0fb
263. Watts S, Prescott P, Mason J, McLeod N, Lewith G. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. *BMJ open*. 2015;5(11):e007618. www.epistemonikos.org/documents/5ada627407efab5106c16ba7ce496ee6eb2b2185
264. Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. *British journal of clinical pharmacology*. 2005;60(2):194-203. www.epistemonikos.org/documents/5b45317920951540f22ead04c228e022ac50aa88
265. Sehoul J., Heiss M., Lordick F., Parsons S.L., Wimberger P., Marschner A., Wagner U.. Prognostic factors for the efficacy of catumaxomab in patients with malignant ascites (MA) due to ovarian cancer (OC): Meta-analysis from two phase III studies. *International Journal of Gynecological Cancer*. 2013;;985. www.epistemonikos.org/documents/5b63e40b5d7a17960958611fb8d45be832be7bad
266. Shapiro S, Stevenson JC, Mueck AO, Baber R. Misrepresentation of the risk of ovarian cancer among women using menopausal hormones. *Spurious findings in a meta-analysis. Maturitas*. 2015;81(2):323-6. www.epistemonikos.org/documents/5bb82aad53ede9d742439f562b7f03fbb2c61514

267. Blake EA, Kodama M, Yunokawa M, Ross MS, Ueda Y, Grubbs BH, Matsuo K. Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature. *European journal of obstetrics, gynecology, and reproductive biology*. 2015;186C((Blake E.A.) Department of Obstetrics and Gynecology, University of Colorado, United States):97-105. www.epistemonikos.org/documents/5c1e7ebf76182067d09fcc2467d523777edb9228
268. Hodeib M., Bristow R.E., Changa S.-J.. Impact of complete cytoreduction to no gross residual disease on survival in patients with advanced ovarian cancer: A meta-analysis. *Gynecologic Oncology*. 2013;:249. www.epistemonikos.org/documents/5d34c25497fdc4ee978fb27e45b0705ca2181daf
269. Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A, IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. *Gynecologic oncology*. 2007;105(3):747-56. www.epistemonikos.org/documents/5d7844eb3ab9a6731e7179186d4e6f3c890256aa
270. Fortner RT, Damms-Machado A, Kaaks R. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection. *Gynecologic oncology*. 2017;147(2):465-480. www.epistemonikos.org/documents/5d93f06942cdd73f8086cae6fae173f5cf43a7f3
271. Li FY, Ren XB, Xie XY, Zhang J. Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer. *Asian Pacific journal of cancer prevention : APJCP*. 2013;14(12):7203-6. www.epistemonikos.org/documents/5db14727101e09e3a0da0ac539288b03d2b4c67b
272. Waldron L, Haibe-Kains B, Culhane AC, Riestler M, Ding J, Wang XV, Ahmadifar M, Tyekucheva S, Bernau C, Risch T, Ganzfried BF, Huttenhower C, Birrer M, Parmigiani G. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. *Journal of the National Cancer Institute*. 2014;106(5):49-49. www.epistemonikos.org/documents/5dfe281b43019021f6ecefca00916ca1d6214
273. Williams C.J., Stewart L., Parmar M., Guthrie D.. Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group. *Seminars in oncology*. 1992;19(1 Suppl 2):120-128. www.epistemonikos.org/documents/5e377613563d54c0680f5f4dd1f95ec8b98be81c
274. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2007;18(12):1943-50. www.epistemonikos.org/documents/5e6acc266f9e075ba13db7d70795174228668197
275. Liu J.-Y., Yang Y., Liu Z.-Z., Xie J.-J., Du Y.-P., Wang W.. Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis. *Molecular Genetics and Genomics*. 2015;290((Liu J.-Y.; Yang Y., sunflower0880@sina.com) Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha, China):739-65. www.epistemonikos.org/documents/5e74aafd3261c725363f2db1ac52677bc2fcded4
276. Reid A, de Klerk N, Musk AW. Does exposure to asbestos cause ovarian cancer? A systematic literature review and meta-analysis. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2011;20(7):1287-95. www.epistemonikos.org/documents/5fcd5e5f2d2b287893a3e8dc43875d472c9ef8933
277. Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. *Journal of cancer research and clinical oncology*. 2009;135(12):1637-45. www.epistemonikos.org/documents/6025b8e4b3e9bea2bb682cadabc7b30861e53012
278. Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-

- analysis. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. 2015;41(12):1578-89.
www.epistemonikos.org/documents/602b2e13e9a5b1f7b7fb36a19ac17946851eb86e
279. Li YY, Zhang WC, Zhang JL, Zheng CJ, Zhu H, Yu HM, Fan LM. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis. *Lipids in health and disease*. 2015;14(1):72.
www.epistemonikos.org/documents/607910dee547ab9e341ee99da6177dceb9a42b0f
280. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. *Gynecologic oncology*. 2005;99(2):447-61.
www.epistemonikos.org/documents/60d022373f6c924492baeccc6e58de658d434f1d
281. Bristow RE, Lagasse LD, Karlan BY. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature. *Cancer*. 1996;78(10):2049-62.
www.epistemonikos.org/documents/60d7c57e958fc8e7e635f5d4a346bf9be876057f
282. Liang XJ, Shen J. Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials. *European review for medical and pharmacological sciences*. 2016;20(12):2701-9.
www.epistemonikos.org/documents/6100aff851fbc6b3937d80d0895b089f7e110c7
283. Zeng ST, Guo L, Liu SK, Wang DH, Xi J, Huang P, Liu DT, Gao JF, Feng J, Zhang L. Egg consumption is associated with increased risk of ovarian cancer: Evidence from a meta-analysis of observational studies. *Clinical nutrition (Edinburgh, Scotland)*. 2015;34(4):635-41.
www.epistemonikos.org/documents/61c4242b7ebf22339fddcb12137c72bfbe794b87
284. Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. *Expert opinion on investigational drugs*. 2010;19(11):1339-54.
www.epistemonikos.org/documents/623e0721d0cafa082c8c4fba2f665170d950ceaa
285. Kietpeerakool C, Supoken A, Laopaiboon M, Lumbiganon P. Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. *Cochrane Database of Systematic Reviews*. 2016;1(1):CD011732.
www.epistemonikos.org/documents/62654355125a757cf2413a62f3ca29f700e61bc2
286. Kwiatkowska K., Pawlowska A., Suszczyk D., Bilaska M., Tarkowski R., Kotarski J., Wertel I.. Does obesity increase the risk of ovarian cancer? A literature review. *Current Gynecologic Oncology*. 2017;15(4):277-283.
www.epistemonikos.org/documents/6269a09a5d2aee2f510bf993528bf2b9830ccbef
287. Prodromidou A, Machairas N, Spartalis E, Kostakis ID, Iavazzo C, Moris D, Tsilimigras DI, Athanasiou A, Nikiteas N. Transperitoneal Versus Extraperitoneal Laparoscopic Lymphadenectomy for Gynecological Malignancies: A Systematic Review and Meta-analysis. *Anticancer research*. 2018;38(8):4677-4681.
www.epistemonikos.org/documents/634dd7463faf1c05931f831eae0b67b01ed24ba8
288. Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, Islami F, Negri E, Boffetta P, Bellocco R, Corrao G, La Vecchia C, Bagnardi V. Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis. *Gynecologic oncology*. 2012;125(3):758-63.
www.epistemonikos.org/documents/646d099a71fcd1fa90a042b44235e38f8634d1ac
289. Lin JY, Qin JB, Li XY, Dong P, Yin BD. Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2012;13(11):5427-32.
www.epistemonikos.org/documents/6501fcd5885109c98598ba2c088b0f5e1cbfa405
290. Liao J., Ding D., Sun C., Weng D., Meng L., Chen G., Ma D.. Polymorphisms of progesterone receptor and ovarian cancer risk: A systemic review and meta-analysis. *Journal of Obstetrics and Gynaecology Research*. 2015;41(2):178-187.
www.epistemonikos.org/documents/65cf5de62a6b8ffeb595b551e16a2409424499c7
291. Kim HS, Kim TH, Chung HH, Song YS. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. *British journal of cancer*. 2014;110(7):1878-90.
www.epistemonikos.org/documents/66126ab7125b4eefb6c26a3e7c7320aa2c370a13

292. García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelial ovarian cancer patients. Long-term single institution experience and literature review. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.* 2011;13(2):121-32. www.epistemonikos.org/documents/6631566a2e569c95068de8b83086adf4142a2028
293. Chuan T, Wei S, Xia T, Yong S. Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis. *European journal of clinical investigation.* 2018;48(5):e12917. www.epistemonikos.org/documents/669b72b88ac3ea4051689d9f50070e7045bdf994
294. Wang J, Yang DL, Chen ZZ, Gou BF. Associations of body mass index with cancer incidence among populations, genders, and menopausal status: A systematic review and meta-analysis. *Cancer epidemiology.* 2016;42:1-8. www.epistemonikos.org/documents/66b97f75e63e8555f6e6fd0d0944a837de654835
295. Geurts SM, de Vegt F, van Altena AM, van Dijck JA, Tjan-Heijnen VC, Verbeek AL, Massuger LF. Considering early detection of relapsed ovarian cancer: a review of the literature. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* 2011;21(5):837-45. www.epistemonikos.org/documents/66caadfe2a3ba55d137b075276ea81edf91c998f
296. Zhang H, Jia L, Xu Y, Zhou XC, Kong B, Li D. Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials. *Journal of chemotherapy (Florence, Italy).* 2012;24(2):67-73. www.epistemonikos.org/documents/66f0a47d4f313746fa522674ae2aebf6b895f551
297. Zhu X, Lang J. The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review. *Gynecologic oncology.* 2016;142(1):184-9. www.epistemonikos.org/documents/6756ebda3c85905a60714653e3c002164ca5caee
298. Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M, Jurkovic D. Use of IOTA simple rules for diagnosis of ovarian cancer: meta-analysis. *Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.* 2014;44(5):503-14. www.epistemonikos.org/documents/677435a0b0324b7aedef79def7b82c2e1bc813a84
299. Meys E.M.J., Kaijser J., Kruitwagen R.F.P.M., Slangen B.F.M., Van Calster B., Aertgeerts B., Verbakel J.Y., Timmerman D., Van Gorp T.. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A review and meta-analysis. *International Journal of Gynecological Cancer.* 2015;:33-34. www.epistemonikos.org/documents/67791d1171ccd3378ec95ed62a637c1f7c9f4b15
300. Paleari L, Gandini S, Provinciali N, Puntoni M, Colombo N, DeCensi A. Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. *Gynecologic oncology.* 2017;146(3):504-513. www.epistemonikos.org/documents/67b0c86ac7bf6bac5bfb639f2e84ee5afc97505e
301. Macedo AC, da Rosa MI, Lumertz S, Medeiros LR. Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.* 2014;24(7):1222-31. www.epistemonikos.org/documents/67d41ef74d2a76bd87033e90e2a4efabfcb98e04
302. Younes N, Zayed H. Genetic epidemiology of ovarian cancer in the 22 Arab countries: A systematic review. *Gene.* 2019;684:154-164. www.epistemonikos.org/documents/688449f4b6af3fd37f53631978c4e7a078c195ba
303. Zeng L, Liang X, Liu Q, Yang Z. The Predictive Value of Circulating Tumor Cells in Ovarian Cancer: A Meta Analysis. *International journal of gynecological cancer : official journal of the*

- International Gynecological Cancer Society. 2017;27(6):1109-1117.
www.epistemonikos.org/documents/689363e97298e1a5bd0aaac7709f7a7ad2864ecb
304. Han B, Li X, Yu T. Cruciferous vegetables consumption and the risk of ovarian cancer: a meta-analysis of observational studies. *Diagnostic pathology*. 2014;9:7. www.epistemonikos.org/documents/68c71d53901df9c8fb28b700a5047a0598a87417
305. Voest E.E., Van Houwelingen J.C., Neijt J.P.. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. *European Journal of Cancer and Clinical Oncology*. 1989;25(4):711-720. www.epistemonikos.org/documents/69a6f60c9b44279575da563d7165377d5ca631c8
306. Li L., Qi X., Xu M., Ding X., Zhou X., Zhang C., Fan Z., Zhao Y., Sheng H., Zhang Y.. The effects of metformin on ovarian cancer: An updated systematic review and meta-analysis. *International Journal of Clinical and Experimental Medicine*. 2016;9(9):17559-17568. www.epistemonikos.org/documents/69c3974cd5919d8ad8f0c38b682d7cc5cd304e50
307. Camargo MC, Stayner LT, Straif K, Reina M, Al-Alem U, Demers PA, Landrigan PJ. Occupational exposure to asbestos and ovarian cancer: a meta-analysis. *Environmental health perspectives*. 2011;119(9):1211-7. www.epistemonikos.org/documents/69c46a592f5300e3df10645a093e4a2a6981bf31
308. Sjoquist KM, Lord SJ, Friedlander ML, John Simes R, Marschner IC, Lee CK. Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. *Therapeutic advances in medical oncology*. 2018;10:1758835918788500. www.epistemonikos.org/documents/69ca749f5082bc13d16d4d2fa82d8906ea9e6229
309. Song GG, Lee YH. Vitamin D receptor FokI, BsmI, ApaI, and TaqI polymorphisms and susceptibility to ovarian cancer: a meta-analysis. *Immunological investigations*. 2013;42(7):661-72. www.epistemonikos.org/documents/6a0709df6af4870425c44f2ae790b49432c9334d
310. He Y, Jiang W, Qian X, Liu F, Zhang Q, You C. Role of Aurora-A in Ovarian Cancer: A Meta-Analysis. *Oncology research and treatment*. 2015;38(9):442-7. www.epistemonikos.org/documents/6a35ef271a320b9525838150253fb2eac6aa1912
311. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. *Journal of the National Cancer Institute*. 2009;101(2):80-7. www.epistemonikos.org/documents/6af8b709592de713f8bd1cc4b82ab128497581e7
312. Berge W, Mundt K, Luu H, Boffetta P. Genital use of talc and risk of ovarian cancer: a meta-analysis. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. 2018;27(3):248-257. www.epistemonikos.org/documents/6b7e333f2a627ce2889223c01982e4592f455d0f
313. Kim H., Chung H., Kim J., Park N., Song Y., Kang S., Kim Y.. Impact of intraoperative rupture of tumor on survival in patients with early-stage epithelial ovarian cancer: A meta-analysis. *Gynecologic Oncology*. 2012;;S95-S96. www.epistemonikos.org/documents/6b9424a08f3a1f84bdb22f8a2f6a8c441430aff8
314. Valachis A., Polyzos N.P., Zavos A., Mauri D., Lind P.A.. Effect of BRCA mutation on prognosis in patients with ovarian cancer: A systematic review and meta-analysis. *Journal of Clinical Oncology*. 2012; www.epistemonikos.org/documents/6b9659ea25dcc9a3cc665a331be7f4a655711c21
315. Zhao W., Zang C., Zhang T., Li J., Liu R., Feng F., Lv Q., Zheng L., Tian J., Sun C.. Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: A meta-analysis. *OncoTargets and Therapy*. 2018;11:1821-1831. www.epistemonikos.org/documents/6c5d395983363431c7cac8d1eda8070230334987
316. Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC. Body size and ovarian cancer: case-control study and systematic review (Australia). *Cancer causes & control : CCC*. 2001;12(9):855-63. www.epistemonikos.org/documents/6c5d8e303769997c6c0f7509661d5c7ca290cf84

317. Gajjar K., Owens G., Martin-Hirsch P., Martin F.. No association between the CYP1B1 VAL432LEU polymorphism and ovarian cancer risk: A meta-analysis. *International Journal of Gynecological Cancer*. 2012;E448.
www.epistemonikos.org/documents/6cb8e4d82142431dd5f8d2e9f2864943bf867796
318. Berretta M., Micek A., Lafranconi A., Rossetti S., Di Francia R., De Paoli P., Rossi P., Facchini G.. Coffee consumption is not associated with ovarian cancer risk: A dose-response meta-analysis of prospective cohort studies. *Oncotarget*. 2018;9(29):20807-20815.
www.epistemonikos.org/documents/6cd395d1cb150a35ef61fc24d09b88665e91689d
319. Bogani G, Ditto A, Martinelli F, Lorusso D, Chiappa V, Donfrancesco C, Di Donato V, Indini A, Aletti G, Raspagliesi F. Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma: A Systematic Review and Meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2016;26(2):371-80.
www.epistemonikos.org/documents/6cfef20f543183fc13f543aef180c67909a16ed7
320. LU Jia, LU Yun, YANG Yong-xiu, WANG Xiao-hui. Effectiveness and Safety of Paclitaxel Liposomes and Carboplatin for Ovarian Cancer: A Systematic Review. *中国循证医学杂志 (Chinese Journal of Evidence-Based Medicine)*. 2012;01(2012):42-48.
www.epistemonikos.org/documents/6d145c347e794080295438445612a388c4696bd6
321. Buehler M, Tse B, Leboucq A, Jacob F, Caduff R, Fink D, Goldstein DR, Heinzelmann-Schwarz V. Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer. *BioMed research international*. 2013;2013(no pagination):238284.
www.epistemonikos.org/documents/6d66736e185f2abb2f46f2550afd5097d2a1b309
322. Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. *Fertility research and practice*. 2016;2:14.
www.epistemonikos.org/documents/6d757013bea862709ab9af11214d794a0e11d8ae
323. Protani M., Nagle C., De Fazio A., Mileskin L., Webb P.. Obesity and survival in women with ovarian cancer: Results from the Australian ovarian cancer study, a systematic review and meta-analysis. *Asia-Pacific Journal of Clinical Oncology*. 2012;:164.
www.epistemonikos.org/documents/6ebed8983fe95476b6454b79392b91a7c6f0bbd2
324. Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, Kjaer SK. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. *Acta obstetrica et gynecologica Scandinavica*. 2013;92(3):245-55.
www.epistemonikos.org/documents/6ef89f98f26151f8dfd1c26697aa2d7989df70a8
325. Hou Y, Yu L, Mi Y, Zhang J, Wang K, Hu L. Association of MTDH immunohistochemical expression with metastasis and prognosis in female reproduction malignancies: a systematic review and meta-analysis. *Scientific reports*. 2016;6:38365.
www.epistemonikos.org/documents/6f2036518e4b656f5a7e45066c0217568eb5dc33
326. Liu Y, Li C, Chen P, Li X, Li M, Guo H, Li J, Chu R, Wang H. Polymorphisms in the vitamin D Receptor (VDR) and the risk of ovarian cancer: a meta-analysis. *PLoS one*. 2013;8(6):e66716.
www.epistemonikos.org/documents/6fae956bdcad92bfdfd7c0a0bcd464199d3fbadf
327. Thomsen LH, Henrichsen Schnack T, Buchardi K, Hummelshoj L, Missmer SA, Forman A, Blaakaer J. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. *Acta obstetrica et gynecologica Scandinavica*. 2017;96(6):761-778.
www.epistemonikos.org/documents/7064a0d1ee7100261b09d503a5ce578e3742df31
328. Assis J, Pereira C, Nogueira A, Pereira D, Carreira R, Medeiros R. Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis. *Cancer treatment reviews*. 2017;61:35-52.
www.epistemonikos.org/documents/708a77bf934a1e91d0127eb179ccede444326564
329. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review.

- Gynecologic oncology. 2009;112(2):422-36.
www.epistemonikos.org/documents/70b805b92c814e244312bbe8af05360f1eef07f6
330. Kim H., Kim J., Ju W., Jee B., Chung H., Park N., Song Y., Kim S., Kang S., Lee H.. Systematic lymphadenectomy for survival in epithelial ovarian cancer: A metaanalysis. *Gynecologic Oncology*. 2010;:S110.
www.epistemonikos.org/documents/70d0a39a9bece19995259b88cd10506c267bd031
331. Cibula D, Widschwendter M, Májek O, Dusek L. Tubal ligation and the risk of ovarian cancer: review and meta-analysis. *Human reproduction update*. 2011;17(1):55-67.
www.epistemonikos.org/documents/7174076afad41b300fbfdf879599b7ccb48c9598
332. Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, Kim SC, Kang SB, Kim JW. Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010;20(4):520-8.
www.epistemonikos.org/documents/71a535922d386d2c8df0d421c364f55f4b9cb3de
333. Zhai M, Wang Y, Jiang MF. Arg188His polymorphism in the XRCC2 gene and the risk of ovarian cancer: a meta-analysis. *Genetics and molecular research : GMR*. 2015;14(3):10808-15.
www.epistemonikos.org/documents/71eb00e789f08c44175e180d7a8582c52832414f
334. Mohammadi V., Dehghani S., Larijani B., Azadbakht L.. Ovarian cancer risk and nonisoflavone flavonoids intake: A systematic review of epidemiological studies. *Journal of Research in Medical Sciences*. 2016;21(9):123.
www.epistemonikos.org/documents/7231b44496a6b2fdc77db0c5d4b5cedacdaff7b2
335. Kogevinas, Manolis, Pearce, Neil. Importance of Meta-analyses for Evaluating Carcinogens...Camargo MC, Stayner LT, Straif K, Reina M, Al-Alem U, Demers PA, et al. 2011. Occupational exposure to asbestos and ovarian cancer: a meta-analysis. *Environ Health Perspect* 119:1211–1217. *Environmental Health Perspectives*. 2012;120(4):483-483.
www.epistemonikos.org/documents/7253061ca104b93dbe81fc7fdbef7c398a741cab
336. Zhou Q, Chen A, Song H, Tao J, Yang H, Zuo M. Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. *International journal of clinical and experimental medicine*. 2015;8(3):3080-8.
www.epistemonikos.org/documents/7264309c6bd260b6c96eef2abdf88f7af832253d
337. Luo H, Li S, Zhao M, Sheng B, Zhu H, Zhu X. Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis. *Oncotarget*. 2017;8(22):36845-36856.
www.epistemonikos.org/documents/72ab94f3bd7fc937f3416db564380ba63ea739be
338. Turkoglu O., Zeb A., Graham S., Szyperski T., Szender J.B., Odunsi K., Bahado-Singh R.. Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature. *Metabolomics*. 2016;12(4).
www.epistemonikos.org/documents/73337a845c689d850cebdee3c010a808fae499ed
339. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. *Gynecologic oncology*. 2006;103(3):1122-9.
www.epistemonikos.org/documents/739baba4f9c33d4db73c8c392192f1e7824e6e90
340. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. *Gynecologic oncology*. 2012;124(2):192-8.
www.epistemonikos.org/documents/739c44673eab780f0fd14168cdf5f71ce253de8e
341. Liyan Cao, Yunjie Zhang, Zhanzhao Fu, Lixin Dong, Sen Yang, Wei Meng, Yiyang Li, Wenchao Zhang, Jialing Zhang, Changjun Zheng, He Zhu, Limei Fan. Diagnostic value of plasma lysophosphatidic acid levels in ovarian cancer patients: A case-control study and updated meta-analysis. *Journal of Obstetrics & Gynaecology Research*. 2015;41(12):1951-1958.
www.epistemonikos.org/documents/74562d8d16c5033839e7c19c70f824f69e476ead
342. Lin J., Ding D.. The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: A meta-analysis. *Cancer Cell International*.

- 2017;17(1):8. www.epistemonikos.org/documents/74b00d195c4d636bd17e404879721a46ec6690d2
343. Barra F, Laganà AS, Ghezzi F, Casarin J, Ferrero S. Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review. *Gynecologic and obstetric investigation*. 2019;84(2):1-11. www.epistemonikos.org/documents/74b995604dd969834cbf2cc2734b76ba99b0906e
344. Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, Hu FB, Giovannucci EL. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. *Journal of the National Cancer Institute*. 2015;107(3):428-428. www.epistemonikos.org/documents/75439d06c3bebbf5b19b304d538c179d20453d07
345. Zhou LM. Recreational physical activity and risk of ovarian cancer: a meta-analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(13):5161-6. www.epistemonikos.org/documents/75cc2ae29d89411f82f3e5cd16c4d811490ee429
346. Davis LL, Carpenter JS. A Systematic Review of Nonpharmacologic Interventions for Treatment-Related Symptoms in Women With Ovarian Cancer. *Clinical journal of oncology nursing*. 2015;19(5):535-542. www.epistemonikos.org/documents/765d2fdc0e7292520b9e860c4cf37cb0aed3c4b3
347. Wu C., Wang J., Wang L., Shi J., Xue W.. Diagnostic value of cancer antigen 72-4 for ovarian cancer: A meta-analysis. *European Journal of Gynaecological Oncology*. 2018;39(2):271-276. www.epistemonikos.org/documents/778a6f309b99bc81161b5663bd19a4425b30c868
348. Huang LJ, Deng XF, Chang F, Wu XL, Wu Y, Diao QZ. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. *Medicine*. 2018;97(43):e12858. www.epistemonikos.org/documents/7820efb614d27c724a5474c47247481a5953cfb3
349. Paleari L., Provinciali N., Puntoni M., Defferrari C., Di Luca M., Gorlero F., Decensi A.. Hormonal therapy for epithelial ovarian cancer: A systematic review and meta-analysis of phase II studies. *Annals of Oncology*. 2016; www.epistemonikos.org/documents/78aa99dc48301f55afb19f42b134359da726257d
350. Cui Y, Cui MH, Jia Y. [Choose which method for the chemotherapy of epithelial ovarian carcinoma: a meta-analysis]. *Zhonghua yi xue za zhi*. 2010;90(17):1177-80. www.epistemonikos.org/documents/7964c29197042bc3277f4f2550b79d4cbda5c4cc
351. Wang K., Guan C., Yu J., Jin X., Sun L., Zheng L., Xia L., Zhang Y.. Prognostic value of HER-2/neu expression in epithelial ovarian cancer: A systematic review and meta-analysis. *Oncotarget*. 2017;8(43):75528-75543. www.epistemonikos.org/documents/79801f328601e8d2b4a32d4612cc1e0cc3b2514d
352. Joint R, Chen ZE, Cameron S. Breast and reproductive cancers in the transgender population: a systematic review. *BJOG : an international journal of obstetrics and gynaecology*. 2018;125(12):1505-1512. www.epistemonikos.org/documents/7984ef261552147b363f730a8222617756348a16
353. Sun H., Zhang X., Sun D., Jia X., Xu L., Qiao Y., Jin Y.. COX-2 expression in ovarian cancer: An updated meta-analysis. *Oncotarget*. 2017;8(50):88152-88162. www.epistemonikos.org/documents/79a1e4bd6e8536c3f3a0ca0341952df8e86b0243
354. Paleari L., Provinciali N., Puntoni M., Defferrari C., Di Luca M., Gorlero F., De Censi A.. Endocrine therapy for ovarian cancer: A systematic review and metaanalysis of phase II studies. *Journal of Clinical Oncology*. 2016; www.epistemonikos.org/documents/7ab1e763ef8c00478fc9cbbfd08518bae6ee2a37
355. Fu Z., Xu S., Xu Y., Ma J., Li J., Xu P.. The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer. *International Journal of Gynecological Cancer*. 2015;25(3):356-362. www.epistemonikos.org/documents/7ab6e48218971f1c1eaba2ef13ee10f17d1ce02e
356. Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH, Cushing-Haugen K, Sieh W, Moysich K, Doherty JA, Nagle CM,

- Berchuck A, Pearce CL, Pike M, Ness RB, Webb PM, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Rossing MA, Schildkraut J, Risch H, Goodman MT, Ovarian Cancer Association Consortium. Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. *Cancer prevention research (Philadelphia, Pa.)*. 2013;6(8):811-21. www.epistemonikos.org/documents/7acdbdff1e7fe6a3f2e6b5929498d86d005211e
357. Zapardiel I, Diestro MD, Aletti G. Conservative treatment of early stage ovarian cancer: oncological and fertility outcomes. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. 2014;40(4):387-93. www.epistemonikos.org/documents/7bb031b1a23c85b9a102603ae4a685bb22870551
358. Liao XY, Huang GJ, Gao C, Wang GH. A meta-analysis of serum cancer antigen 125 array for diagnosis of ovarian cancer in Chinese. *Journal of cancer research and therapeutics*. 2014;10 Suppl(7):C222-4. www.epistemonikos.org/documents/7c5c860b2ebf7d76b471d69d6e48d3abdc3b6525
359. Shi LF, Wu Y, Li CY. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. *Menopause (New York, N.Y.)*. 2016;23(4):417-24. www.epistemonikos.org/documents/7cb074e0d88b4ac41005027f605e8199fb489431
360. Jin Y, Hao Z. Polymorphisms of glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) in ovarian cancer risk. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(6):5267-72. www.epistemonikos.org/documents/7d09071e517bd0d9bd593047d0ac8e9268522086
361. de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. *British journal of cancer*. 2009;101(1):149-59. www.epistemonikos.org/documents/7d430a823966147539132362ff99357486fbacd6
362. Lu Y, Yao DS, Xu JH. Systematic review of laparoscopic comprehensive staging surgery in early stage ovarian cancer: A meta-analysis. *Taiwanese journal of obstetrics & gynecology*. 2015;54(1):29-38. www.epistemonikos.org/documents/7d458d235a0e0cf793e4d5d04723c027ad8b8716
363. Liu T, Chen L, Sun X, Wang Y, Li S, Yin X, Wang X, Ding C, Li H, Di W. Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(3):2427-36. www.epistemonikos.org/documents/7d68a7ac65f8595dfc3d4c7dabfdc9153c27a29f
364. Liu Y, Zhang T, Wu Q, Jiao Y, Gong T, Ma X, Li D. Relationship between initiation time of adjuvant chemotherapy and survival in ovarian cancer patients: a dose-response meta-analysis of cohort studies. *Scientific reports*. 2017;7(1):9461. www.epistemonikos.org/documents/7d69be74b3684a8bb45aacb2c43ba15c645c831c
365. Zhou Z., Zeng F., Yuan J., Tang J., Colditz G.A., Tworoger S.S., Trabert B., Su X.. Pelvic inflammatory disease and the risk of ovarian cancer: a meta-analysis. *Cancer Causes and Control*. 2017;28(5):415-428. www.epistemonikos.org/documents/7d836baf4b7737c063fb494e97e8206694e6452d
366. Peng Lihua, Xiao Y Chen, Taixiang Wu. Topotecan for ovarian cancer. *Cochrane Database of Systematic Reviews*. 2008;(2):CD005589. www.epistemonikos.org/documents/7e70176f0866a32292be367fdb57294944c6ec35
367. Xu H, Ding Y, Xin X, Wang W, Zhang D. Dietary fiber intake is associated with a reduced risk of ovarian cancer: a dose-response meta-analysis. *Nutrition research (New York, N.Y.)*. 2018;57:1-11. www.epistemonikos.org/documents/7e921e7852d030fc8906c66d657382ceef769dca
368. Kuchenbaecker K.B., Ramus S.J., Tyrer J., Lee A., Shen H.C., Beesley J., Lawrenson K., McGuffog L., Healey S., Lee J.M., Spindler T.J., Lin Y.G., Pejovic T., Bean Y., Li Q., Coetzee S.,

- Hazelett D., Miron A., Southey M., Terry M.B., Goldgar D.E., Buys S.S., Janavicius R., Dorfling C.M., van Rensburg E.J., Neuhausen S.L., Ding Y.C., Hansen T.V.O., Jonson L., Gerdes A.-M., Ejertsen B., Barrowdale D., Dennis J., Benitez J., Osorio A., Garcia M.J., Komenaka I., Weitzel J.N., Ganschow P., Peterlongo P., Bernard L., Viel A., Bonanni B., Peissel B., Manoukian S., Radice P., Papi L., Ottini L., Fostira F., Konstantopoulou I., Garber J., Frost D., Perkins J., Platte R., Ellis S., Godwin A.K., Schmutzler R.K., Meindl A., Engel C., Sutter C., Sinilnikova O.M., Damiola F., Mazoyer S., Stoppa-Lyonnet D., Claes K., de Leeneer K., Kirk J., Rodriguez G.C., Piedmonte M., O'Malley D.M., de la Hoya M., Caldes T., Aittomaki K., Nevanlinna H., Collee J.M., Rookus M.A., Oosterwijk J.C., Tihomirova L., Tung N., Hamann U., Isacacs C., Tischkowitz M., Imyanitov E.N., Caligo M.A., Campbell I.G., Hogervorst F.B.L., Olah E., Diez O., Blanco I., Brunet J., Lazaro C., Pujana M.A., Jakubowska A., Gronwald J., Lubinski J., Sukiennicki G., Barkardottir R.B., Plante M., Simard J., Soucy P., Montagna M., Tognazzo S., Teixeira M.R., Pankratz V.S., Wang X., Lindor N., Szabo C.I., Kauff N., Vijai J., Aghajanian C.A., Pfeiler G., Berger A., Singer C.F., Tea M.-K., Phelan C.M., Greene M.H., Mai P.L., Rennert G., Mulligan A.M., Tchatchou S., Andrulis I.L., Glendon G., Toland A.E., Jensen U.B., Kruse T.A., Thomassen M., Bojesen A., Zidan J., Friedman E., Laitman Y., Soller M., Liljegren A., Arver B., Einbeigi Z., Stenmark-Askmal M., Olopade O.I., Nussbaum R.L., Rebbeck T.R., Nathanson K.L., Domchek S.M., Lu K.H., Karlan B.Y., Walsh C., Lester J., Hein A., Ekici A.B., Beckmann M.W., Fasching P.A., Lambrechts D., van Nieuwenhuysen E., Vergote I., Lambrechts S., Dicks E., Doherty J.A., Wicklund K.G., Rossing M.A., Rudolph A., Chang-Claude J., Wang-Gohrke S., Eilber U., Moysich K.B., Odunsi K., Sucheston L., Lele S., Wilkens L.R., Goodman M.T., Thompson P.J., Shvetsov Y.B., Runnebaum I.B., Durst M., Hillemanns P., Dork T., Antonenkova N., Bogdanova N., Leminen A., Peltari L.M., Butzow R., Modugno F., Kelley J.L., Edwards R.P., Ness R.B., du Bois A., Heitz F., Schwaab I., Harter P., Matsuo K., Hosono S., Orsulic S., Jensen A., Kjaer S.K., Hogdall E., Hasmad H.N., Azmi M.A.N., Teo S.-H., Woo Y.-L., Fridley B.L., Goode E.L., Cunningham J.M., Vierkant R.A., Bruinsma F., Giles G.G., Liang D., Hildebrandt M.A.T., Wu X., Levine D.A., Bisogna M., Berchuck A., Iversen E.S., Schildkraut J.M., Concannon P., Weber R.P., Cramer D.W., Terry K.L., Poole E.M., Tworoger S.S., Bandera E.V., Orlow I., Olson S.H., Krakstad C., Salvesen H.B., Tangen I.L., Bjorge L., van Altena A.M., Aben K.K.H., Kiemenev L.A., Massuger L.F.A.G., Kellar M., Brooks-Wilson A., Kelemen L.E., Cook L.S., Le N.D., Cybulski C., Yang H., Lissowska J., Brinton L.A., Wentzensen N., Hogdall C., Lundvall L., Nedergaard L., Baker H., Song H., Eccles D., McNeish I., Paul J., Carty K., Siddiqui N., Glasspool R., Whittemore A.S., Rothstein J.H., McGuire V., Sieh W., Ji B.-T., Zheng W., Shu X.-O., Gao Y.-T., Rosen B., Risch H.A., McLaughlin J.R., Narod S.A., Monteiro A.N., Chen A., Lin H.-Y., Permuth-Wey J., Sellers T.A., Tsai Y.-Y., Chen Z., Ziogas A., Anton-Culver H., Gentry-Maharaj A., Menon U., Harrington P., Lee A.W., Wu A.H., Pearce C.L., Coetzee G., Pike M.C., Dansonka-Mieszkowska A., Timorek A., Rzepecka I.K., Kupryjanczyk J., Freedman M., Noushmehr H.. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*. 2015;47((Kuchenbaecker K.B.) Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.):164-71.
www.epistemonikos.org/documents/7f93ebba46dfdd150a888765c54dc281aac410f1
369. Ge LN, Wang F. Prognostic significance of preoperative serum albumin in epithelial ovarian cancer patients: a systematic review and dose-response meta-analysis of observational studies. *Cancer management and research*. 2018;10:815-825.
www.epistemonikos.org/documents/7fb35f5ca826e63b06f4707508c5eb75b114c08b
370. Huncharek M, Muscat J, Onitilo A, Kupelnick B. Use of cosmetic talc on contraceptive diaphragms and risk of ovarian cancer: a meta-analysis of nine observational studies. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. 2007;16(5):422-9.
www.epistemonikos.org/documents/7fc177613bf260156a58ec7adf6ffcf980997f6d
371. Encinas, Giselly, Fogueira, Maria Aparecida Azevedo Koike, Bock, Geertruida Hendrika de, Brentani, Maria Mitzi, Katayama, Maria Lucia Hirata, Pasini, Fátima Solange, Maistro, Simone. Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and

- meta-analysis. *Rev Assoc Med Bras.* 2015;61(5):474-483.www.epistemonikos.org/documents/8079266d3ce37e421dc11de7b63535df77763b25
372. Si JG, Su YY, Han YH, Chen RH. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis. *Genetic testing and molecular biomarkers.* 2014;18(6):394-402.
www.epistemonikos.org/documents/80cdb23e9d028ae29aa720da65f7caf4fb83715b
373. Deuster E, Jeschke U, Ye Y, Mahner S, Czogalla B. Vitamin D and VDR in Gynecological Cancers-A Systematic Review. *International journal of molecular sciences.* 2017;18(11).
www.epistemonikos.org/documents/824605a804b63f684eb3ff3d6cf86bc85e228399
374. Qu C.-P., Sun G.-X., Yang S.-Q., Tian J., Si J.-G., Wang Y.-F.. Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis. *Medicine (United States).* 2017;96(2):e5797.
www.epistemonikos.org/documents/82aea5a0de6a2cdd7e12fa17ffdfaf4c0046d3a1
375. Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahtooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. *European journal of cancer (Oxford, England : 1990).* 2007;43(4):690-709.
www.epistemonikos.org/documents/82ca693bbcaadd5a2d5284c994e1bc5e69139c07
376. Nagrial A., Long A., Chin V.T., Carter J.R., Beale P.J.. Duration of systemic therapy for ovarian cancer: A systematic review and meta-analysis. *Journal of Clinical Oncology.* 2014;
www.epistemonikos.org/documents/838df56ab7d5c7add4dd96949cb2d530869f7939
377. Laraqui A, Uhrhammer N, El Rhaffouli H, Sekhsokh Y, Lahlou-Amine I, Bajjou T, Hilali F, El Baghdadi J, Al Bouzidi A, Bakri Y, Amzazi S, Bignon YJ. BRCA Genetic Screening in Middle Eastern and North African: Mutational Spectrum and Founder BRCA1 Mutation (c.798_799delTT) in North African. *Disease markers.* 2015;2015((Laraqui A., loranjad@yahoo.fr; El Rhaffouli H., elrhaffoulihicham@live.fr; Sekhsokh Y., yassinsekhsokh@gmail.com; Lahlou-Amine I., idr_lahlou@yahoo.com; Bajjou T., taharbajjou@gmail.com; Hilali F., faridahilali@yahoo.fr) Laboratoire de Recherche et de Biosecurite-P3, Hopital Militaire d'Instruction Mohammed v, Rabat, Morocco):194293.www.epistemonikos.org/documents/83ec40be940c58b92a7c260f3db089be69e4274b
378. Ciccone MA, Maoz A, Casabar JK, Machida H, Mabuchi S, Matsuo K. Clinical Outcome of treatment with Serine-Threonine Kinase Inhibitors in Recurrent Epithelial Ovarian Cancer: A Systematic Review of Literature. *Expert opinion on investigational drugs.* 2016;25(7):781-96.www.epistemonikos.org/documents/850a77931d6ef2d719ddeefc81c1e76a252b725f
379. Hazel A Billson, Cathrine Holland, Janet Curwell, Valerie L Davey, Laura Kinsey, Lianna J Lawton, Alison J Whitworth, Sorrel Burden. Perioperative nutrition interventions for women with ovarian cancer. *Cochrane Database of Systematic Reviews.* 2013;9(9):CD009884.www.epistemonikos.org/documents/8556a875201dc014e62501fdb70d941d26f93d6
380. Xu CH, He ZH, Xu H. Association of four genetic polymorphisms in the vascular endothelial growth factor-A gene and development of ovarian cancer: a meta-analysis. *Oncotarget.* 2017;8(42):73063-73078.
www.epistemonikos.org/documents/856a9d8b3ddf58ebbedbc8a48acc15ab581ffd30
381. Zhang Y, Fan S, Xiang Y, Duan H, Sun L. Comparison of the prognosis and recurrence of apparent early-stage ovarian tumors treated with laparoscopy and laparotomy: a meta-analysis of clinical studies. *BMC cancer.* 2015;15(1):597.
www.epistemonikos.org/documents/85a3e493836e0650dd10206fc5c0377a6842eafb
382. Shoji T, Takatori E, Murakami K, Kaido Y, Takeuchi S, Kikuchi A, Sugiyama T. A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review. *Journal of ovarian research.* 2016;9(1):48.
www.epistemonikos.org/documents/85a87e6f87564d41ced6422c749c56e3320c466f
383. Chen Y., Du H., Bao L., Liu W.. Opportunistic salpingectomy at benign gynecological surgery for reducing ovarian cancer risk: A 10-year single centre experience from China and a

- literature review. *Journal of Cancer*. 2018;9(1):141-147.
www.epistemonikos.org/documents/866bc1ccad175c98988ddc307a4fd551f3771ea8
384. Liang H., Jiang Z., Xie G., Lu Y.. Serum microRNA-145 as a novel biomarker in human ovarian cancer. *Tumor Biology*. 2015;36((Liang H., huichaoliang@outlook.com) Department of Gynecology Oncology, Guangzhou Women and Childrens Medical Center, Guangzhou Medical University, Guangzhou, China):5305-5313.
www.epistemonikos.org/documents/86d29c153476077e367899f2901eb271b0bc2fd6
385. Gibson JM, Alzghari S, Ahn C, Trantham H, La-Beck NM. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials. *The oncologist*. 2013;18(9):1022-31.
www.epistemonikos.org/documents/872852de19e8a32297506a2bd6c923f0f3916e23
386. Guirguis-Blake JM, Henderson JT, Perdue LA. Periodic Screening Pelvic Examination: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2017;317(9):954-966.
www.epistemonikos.org/documents/87893acdfaf682dafd5efe0d0a5fad6f5e96e2a7
387. Yan-Hong H, Jing L, Hong L, Shan-Shan H, Yan L, Ju L. Association between alcohol consumption and the risk of ovarian cancer: a meta-analysis of prospective observational studies. *BMC public health*. 2015;15(1):223.
www.epistemonikos.org/documents/87d8aab63c119d07e49a7bf62a40aa880c6a68cb
388. Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2013;31(33):4188-98.
www.epistemonikos.org/documents/87e09cd8c3d0d4d2c96be5fa5f4f7af623b198e0
389. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Taxanes for ovarian cancer during pregnancy: a systematic review. *Oncology*. 2012;83(4):234-8.
www.epistemonikos.org/documents/8810927f5fd04088126637e0ea59f5ef0b230c07
390. Zhang XS, Zhang YM, Li B, Fan B, Zhao Y, Yang SJ. Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis. *Gynecologic oncology*. 2018;150(3):509-514.
www.epistemonikos.org/documents/884b8cfa052266fa8a15be6c9752f2385db759d3
391. Staropoli N., Ciliberto D., Chiellino S., Del Giudice T., Caglioti F., Strangio A., Salvino A., Tassone P., Tagliaferri P.. Role of targeted therapy in ovarian cancer treatment: A systematic review and meta-analysis of randomized trials. *Annals of Oncology*. 2015;vi34.
www.epistemonikos.org/documents/88506d7db04b7fd5dfdd62d82089cea3c7777c1a
392. Dai L., Xie L., Liu Y., Qiu L., Di W.. Clinicopathological and prognostic significance of serum interleukin-8 in ovarian cancer: A meta-analysis. *International Journal of Clinical and Experimental Medicine*. 2017;10(1):97-105.
www.epistemonikos.org/documents/8875a2a25b1bc11fdf93274545fe734b72054f2a
393. Li S, Xu H, Li SC, Qi XQ, Sun WJ. Vitamin D receptor rs2228570 polymorphism and susceptibility to ovarian cancer: a meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(2):1319-22.
www.epistemonikos.org/documents/89145b5dbe2d86afd371ebc9d3944e653b67b468
394. Tempfer C, Giger-Pabst U, Hilal Z, Dogan A, Reznicek GA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. *Archives of gynecology and obstetrics*. 2018;298(2):243-257.
www.epistemonikos.org/documents/8916616e2e92bfa8b4c40c3e77532a52a87f7326
395. Theresa A Lawrie, Andrew Bryant, Alison Cameron, Emma Gray, Jo Morrison. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. *Cochrane Database of Systematic*

- Reviews. 2013;7(7):CD006910.
www.epistemonikos.org/documents/89232b3fe558aec9fcc49c38b00d0054488b2f02
396. Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A. Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2017;27(6):1274-1282.
www.epistemonikos.org/documents/892b7fb16d79b62cdb58bd58dd68fe5e588f4915
397. Song X, Li Z, Ji X, Zhang D. Calcium Intake and the Risk of Ovarian Cancer: A Meta-Analysis. *Nutrients*. 2017;9(7):679-693.
www.epistemonikos.org/documents/8933894b34fc580b8a8031662cf0081e39effa2a
398. Qian X, Qin J, Pan S, Li X, Pan Y, Ma S. Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis. *PloS one*. 2015;10(9):e0139026.
www.epistemonikos.org/documents/8946959634a03479e35398f13ffb6982f6fd7a09
399. Zeng Y., Xu P., Chen C.. Diagnostic value of miRNAs in peripheral blood circulation for ovarian cancer: A meta-analysis. *Journal of Practical Oncology*. 2016;31(1):52-59.
www.epistemonikos.org/documents/8947c118cae100a103c9f1e890f3df99fa1aeead
400. Chen F, Gaitskell K, Garcia MJ, Albukhari A, Tsaltas J, Ahmed AA. Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review. *BJOG : an international journal of obstetrics and gynaecology*. 2017;124(6):872-878.
www.epistemonikos.org/documents/899e6ef8d41e573ad5259591d36feb6cb63a90c4
401. Raavé R, de Vries RB, Massuger LF, van Kuppevelt TH, Daamen WF. Drug delivery systems for ovarian cancer treatment: a systematic review and meta-analysis of animal studies. *PeerJ*. 2015;3(12):e1489.
www.epistemonikos.org/documents/89ab64b9fb11ab8783b850ac85537a1d2f2090e6
402. Wang TS, Lei W, Cui W, Wen P, Guo HF, Ding SG, Yang YP, Xu YQ, Lv SW, Zhu YL. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. *Indian journal of cancer*. 2014;51 Suppl 3(7):e95-8.
www.epistemonikos.org/documents/8a899007cc7605c9cccf03a0cecf005bf3e9964
403. Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. *Gynecologic oncology*. 2013;130(3):493-8.
www.epistemonikos.org/documents/8a9af51ac16468eeaf77bcbd974ca254d370be16
404. Birrer M.J., Riestler M., Wei W., Waldron L., Culhane A., Trippa L., Oliva E., Kim S., Michor F., Huttenhower C., Parmigiani G.. Meta-analysis of public microarray databases for prognostic and predictive gene signatures of late-stage ovarian cancer. *Journal of Clinical Oncology*. 2014;
www.epistemonikos.org/documents/8abcd611ed1e4203edfbd6e44b656cac305233c
405. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. *European journal of obstetrics, gynecology, and reproductive biology*. 2009;142(2):99-105.
www.epistemonikos.org/documents/8b016a9f98d0bc12781707aba6b1fe377d82fb7f
406. Tang Z, Ow GS, Thiery JP, Ivshina AV, Kuznetsov VA. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. *International journal of cancer. Journal international du cancer*. 2014;134(2):306-318.
www.epistemonikos.org/documents/8b1223a9ee8d3cff556bd13a413a589a242a1db3
407. Chawla A., Nellesen D., Yee K., Brown J., Boye M.E.. A systematic review of the heterogeneity of treatment effect in ovarian cancer (OC)-Are there implications for outcomes research?. *Value in Health*. 2012;;A410.
www.epistemonikos.org/documents/8b25f0600ba79d7b5f6695616e791ba0cb62f7a4

408. Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2018;319(6):595-606. www.epistemonikos.org/documents/8c2060753b3898a9c433d007bbcf29d9f42bd266
409. Huang X, Wang X, Shang J, Lin Y, Yang Y, Song Y, Yu S. Association between dietary fiber intake and risk of ovarian cancer: a meta-analysis of observational studies. *The Journal of international medical research*. 2018;46(10):300060518792801. www.epistemonikos.org/documents/8c2b7dd29f54f94e01be6d0a9ae7a423caa71e1d
410. Hickman LC, Llarena NC, Valentine LN, Liu X, Falcone T. Preservation of gonadal function in women undergoing chemotherapy: a systematic review and meta-analysis of the potential role for gonadotropin-releasing hormone agonists. *Journal of assisted reproduction and genetics*. 2018;35(4):571-581. www.epistemonikos.org/documents/8c368011e4a5c2268fc3d52c6fc9bfc6fd67cd27
411. Sørensen RD, Schnack TH, Karlsen MA, Høgdall CK. Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities - A systematic review. *Gynecologic oncology*. 2015;136(3):571-581. www.epistemonikos.org/documents/8c7f27a036a7ca8ae3520b34408f8e29e41dd63b
412. Li J, Liu R, Tang S, Feng F, Liu C, Wang L, Zhao W, Zhang T, Yao Y, Wang X, Sun C. Impact of endometriosis on risk of ovarian, endometrial and cervical cancers: a meta-analysis. *Archives of gynecology and obstetrics*. 2019;299(1):35-46. www.epistemonikos.org/documents/8ca1a54f2e2100b0ddb8faf00786223361f2001c
413. Fung-Kee-Fung M, Kennedy EB, Biagi J, Colgan T, D'Souza D, Elit LM, Hunter A, Irish J, McLeod R, Rosen B. The optimal organization of gynecologic oncology services: a systematic review. *Current oncology (Toronto, Ont.)*. 2015;22(4):e282-93. www.epistemonikos.org/documents/8cb3d9a29056dd0ba697ae34ba6936b8766ee284
414. Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, Tassone P, Tagliaferri P. Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. *Cancer biology & therapy*. 2014;15(6):707-20. www.epistemonikos.org/documents/8cef226ff2f09bfb2e58b5e8a04f8811cb23aeb3
415. Rosa MI, Silva GD, de Azedo Simões PW, Souza MV, Panatto AP, Simon CS, Madeira K, Medeiros LR. The prevalence of human papillomavirus in ovarian cancer: a systematic review. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2013;23(3):437-41. www.epistemonikos.org/documents/8cfe4d84082882d95c44552c582fed82773b2e3b
416. Li J, Li B, Jiang Q, Zhang Y, Liu A, Wang H, Zhang J, Qin Q, Hong Z, Li BA. Do genetic polymorphisms of the vitamin D receptor contribute to breast/ovarian cancer? A systematic review and network meta-analysis. *Gene*. 2018;677:211-227. www.epistemonikos.org/documents/8e8a578e6d9a596b0e8d75a383e8541fe5a6d751
417. Liu CF, Liu SY, Min XY, Ji YY, Wang N, Liu D, Ma N, Li ZF, Li K. The prognostic value of CXCR4 in ovarian cancer: a meta-analysis. *PloS one*. 2014;9(3):e92629. www.epistemonikos.org/documents/8e93f3bd1038024f867750b8d8a21de12e dbaba7
418. Jia LT, Zhang YC, Li J, Tian Y, Li JF. The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*. 2016;18(3):233-9. www.epistemonikos.org/documents/8f2da01e4082ff0fbaea85de394976871101261c
419. Oppeneer SJ, Robien K. Tea Consumption and Epithelial Ovarian Cancer Risk: A Systematic Review of Observational Studies. *Nutrition and cancer*. 2011;63(6):817-26. www.epistemonikos.org/documents/8f48821751cfc63e7316ac03f2d35e63d8ed4bc3
420. Wang H, Xu T, Zheng L, Li G. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. *International*

- journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2018;28(5):903-914.
www.epistemonikos.org/documents/8f607cdceb5ed31e6d4c2bd3d506d495a6443ded
421. Einhorn N, Tropé C, Ridderheim M, Boman K, Sorbe B, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in ovarian cancer. *Acta oncologica (Stockholm, Sweden)*. 2003;42(5-6):562-6.
www.epistemonikos.org/documents/8f722e90a50049d56cd9ea313b7b19719bf21c3e
422. Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. *Health technology assessment (Winchester, England)*. 2006;10(9):1-132. iii-iv.
www.epistemonikos.org/documents/8f9d504cb662c7a4e74c0d8a69511a830d7c00f3
423. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2016;1(1):CD006014.
www.epistemonikos.org/documents/8fb984504dd4bd440a5e03a2ce4649676414e482
424. Fawunmi D., Gojon H., Valachis A.. The effectiveness of ovarian cancer screening in high-risk population and BRCA 1/2 carriers: A systematic review and meta-analysis. *Journal of Clinical Oncology*. 2013;
www.epistemonikos.org/documents/90fcc385133673703156f20be2f0cc305842331c
425. Li DP, Du C, Zhang ZM, Li GX, Yu ZF, Wang X, Li PF, Cheng C, Liu YP, Zhao YS. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(12):4829-37.
www.epistemonikos.org/documents/913aec70905e2a5578410c3c7d1c3756ca3067ed
426. Nam JH, Park JY. Fertility-sparing surgery for young women with early-stage epithelial ovarian cancer. *Gynecologic and obstetric investigation*. 2013;76(1):14-24.
www.epistemonikos.org/documents/928e624a5acdfeb4beff33b4308605040d40a463
427. Kho RM, Wechter ME. Operative Outcomes of Opportunistic Bilateral Salpingectomy at the Time of Benign Hysterectomy in Low-Risk Premenopausal Women: A Systematic Review. *Journal of minimally invasive gynecology*. 2017;24(2):218-229.
www.epistemonikos.org/documents/92e0a8b7f3fd81a829086eea48d1fc286aecdf43
428. Petrillo M, Nero C, Carbone V, Bruno M, Scambia G, Fagotti A. Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. *Annals of surgical oncology*. 2018;25(1):1-8.
www.epistemonikos.org/documents/9305b96264a4be7dad65f744aeac4128d094df69
429. Zhu Y, Zhou S, Liu Y, Zhai L, Sun X. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. *BMC cancer*. 2018;18(1):443.
www.epistemonikos.org/documents/93549d464a3cda6d66ccfb6b8c7a28d3b3c9e946
430. Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. *Oncotarget*. 2017;8(1):285-302.
www.epistemonikos.org/documents/9410957210a8cc555f3990c6df39b1a1db9e5c44
431. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. *Human reproduction update*. 2007;13(5):453-63.
www.epistemonikos.org/documents/948efb20263ba01cff55e7efe0743370663c8871
432. Zhao Z, Zhao X, Lu J, Xue J, Liu P, Mao H. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. *Archives of gynecology and obstetrics*. 2018;297(4):1-9.
www.epistemonikos.org/documents/949e26d07c99255ce3858ccea213c4e2e8ce6a7e
433. Hu Z.-Y., Tang L.-D., Zhang H.-Y., Niu J.-Y., Lou M.. Clinicopathological significance of steroidogenic factor-1 expression in ovarian cancer versus ovarian sex cord stromal tumor. *Tumor Biology*. 2015;36((Hu Z.-Y.; Tang L.-D., liangdantang@gmail.com; Niu J.-Y.; Lou M.) Department of

- Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China):1429-35.
www.epistemonikos.org/documents/94a279cd2610e3cadbf3fab286c01948156f1a50
434. Qu XL, Fang Y, Zhang M, Zhang YZ. Phytoestrogen intake and risk of ovarian cancer: a meta-analysis of 10 observational studies. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(21):9085-91.
www.epistemonikos.org/documents/9515c3de32cdae797b8406f6fce0bd4ee5d888ec
435. Li J, Liu R, Tang S, Feng F, Wang X, Qi L, Liu C, Yao Y, Sun C. The effect of long noncoding RNAs HOX transcript antisense intergenic RNA single-nucleotide polymorphisms on breast cancer, cervical cancer, and ovarian cancer susceptibility: A meta-analysis. *Journal of cellular biochemistry*. 2018;
www.epistemonikos.org/documents/962940c3de3347698a231e1aa0288624cb4f8bba
436. Zhang Y, Tong SC, Guan LH, Na F, Zhao W, Wei L. Meta-analysis of the relation between vitamin D receptor gene BsmI polymorphism and susceptibility to ovarian cancer. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2013;34(6):3317-21.
www.epistemonikos.org/documents/9695157275fa829418f608998a9eff520ba962a6
437. Ding SS, Li L, Yu CX. Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment. *Journal of B.U.ON. : official journal of the Balkan Union of Oncology*. 2014;19(4):965-72.
www.epistemonikos.org/documents/96d9e40c6b7f1923281572758cb205c9aa2bcb44
438. Egloff H, Jatoi A. Pemetrexed for ovarian cancer: a systematic review of the published literature and a consecutive series of patients treated in a nonclinical trial setting. *Case reports in oncology*. 2014;7(2):541-9.
www.epistemonikos.org/documents/9743bccb8f6a63e5c0518c2507db7c9f5ece7f51
439. Shi M, Mu Y, Zhang H, Liu M, Wan J, Qin X, Li C. MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis. *Medicine*. 2018;97(32):e11505.
www.epistemonikos.org/documents/97a495bbb4d7839374a9971b414e56febae9a870
440. Zhong S, Chen L, Lv M, Ma T, Zhang X, Zhao J. Nonoccupational physical activity and risk of ovarian cancer: a meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(11):11065-73.
www.epistemonikos.org/documents/97c366e3c9e20e4fcae4f236f4178c70cbc83f9e
441. Ruiz-Hernández G, Delgado-Bolton RC, Fernández-Pérez C, Lapeña-Gutiérrez L, Carreras-Delgado JL. [Meta-analysis of the diagnostic efficacy of FDG-PET in patients with suspected ovarian cancer recurrence]. *Revista española de medicina nuclear*. 2005;24(3):161-73.
www.epistemonikos.org/documents/983c0ce804b797092b25e0a7bf595f623797771b
442. Chen Q, Xu B, Lan L, Yang D, Yang M, Jiang J, Lu B, Shen Y. High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. *Scientific reports*. 2017;7(1):8769.
www.epistemonikos.org/documents/984fa72dda8454c68881a769f1dfba06c82a6e9c
443. Ebell MH, Culp MB, Radke TJ. A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer. *American journal of preventive medicine*. 2016;50(3):384-94.
www.epistemonikos.org/documents/999c15c995d001af82c0c92ad042b65235c560e9
444. Aramide O Lawal, Alfred Musekiwa, Liesl Grobler. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2013;6(6):CD009620.
www.epistemonikos.org/documents/9a17c014224e6b596cba39835cac07983fff3ccd
445. Li J, Wang J, Chen R, Bai Y, Lu X. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. *Oncotarget*. 2017;8(9):15621-15631.
www.epistemonikos.org/documents/9a719d8de998c87f7700da36d873abe8a7ce6cbd
446. Qiao B, Zhang Z, Li Y. Association of MGMT promoter methylation with tumorigenesis features in patients with ovarian cancer: A systematic meta-analysis. *Molecular genetics &*

- genomic medicine. 2018;6(1):69-76.
www.epistemonikos.org/documents/9ab69c77d27b4972c2df3eecb8da6613f4295938
447. Sehoul J, Erol E, Richter R, Reuss A, Fotopoulou C, Mahner S, Pfisterer J, Du Bois A.. Does alopecia predict response to chemotherapy and prognosis in patients with advanced ovarian cancer? A meta-analysis of prospective randomized phase III trials with 5,114 patients of the AGO meta data base. *Journal of Clinical Oncology*. 2013;www.epistemonikos.org/documents/9b3de1affa0911ed05c6850d42275c34a5d9388d
448. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. *Annals of surgical oncology*. 2009;16(8):2315-20.
www.epistemonikos.org/documents/9b57f90052eb5f01562a58efb5dfbd3a9dc175a7
449. Liu Z, Zhang TT, Zhao JJ, Qi SF, Du P, Liu DW, Tian QB. The association between overweight, obesity and ovarian cancer: a meta-analysis. *Japanese journal of clinical oncology*. 2015;45(12):1107-15.
www.epistemonikos.org/documents/9b71fe5fd2dceb0095b7aa9af76866e51384dc11
450. Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(6):6127-38.www.epistemonikos.org/documents/9c7944db806afe4807ab2b75404c36cc319ff8ce
451. Ruan G, Ye L, Liu G, An J, Sehoul J, Sun P. The role of bevacizumab in targeted vascular endothelial growth factor therapy for epithelial ovarian cancer: an updated systematic review and meta-analysis. *OncoTargets and therapy*. 2018;11:521-528.
www.epistemonikos.org/documents/9c7ec90778d3e010b88b5a62e40f564c895b9f87
452. Qin M, Jin Y, Ma L, Zhang YY, Pan LY. The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. *Oncotarget*. 2018;9(9):8614-8628.www.epistemonikos.org/documents/9ce956df5a8e02aa8da03698dc5293b2bddd9932
453. Zeng C., Zhang X.Q., Fan W.D., Ting T.. The prognostic role of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: A systematic review and meta-analysis. *European Journal of Gynaecological Oncology*. 2017;38(4):504-510.
www.epistemonikos.org/documents/9d53a2d27bf84dc0f35b7fa5e93b4a41975c954e
454. Marchetti C, De Felice F, Perniola G, Lecce F, Vertechy L, Monti M, Musio D, Muzii L, Tombolini V, Benedetti Panici P. Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis. *Current problems in cancer*. 2018;42(2):235-240.www.epistemonikos.org/documents/9d9ffb75fd05a8be18f3bad0066f92df875643c3
455. Poonawalla IB, Parikh RC, Du XL, VonVille HM, Lairson DR. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review. *PharmacoEconomics*. 2015;33(11):1155-85.
www.epistemonikos.org/documents/9da64c1c8a83fbc925fe7b2ad8066bb1ae837ab7
456. Mao S, Wang X, Wu L, Zang D, Shi W. Association between klotho expression and malignancies risk and progression: A meta-analysis. *Clinica chimica acta; international journal of clinical chemistry*. 2018;484:14-20.
www.epistemonikos.org/documents/9dd946a7881e85cf01bebceb8fee750e08687311
457. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?. *American journal of obstetrics and gynecology*. 1992;166(2):504-11.
www.epistemonikos.org/documents/9f9609e9fec23be42ced8b301e9d37b206ac444d
458. Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2013;23(4):598-607.www.epistemonikos.org/documents/a00b9db9e3e70b139788048e19d123ca022bd445

459. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. *PLoS medicine*. 2012;9(4):e1001200.
www.epistemonikos.org/documents/a00f15ece5ea270158996b0c38b9992744702301
460. Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI. The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis. *Gynecologic oncology*. 2018;150(1):151-157.
www.epistemonikos.org/documents/a026240fcf16a1719172a11f1cca1f02d6ec05e8
461. Suppiah S, Chang WL, Hassan HA, Kaewput C, Asri AAA, Saad FFA, Nordin AJ, Vinjamuri S. Systematic Review on the Accuracy of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging in the Management of Ovarian Cancer: Is Functional Information Really Needed?. *World journal of nuclear medicine*. 2017;16(3):176-185.
www.epistemonikos.org/documents/a06425308254b1c150f26f31eba235dc1ab982d2
462. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. *British Journal of Obstetrics & Gynaecology*. 1998;105(5):493-499.
www.epistemonikos.org/documents/a06d796a9f5e6e15382e071d360b14c2f3663288
463. Haifeng G., Yun Z., Yongxue L., Yulan O., Jihong L.. Prognostic significance of systematic retroperitoneal lymphadenectomy in patients with epithelial ovarian cancer: A Meta-Analysis. *National Medical Journal of China*. 2016;96(37):3020-3025.
www.epistemonikos.org/documents/a09f18e50d84fafa5f40a4b9ec23057f3603a93d
464. Murphy M, Stordal B. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*. 2011;14(3):177-90.
www.epistemonikos.org/documents/a0cf459521162ea99eefd46f15a8638ea52acdaf
465. Su L, Wang J, Tao Y, Shao X, Ding Y, Cheng X, Zhu Y. BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer: An Updated Meta-Analysis With 2344 Cases and 9672 Controls. *Medicine*. 2015;94(42):e1695.
www.epistemonikos.org/documents/a136876e425a1cf3e059c86ffa299a3355c21bd3
466. Zhou B, Yang L, Wang L, Shi Y, Zhu H, Tang N, Wang B. The association of tea consumption with ovarian cancer risk: A metaanalysis. *American journal of obstetrics and gynecology*. 2007;197(6):594.e1-6.
www.epistemonikos.org/documents/a1839d789498465e1f697a92146223fdf8e00eea
467. Trivers KF, Patterson JR, Roland KB, Rodriguez JL. Issues of ovarian cancer survivors in the USA: a literature review. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. 2013;21(10):2889-98.
www.epistemonikos.org/documents/a2019208228a7a26955c806106ac42a30e0062c1
468. Bogani G., Ditto A., Chiappa V., Martinelli F., Donfrancesco C., Di Donato V., Lorusso D., Raspagliesi F.. Surgical techniques for diaphragmatic resection during cytoreduction in advanced or recurrent ovarian carcinoma: A systematic review and meta-analysis. *International Journal of Gynecological Cancer*. 2015;408-409.
www.epistemonikos.org/documents/a2ab46a34b752cfd1e8427fa1d7552a82a62de20
469. Diab Y, Muallem MZ. Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature. *Anticancer research*. 2017;37(6):2809-2815.
www.epistemonikos.org/documents/a2d034e82f57cd80b607177ba87d40b966a9193c
470. Liu LL, Wei YP, Xu H, Huang Y, Luo FE, Huang ZJ, Mai H, Deng L, Yin Y. A systematic review and meta-analysis of the association of transforming growth factor β receptor I 6A/9A gene polymorphism with ovarian cancer risk. *Journal of receptor and signal transduction research*.

- 2014;34(4):313-
6.www.epistemonikos.org/documents/a2eaeca44f589a127055e6a31ad7f030c1fa88b8
471. Marchetti C., De Felice F., Palaia I., Musella A., Di Donato V., Gasparri M.L., Musio D., Muzii L., Tombolini V., Panici P.B. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: An update meta-analysis on phase III trials. *Oncotarget*. 2016;7(11):13221-13227.www.epistemonikos.org/documents/a2eb155a803e75650348afadb3a6e068135453c7
472. Hu TWY, Nie D, Gou JH, Li ZY. Predictive significance of preoperative CT findings for suboptimal cytoreduction in advanced ovarian cancer: a meta-analysis. *Cancer management and research*. 2018;10:2019-2030.
www.epistemonikos.org/documents/a31c55c58706e86b917f904a64d8ac5e16152e3e
473. Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2015;12(12):CD004706.
www.epistemonikos.org/documents/a365b0866455730c34f2b6bd0ba6b43204f3d6b0
474. Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. *Cancer*. 2007;109(4):692-702.
www.epistemonikos.org/documents/a39c1e7edd173142aa6c98ed9f43c9f02f7014ce
475. Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. Centralisation of services for gynaecological cancers - a Cochrane systematic review. *Gynecologic oncology*. 2012;126(2):286-90. www.epistemonikos.org/documents/a3a881b0a5403f006d0414576daa7462bcc8a28d
476. Han S, Woo S, Suh CH, Lee JJ. Performance of pre-treatment ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography for detecting metastasis in ovarian cancer: a systematic review and meta-analysis. *Journal of gynecologic oncology*. 2018;29(6):e98.www.epistemonikos.org/documents/a3ee890ba813829d0cb2f062ccc1ad730bfaa7eb
477. He L., Shen Y.. Mthfr C677T polymorphism and breast, ovarian cancer risk: A meta-analysis of 19,260 patients and 26,364 controls. *OncoTargets and Therapy*. 2017;10:227-238.
www.epistemonikos.org/documents/a44ca09d1685649bafba8f3163367f5259ad9dad
478. Asadinejad E., Abdirad A., Nili F., Soleimani V.. HER2 overexpression in borderline and malignant Ovarian tumors: A cross-sectional study in an Iranian population and literature review. *Middle East Journal of Cancer*. 2018;9(4):300-309.
www.epistemonikos.org/documents/a48331d9cde8331e6f76a6eb3707cd08140eaa9e
479. Kollahdooz F, van der Pols JC, Bain CJ, Marks GC, Hughes MC, Whiteman DC, Webb PM, Australian Cancer Study (Ovarian Cancer) and the Australian Ovarian Cancer Study Group. Meat, fish, and ovarian cancer risk: Results from 2 Australian case-control studies, a systematic review, and meta-analysis. *The American journal of clinical nutrition*. 2010;91(6):1752-63.
www.epistemonikos.org/documents/a5a81cb57f2da482dafdabcb6dc4b5544f94a03e
480. Pozzar RA, Berry DL. Patient-centered research priorities in ovarian cancer: A systematic review of potential determinants of guideline care. *Gynecologic oncology*. 2017;147(3):714-722.
www.epistemonikos.org/documents/a84dbcf09e2e8de4d5ae7df7dd12dd10ee87bcd4
481. Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W, Ma X. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. *Gynecologic oncology*. 2017;147(1):181-187.
www.epistemonikos.org/documents/a8519f86576eb3c08a4b57f485c42c15eed87ade
482. Hess LM, Benham-Hutchins M, Herzog TJ, Hsu CH, Malone DC, Skrepnek GH, Slack MK, Alberts DS. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2007;17(3):561-70.www.epistemonikos.org/documents/a87903da86398952845b8367f5e48e69e20454f7

483. Kim HS, Kim MA, Lee M, Suh DH, Kim K, No JH, Chung HH, Kim YB, Song YS. Effect of Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma: A Two-Center Cohort Study and Meta-analysis. *Annals of surgical oncology*. 2015;22(8):2738-45.
www.epistemonikos.org/documents/a8924751e91b52389f0f0f5cc6f912e91734edab
484. Yan Y, Liang H, Li R, Xie L, Li M, Li S, Qin X. XRCC3 Thr241Met polymorphism and ovarian cancer risk: a meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(3):2711-5.
www.epistemonikos.org/documents/a938254eca74bedae42fced40b923fd0d1a32f68
485. Han E, Mikhael E, Smith D., Wakabayashi M., Morgan R., Dellinger T.. Hyperthermic intraperitoneal chemotherapy (HIPEC) in primary and recurrent epithelial ovarian cancer (EOC): A meta-analysis of observational studies. *International Journal of Gynecological Cancer*. 2014;:329-330.
www.epistemonikos.org/documents/a9afec666549daf8fd02ee85e6e96a6bc7732518
486. Zhao L, Li J, Liu M, Zhou H, Zou H, Wei Y, Sun K, Li G, Li S, Pang L. The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis. *Future oncology (London, England)*. 2017;13(28):2555-2570.
www.epistemonikos.org/documents/a9be849f6b307acc4433894df4cd0d7b6740929a
487. Ni X, Ma J, Zhao Y, Wang Y, Wang S. Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer. *British journal of clinical pharmacology*. 2013;75(1):26-35.
www.epistemonikos.org/documents/a9c95c6e1eef407f9114622c7372441ad5938907
488. Bristow RE, Karlan BY. Ovulation induction, infertility, and ovarian cancer risk. *Fertility and sterility*. 1996;66(4):499-507.
www.epistemonikos.org/documents/aa2060034e7df6bbdaebec5c91927972690dc1ce
489. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis. *British journal of cancer*. 2008;99(3):434-41.
www.epistemonikos.org/documents/aadd4c3a25efa47e27840064767dd5174ae0ffd7
490. Morrison J, Thoma C, Goodall RJ, Lyons TJ, Gaitskell K, Wiggans AJ, Bryant A. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. *The Cochrane database of systematic reviews*. 2018;10:CD007927.
www.epistemonikos.org/documents/aafc985769c2890ac86510e694c2df3149b7cd36
491. Xu, Bo, Ma, Jun, Jiang, Guojing, Wang, Yu, Ma, Qingliang. Diagnostic value of positron emission tomography (PET) and PET/computed tomography in recurrent/metastatic ovarian cancer: A meta-analysis. *Journal of Obstetrics & Gynaecology Research*. 2017;43(2):378-386.
www.epistemonikos.org/documents/ab14c0f6ece4a9c96a974315cf2486f89f64e00d
492. Zeng LJ, Xiang CL, Gong YZ, Kuang Y, Lu FF, Yi SY, Zhang Y, Liao M. Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis. *Scientific reports*. 2016;6:35914.
www.epistemonikos.org/documents/ab3ea897aaa3071687c197a0ff573080c25e39b4
493. Woopen H., Richter R., Chekerov R., Siepmann T., Sehouli J.. The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and survival in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1,213 patients. *Journal of Clinical Oncology*. 2015;
www.epistemonikos.org/documents/abe2216c18e61a066084acb922b33bafd2eba693
494. Raja F.A., Counsell N., Colombo N., Parmar M.K., Pfisterer J., Vergote I.B., Gonzalez Martin A., Alberts D., Plante M., Ledermann J.A.. Platinum combination chemotherapy versus platinum monotherapy in platinum-sensitive recurrent ovarian cancer: A meta-analysis of randomised trials using individual patient data (IPD). *Annals of Oncology*. 2012;:ix324.
www.epistemonikos.org/documents/ac10d160dc7e55aed40ae91bfcdc66774546b634
495. Rice M.S., Murphy M.A., Tworoger S.S.. Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis. *Journal of Ovarian Research*.

- 2012;5(1):13. www.epistemonikos.org/documents/acc9b56214fd15b298c92d359f2aad11363579da
496. Muscat J, Huncharek M.S.. Meta-analysis of talc-dusted sanitary napkin and ovarian cancer risk. *International Journal of Gynecological Cancer*. 2012;;E433. www.epistemonikos.org/documents/acd1b7c0e7143046066cd35c61cc6eda2a248f13
497. Larsson SC, Orsini N, Wolk A. Milk, milk products and lactose intake and ovarian cancer risk: a meta-analysis of epidemiological studies. *International journal of cancer*. 2006;118(2):431-41. www.epistemonikos.org/documents/ad8bd962cb5f1684a1c56bdf5649c6ebd5bb865b
498. Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. *Critical reviews in oncology/hematology*. 2010;75(1):27-42. www.epistemonikos.org/documents/ad8d2f307a3ba1dc83d06aaafd4a4987da05829a
499. Zhao Z, Xue J, Zhao X, Lu J, Liu P. Prognostic role of autophagy-related proteins in epithelial ovarian cancer: a meta-analysis of observational studies. *Minerva medica*. 2017;108(3):277-286. www.epistemonikos.org/documents/ae2e1e923c670a151ebaeb5f77cdab7423b4128e
500. Bounin A, Charbotel B, Fervers B, Bergeret A. [Professional risk factors associated with the cancer of the ovary. Literature review]. *Bulletin du cancer*. 2014;101(12):1089-108. www.epistemonikos.org/documents/ae6c1a27ec7480b316d98d2b729dae50785ea1bd
501. Marchetti C., De Felice F., Musella A., Palaia I., Monti M., Musio D., Muzii L., Tombolini V., Panici P.B.. Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis. *Oncotarget*. 2016;7(36):58709-58715. www.epistemonikos.org/documents/ae76822684f45059535f08c0bd48cefca6f0dbd3
502. Ma C, Liu Y, Zhang W, Liu P. The association between MTHFR C677T polymorphism and ovarian cancer risk: a meta-analysis of 18,628 individuals. *Molecular biology reports*. 2013;40(3):2061-8. www.epistemonikos.org/documents/aef0634e716530653c7a9857f332f9abdf1f0c42
503. Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. *BMC cancer*. 2012;12(no pagination):258. www.epistemonikos.org/documents/b01c07e358c44b47c72fe75743c8a78809c09641
504. Holloway R.W., Grendys E.C., McMeekin S.. Tolerability, efficacy and safety of pegylated liposomal doxorubicin in combination with carboplatin versus gemcitabine/carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: A systematic review. *Gynecologic Oncology*. 2009;;S160. www.epistemonikos.org/documents/b070a97352ad50100ab83471262c40c34f5944ff
505. Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis. *European journal of cancer (Oxford, England : 1990)*. 2016;55:38-46. www.epistemonikos.org/documents/b0b4616d99ea5d1b01e9c2083e925cd9fcae805e
506. Dayyani F., Uhlig S., Colson B., Simon K., Rolny V., Morgenstern D., Schlumbrecht M.. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection with Ovarian Cancer: A Meta-analysis. *International Journal of Gynecological Cancer*. 2016;26(9):1586-1593. www.epistemonikos.org/documents/b0d3e9d66d8bbe64c9f7cc4c110188a9b30cb6ff
507. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. *Annals of internal medicine*. 2005;143(5):355-61. www.epistemonikos.org/documents/b10946fea5d700541b05bacab126ec16235a41cf
508. Bogani G., Borghi C., Ditto A., Signorelli M., Martinelli F., Chiappa V., Scaffa C., Perotto S., Leone Roberti Maggiore U., Montanelli L., Di Donato V., Infantino C., Lorusso D., Raspagliesi F..

- Impact of Surgical Route in Influencing the Risk of Lymphatic Complications After Ovarian Cancer Staging. *Journal of Minimally Invasive Gynecology*. 2017;24(5):739-746.
www.epistemonikos.org/documents/b1378f84604d9c181a3467c713fe31e8fcc32bcf
509. Huang M, Chen Q, Xiao J, Zhao X, Liu C. CYP1A1 Ile462Val is a risk factor for ovarian cancer development. *Cytokine*. 2012;58(1):73-8.
www.epistemonikos.org/documents/b14ce7509610f1f4466f109b7634c8dff59ab951
510. Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, Botta C, Pignata S, Tassone P, Tagliaferri P. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation. *Oncotarget*. 2016;7(50):82741-82756.
www.epistemonikos.org/documents/b15daabebc808ed27637bec25221375489231ea4
511. Chen P.-P., Yang C.-M.. Correlation between polymorphisms of DNA repair gene XRCC3 and ovarian cancer: a meta-analysis. *Journal of Shanghai Jiaotong University (Medical Science)*. 2015;35(5):718-723.
www.epistemonikos.org/documents/b1a3bc80add21b76bb59e2df49d38037cccce4ee
512. Roland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. *Psycho-oncology*. 2013;22(11):2408-18.
www.epistemonikos.org/documents/b21e26bf0299aa2aa2299947374fd0014f73bf3a
513. Rosen B, Kwon J, Fung Kee Fung M, Gagliardi A, Chambers A, Cancer Care Ontario's Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Systematic review of management options for women with a hereditary predisposition to ovarian cancer. *Gynecologic oncology*. 2004;93(2):280-6.
www.epistemonikos.org/documents/b223a85e6005f86bf86b4884deaf281e9ba95145
514. Liang B, He Q, Zhong L, Wang S, Pan Z, Wang T, Zhao Y. Circulating VEGF as a biomarker for diagnosis of ovarian cancer: a systematic review and a meta-analysis. *OncoTargets and therapy*. 2015;8:1075-82.
www.epistemonikos.org/documents/b2fd292ac5906e391ea5f035a777d0216d1d42fd
515. Ntanasis-Stathopoulos I, Fotopoulos G, Tzanninis IG, Kotteas EA. The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review. *Cancer investigation*. 2016;34(7):1-27.
www.epistemonikos.org/documents/b37744dec7f054b5c58009fc99eeb5a188c15f2a
516. Mousavi A, Karimi-Zarchi M, Behtash N, Modares-Gilani M, Mokhtari-Gorgani M, Mehrdad N, Rouhi M, Anari PY. The Role of Intraperitoneal Carboplatin as Consolidation Chemotherapy in Women with Ovarian Carcinoma: Report of Our Experience and Systematic Review. *International journal of biomedical science : IJBS*. 2016;12(4):120-124.
www.epistemonikos.org/documents/b38377540ff9d27593e76b6178acb546cacc5ddd
517. Trinh X.B., Tjalma W.A., Dirix L.Y., Vermeulen P.B., Bachvarov D., Plante M., Berns E., Helleman J., Van Laere S.J., Van Dam P.A.. Oncogenic pathway profiling in advanced serous papillary ovarian carcinoma: A meta-analysis of 6 datasets. *International Journal of Gynecological Cancer*. 2011;;S53.
www.epistemonikos.org/documents/b40e5f9655f89e0096bcef53bbb1238447e38153
518. Corso G, Feroce I, Intra M, Toesca A, Magnoni F, Sargenti M, Naninato P, Caldarella P, Pagani G, Vento A, Veronesi P, Bonanni B, Galimberti V. BRCA1/2 germline missense mutations: a systematic review. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. 2018;27(3):279-286.
www.epistemonikos.org/documents/b459c73dd72896fa67cf05539e0e1c0cebe94ba8
519. Dilokthornsakul P, Chaiyakunapruk N, Termrungruanglert W, Pratoomsot C, Saokeaw S, Sruamsiri R. The effects of metformin on ovarian cancer: a systematic review. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2013;23(9):1544-51.
www.epistemonikos.org/documents/b49e1741f8426c0b27a7e7ba9c59647d8b05e238

520. Qu N., Guo K.-J.. Meta-analysis of serum HE4's expression in ovarian cancer. *Chinese Journal of Cancer Prevention and Treatment*. 2012;19(16):1258-1262. www.epistemonikos.org/documents/b4b811fd240bfec1c593722fb7d72241ab277b5a
521. Capriglione S, Luvero D, Plotti F, Terranova C, Montera R, Scaletta G, Schirò T, Rossini G, Benedetti Panici P, Angioli R. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. *Medical oncology (Northwood, London, England)*. 2017;34(9):164. www.epistemonikos.org/documents/b506fce0f84ce998eee019f04a226ff5ac1edb39
522. Morotti M, Valenzano Menada M, Venturini PL, Ferrero S. Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment. *Expert opinion on drug metabolism & toxicology*. 2011;7(6):707-20. www.epistemonikos.org/documents/b5c47b7503c49453db51837095f357296e7d9b21
523. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, Park SY. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. *Journal of surgical oncology*. 2010;101(1):13-7. www.epistemonikos.org/documents/b5deb6425f21e3d1b00135ddb11f8da310c195c1
524. Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. *Obstetrics and gynecology*. 1992;80(6):954-60. www.epistemonikos.org/documents/b70cdf527e25f2b67136365f09ed54b94d8b9da4
525. Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. *International journal of technology assessment in health care*. 2006;22(3):327-37. www.epistemonikos.org/documents/b76cadb00a732f65deda87e9545d3924e0d3221f
526. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. *Journal of the National Cancer Institute*. 2006;98(22):1655-63. www.epistemonikos.org/documents/b78005921b21dd5c442e039fd9dcec7b01093d06
527. Jordan SJ, Nagle CM, Coory MD, Maresco D, Protani MM, Pandeya NA, Balasubramaniam KD, Webb PM. Has the association between hysterectomy and ovarian cancer changed over time? A systematic review and meta-analysis. *European journal of cancer (Oxford, England : 1990)*. 2013;49(17):3638-47. www.epistemonikos.org/documents/b8487238672b0f704e8077125c369cab85569c3e
528. Zhu XM, Sun WF. Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review. *PloS one*. 2017;12(9):e0185456. www.epistemonikos.org/documents/b85ab36a7d501bfbde7c669ef92ae04132caeca7
529. Sayasneh A, Tsivos D, Crawford R. Endometriosis and ovarian cancer: a systematic review. *ISRN obstetrics and gynecology*. 2011;2011:140310. www.epistemonikos.org/documents/b88706c6ad0ccf404086d20cff30d9020dc1dee2
530. PEBC's Ovarian Oncology Guidelines Group. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer. *Gynecologic oncology*. 2017;146(2):392-398. www.epistemonikos.org/documents/b89a12a067f2cd4e233c3232581e29a3549fef8d
531. Romero N, Olmos D, Fehm T, Garcia-Donas J, Diaz-Padilla I. Circulating and disseminated tumor cells in ovarian cancer: a systematic review. *Gynecologic oncology*. 2014;133(3):632-9. www.epistemonikos.org/documents/b97219c76ee5cdf9b646d043ac54f799a38cb6ab
532. Sung PL, Chang YH, Chao KC, Chuang CM, Task Force on Systematic Review and Meta-analysis of Ovarian Cancer. Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. *Gynecologic oncology*. 2014;133(2):147-54. www.epistemonikos.org/documents/b99ceef23f8a20b3f9239ee897ffb259255ca5b8

533. Wu S.-Y., Li M.-Z., Liu Y., Wei M.-X.. Meta-analysis of correlation between tea consumption and risk of ovarian cancer. *Journal of Shanghai Jiaotong University (Medical Science)*. 2011;31(6):840-843.
www.epistemonikos.org/documents/ba6122ba8b8f2240786eb3073c1345e372495ac4
534. Shen SQ, Jiang DK, Liu GY, Chen F, Yu L. Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk. *Molecular biology reports*. 2012;39(4):4683-90.
www.epistemonikos.org/documents/ba7a2e295e9aa9de6a45a87e1342b64c576e3248
535. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. *Gynecologic oncology*. 2005;97(1):183-91.
www.epistemonikos.org/documents/ba8c9fa11ddc23b68740a1771106f541058a5dc9
536. Reviews of effectiveness. Screening for ovarian cancer: a systematic review...R. Bell, M. Petticrew, S. Luengo, and T.A. Sheldon. *Health Technology Assessment Vol 2 No. 2 1998 pp. 1-84*. *British Journal of Clinical Governance*. 1999;4(3):117-118.
www.epistemonikos.org/documents/bb0ef2de9b57dbfdce1c2171e41d3605eeaf71fd
537. Sattaratnamai A., Eslick G.D.. The brcacancer gene as a useful predictor for double primary breast and ovarian cancer: A meta-analysis. *Annals of Oncology*. 2014;i6.
www.epistemonikos.org/documents/bb230e78a4e85bc15d52298c315cbd37cc1d2bc8
538. Zhang YJ, Cao LY, Fu ZZ, Wang YJ, Wang GX, Gu T. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer. *Journal of cancer research and therapeutics*. 2015;11(2):375-80.
www.epistemonikos.org/documents/bb34db13a7ff54a25842c767183037471cc802b7
539. Zhang D, Bai B, Xi Y, Wang T, Zhao Y. Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. *Gynecologic oncology*. 2016;142(2):368-77.
www.epistemonikos.org/documents/bb70b4ff89e03d6440b0af61f49bc702d6bf4bb4
540. Menczer J, Schreiber L, Peled O, Levy T. Very late recurrence (after more than 20 years) of epithelial ovarian carcinoma: case report and literature review. *Archives of gynecology and obstetrics*. 2015;291(6):1199-203.
www.epistemonikos.org/documents/bbd1b320b8c0a2e0a7d0a1ffdd01517b3609bb15
541. Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. *Obstetrics and gynecology*. 2013;122(1):139-47.
www.epistemonikos.org/documents/bbf50d2061df43dd928285c598234fced520005e
542. Wang X, Qi X, Ming X, Wang L, Wang Y, Zhao X. Prognostic value of cyclin E expression in patients with ovarian cancer: a Meta-analysis. *Journal of B.U.ON. : official journal of the Balkan Union of Oncology*. 2017;22(1):64-71.
www.epistemonikos.org/documents/bc31e0f553cd8a48e380620eb33335a047a800f0
543. Yang L, Zhang B, Xing G, Du J, Yang B, Yuan Q, Yang Y. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome. *PLoS ONE*. 2017;12(10):e0186725.
www.epistemonikos.org/documents/bc5ed46a695f16a7fcdf7ce056e3319c9bc12e51
544. Huncharek M, Klassen H, Kupelnick B. Dietary beta-carotene intake and the risk of epithelial ovarian cancer: a meta-analysis of 3,782 subjects from five observational studies. *In vivo (Athens, Greece)*. 2001;15(4):339-43.
www.epistemonikos.org/documents/bce8d6ed22621c1aacf7be4011f58dac95812314
545. Qin X, Ma L, Yang S, Zhao J, Chen S, Xie Y, Wang J, Li T, He Y, Peng Q, Deng Y, Li S, Qin A. The Asn680Ser polymorphism of the follicle stimulating hormone receptor gene and ovarian cancer risk: a meta-analysis. *Journal of assisted reproduction and genetics*. 2014;31(6):683-8.
www.epistemonikos.org/documents/bd2389e51a862e470d1a1edab8722f49ad29f92e
546. Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, Muzii L, Tombolini V, Panici P. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk

- and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. *BMC women's health*. 2014;14(1):150.www.epistemonikos.org/documents/bd91e27a9850bc5cc3fb9db51eed5c5d81eb195d
547. Yang Z, Wei C, Luo Z, Li L. Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis. *OncoTargets and therapy*. 2013;6:957-66.
www.epistemonikos.org/documents/bdb2c0078f816c91b8ade5dfdeb6591258361035
548. Wang X., Qi X., Ming X., Wang L., Wang Y., Zhao X.. Prognostic value of cyclin e expression in patients with ovarian cancer: A Meta-analysis. *Journal of B.U.ON.* 2017;22(1):64-71.
www.epistemonikos.org/documents/bde4f905d541584b718f241cc8738046685c735e
549. Huo YL, Qiao JM, Gao S. Association between antidepressant medication use and epithelial ovarian cancer risk: a systematic review and meta-analysis of observational studies. *British journal of clinical pharmacology*. 2018;84(4):649-658.
www.epistemonikos.org/documents/be735dd88a9812e0031a199d25e8c9091150b041
550. Jiang Y, Sun X, Kong B, Jiang J. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials. *Medicine*. 2018;97(34):e11920.
www.epistemonikos.org/documents/beadaebb35e3024daf6506e8f03986cbb56a3a7a
551. Ohler A, Dudziak M, Sznurkowski JJ. Primary ovarian clear cell carcinoma of the abdominal wall—a systematic review of the literature to establish optimal surgical management. *Ginekologia polska*. 2015;86(8):574-81.
www.epistemonikos.org/documents/bf245c6c06b6b0f95ee2bfa26f7e513b9fd9186a
552. Sundar S, Wu J, Hillaby K, Yap J, Lilford R. A systematic review evaluating the relationship between progression free survival and post progression survival in advanced ovarian cancer. *Gynecologic oncology*. 2012;125(2):493-9.
www.epistemonikos.org/documents/bf2a039dab1a0c00951fd9d31da51869f8ac29dd
553. Luo P, Liu XF, Wang YC, Li ND, Liao SJ, Yu MX, Liang CZ, Tu JC. Prognostic value of abnormally expressed lncRNAs in ovarian carcinoma: a systematic review and meta-analysis. *Oncotarget*. 2017;8(14):23927-23936.
www.epistemonikos.org/documents/bf6402b6ec7cce8a030ef5e0fbb0ea6e6664f910
554. Yang HS, Yoon C, Myung SK, Park SM. Effect of obesity on survival of women with epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2011;21(9):1525-32.
www.epistemonikos.org/documents/bf789cbe755df12e8ec4176c12b5e772afdbc239
555. Thomassen M, Jochumsen KM, Mogensen O, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromosomal regions involved in ovarian cancer survival. *Genes, chromosomes & cancer*. 2009;48(8):711-24.
www.epistemonikos.org/documents/bfbceefbb97f31d123c2ab1432fe81412334dbab
556. Cibula D., Zikan M., Dusek L., Majek O.. Oral contraceptives and risk of ovarian and breast cancers in brca mutation carriers: Meta-analysis. *International Journal of Gynecological Cancer*. 2011;:S122.
www.epistemonikos.org/documents/c00ab8416ce663da9536d347a9a60b66f4eaca08
557. Liu S, Liu C, Min X, Ji Y, Wang N, Liu D, Cai J, Li K. Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. *PloS one*. 2013;8(11):e81050.
www.epistemonikos.org/documents/c026dca9d286a874163462e78eb7cec4d3f0ec3d
558. Christine Ang, Karen K L Chan, Andrew Bryant, Raj Naik, Heather O Dickinson. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2011;(4):CD007697.
www.epistemonikos.org/documents/c0bd3fc71313f0f6490d415f9aa911f1dfd4df
559. Li C, Chen P, Hu P, Li M, Li X, Guo H, Li J, Chu R, Zhang W, Wang H. Folate intake and MTHFR polymorphism C677T is not associated with ovarian cancer risk: evidence from the meta-

- analysis. *Molecular biology reports*. 2013;40(12):6547-60.
www.epistemonikos.org/documents/c147efe3eb86c8ed124dd9b985df6b01a9ca6a1d
560. Park HJ, Kim DW, Yim GW, Nam EJ, Kim S, Kim YT. Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis. *American journal of obstetrics and gynecology*. 2013;209(1):58.e1-8.
www.epistemonikos.org/documents/c19160c01177fa0ac44b959a446fbfd111b3e2b1
561. Brockbank EC, Harry V, Kolomainen D, Mukhopadhyay D, Sohaib A, Bridges JE, Nobbenhuis MA, Shepherd JH, Ind TE, Barton DP. Laparoscopic staging for apparent early stage ovarian or fallopian tube cancer. First case series from a UK cancer centre and systematic literature review. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. 2013;39(8):912-7.
www.epistemonikos.org/documents/c24d299f5f7a5c5b323a4ea1fadc48ec2c334054
562. Pal T, Permeth-Wey J, Kumar A, Sellers TA. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2008;14(21):6847-54.
www.epistemonikos.org/documents/c25a3fff688612cc97a0b1f30b85b4b2a7693bac
563. Zhao L., Gu C., Huang K., Zhang Z., Ye M., Fan W., Han W., Meng Y.. The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis. *Archives of Gynecology and Obstetrics*. 2016;294(5):1019-1029.
www.epistemonikos.org/documents/c2736aec4ac2f0f7af8216ee07f028d7ebce8bf5
564. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. *European journal of radiology*. 2009;71(1):164-74.
www.epistemonikos.org/documents/c280c482d64487a9573b58eee1a6f67c345b4f79
565. Tilean Clarke, Khadra Galaal, Andrew Bryant, Raj Naik. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. *Cochrane Database of Systematic Reviews*. 2014;9(9):CD006119.
www.epistemonikos.org/documents/c32442a6cc78ccbf9138bfe40baf92fdf7aba390
566. Anggraeni TD, Al Fattah AN, Surya R. Prophylactic salpingectomy and ovarian cancer: An evidence-based analysis. *South Asian journal of cancer*. 2018;7(1):42-45.
www.epistemonikos.org/documents/c34e183a80656eb03f77940663fa2859ce11817a
567. Gao J, Yang X, Zhang Y. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. *Japanese journal of clinical oncology*. 2015;45(1):49-60.
www.epistemonikos.org/documents/c40a0440f1185ef8628cdaf429de0f5526a5fe31
568. Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. *Clinical chemistry and laboratory medicine : CCLM / FESCC*. 2012;50(8):1439-46.
www.epistemonikos.org/documents/c4731610a768966231c32c9b626b4cb8823db989
569. Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review. *The British journal of radiology*. 2008;81(963):172-9.
www.epistemonikos.org/documents/c4c2e982b591fbce1f36d0cf6004db18b9958080
570. Feng LP, Chen HL, Shen MY. Breastfeeding and the risk of ovarian cancer: a meta-analysis. *Journal of midwifery & women's health*. 2014;59(4):428-37.
www.epistemonikos.org/documents/c4faa083aaab0f795d11228a91571adc25213bc6
571. Lloyd K.L., Cree I.A., Savage R.S.. Prediction of resistance to chemotherapy in ovarian cancer: A systematic review. *BMC Cancer*. 2015;15(1):117.
www.epistemonikos.org/documents/c5a57f207daaa68cf6c91853e0c8bce3358fe163
572. Kang S., Nam B., Lim M., Seo S., Park S.. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. *International*

- Journal of Gynecology and Obstetrics. 2009;;S218-S219.
www.epistemonikos.org/documents/c6373ac6563284557d81498822a0b1a24b71bb09
573. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Circulating vitamin D and ovarian cancer risk. *Gynecologic oncology*. 2011;121(2):369-75.
www.epistemonikos.org/documents/c63eed2bb8d9b5ec0726ff4734febd483a4c33da
574. Shi H, Li Y, Wang X, Lu C, Yang L, Gu C, Xiong J, Huang Y, Wang S, Lu M. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis. *PloS one*. 2013;8(10):e76787.
www.epistemonikos.org/documents/c652105af9ac1ee6fde4187d54399118fdf39da5
575. Mei L., Hou Q., Fang F., Wang H.. The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: A meta-analysis. *European Journal of Gynaecological Oncology*. 2016;37(4):455-460.
www.epistemonikos.org/documents/c65fa1539b6c5bd4bcdf5836f224617bc4cb639d
576. Chen, Shubo, Zhang, Liu, Yan, Guangyue, Cheng, Sijin, Fathy, Abdel Hamid, Yan, Nana, Zhao, Yongzhao. Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis. *BioMed Research International*. 2017;2017(no pagination):1-7.
www.epistemonikos.org/documents/c666bdfc6968dc2c693421d766896a3289afeb87
577. Qin X, Lu Y, Qin A, Chen Z, Peng Q, Deng Y, Xie L, Wang J, Li R, Zeng J, Li S, Zhao J. Vitamin D receptor Bsm1 polymorphism and ovarian cancer risk: a meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2013;23(7):1178-83.
www.epistemonikos.org/documents/c6e1f9446a13af355481dd3f2e69f7535266456b
578. Zhen S, Bian LH, Chang LL, Gao X. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. *Molecular and clinical oncology*. 2014;2(4):559-566.
www.epistemonikos.org/documents/c756f974f8cb6abc55b7d38ea9eaa439b98044f0
579. Li J, Li S, Chen R, Lu X. Increased risk of poor survival in ovarian cancer patients with high expression of SNAI2 and lymphovascular space invasion. *Oncotarget*. 2017;8(6):9672-9685.
www.epistemonikos.org/documents/c784195720c6c1db77db7278a468a72584b8b0f6
580. Roviello, Giandomenico, Bachelot, Thomas, Hudis, Clifford A., Curigliano, Giuseppe, Reynolds, Andrew R., Petrioli, Roberto, Generali, Daniele. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. *European Journal of Cancer*. 2017;75:245-258.
www.epistemonikos.org/documents/c7a888c391c009530a366b5a043c731f4c28a9af
581. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. *Gynecologic oncology*. 2002;85(1):71-80.
www.epistemonikos.org/documents/c8312fc05f2fd613b281d471220c577791f8f032
582. Pan X, Lu Y, Long Y, Yao D. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene Ala222Val and susceptibility to ovary cancer: a systematic review and meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(3):2133-9.
www.epistemonikos.org/documents/c84e4a8a4c8d66822036e1488ec4d0fced12d0a0
583. Zhao W, Zang C, Zhang T, Li J, Liu R, Feng F, Lv Q, Zheng L, Tian J, Sun C. Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: a meta-analysis. *OncoTargets and therapy*. 2018;11:1821-1831.
www.epistemonikos.org/documents/c88ff4c5fc4663d6058a2f5b5f259393beea2eaa
584. Sergentanis TN, Economopoulos KP, Choussein S, Vlahos NF. Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysis. *Molecular biology reports*. 2012;39(11):9921-30.
www.epistemonikos.org/documents/c8a9cc5c28e0230ab895f2ba1606c7ba935714b2

585. Kim H.S., Kim J.W., Shouten L.J., Larsson S.C., Chung H.H., Kim Y.B., Ju W., Park N.H., Song Y.S., Kim S.C., Kang S.-B.. Wine drinking and epithelial ovarian cancer risk: a meta-analysis. *Journal of Gynecologic Oncology*. 2010;21(2):112-118.
www.epistemonikos.org/documents/c9c2bab31a009f2b38d840d20f3bad05f0a89ff0
586. Ibeanu OA, Bristow RE. Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2010;20 Suppl 1(SUPPL.1):S1-11.
www.epistemonikos.org/documents/c9f7276232b9d6ceb720d5f7082dace52be872da
587. Fekete T, Rásó E, Pete I, Tegze B, Liko I, Munkácsy G, Sipos N, Rigó J, Györffy B. Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. *International journal of cancer. Journal international du cancer*. 2012;131(1):95-105.
www.epistemonikos.org/documents/ca7c843013c41a2e2e1a04b65af31681657962d0
588. Zhong JH, Zhang ZM, Li LQ. mEH Tyr113His polymorphism and the risk of ovarian cancer development. *Journal of ovarian research*. 2013;6(1):40.
www.epistemonikos.org/documents/caf370a0c6381a8c50e6c539676fb009fa7cc66e
589. Chen G, Zhu L, Yang Y, Long Y, Li X, Wang Y. Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis. *Technology in cancer research & treatment*. 2018;17:1533033818791500.
www.epistemonikos.org/documents/cb2ece0e7f8d34503ea43e7271e3c0655467f515
590. Li Y, Hu P, Cao Y, Wang GY, Wang N, Zhou RM. Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis. *Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals*. 2014;19(2):128-34.
www.epistemonikos.org/documents/cb651f05137503cab185e40c6139c071e640aac0
591. Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: A systematic review and meta-analysis. *Gynecologic oncology*. 2015;139(2):355-62.
www.epistemonikos.org/documents/cbfc16e6a0d989a5875e6acb0d73ae028b0dcc93
592. Gadducci A, Conte PF. Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2008;18(5):943-53.
www.epistemonikos.org/documents/cc352e29cb136625c621b5f71de4e377004da1e2
593. Rai N., Davenport C., Champaneria R., Snell K., Bayliss S., Stevens S., Neal R., Balogun M., Mallet S., Kehoe S., Deeks J., Sundar S.. Symptoms, ultrasound and biomarkers in combination for the diagnosis of ovarian cancer in women with suspicious symptoms: A systematic review and meta-analysis. *BJOG: An International Journal of Obstetrics and Gynaecology*. 2016;:102-103.
www.epistemonikos.org/documents/cc60cf19d4103b18e1b5eeb7a7e6cf3423420e18
594. Yu L, Deng L, Li J, Zhang Y, Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. *Gynecologic oncology*. 2013;128(2):391-6.
www.epistemonikos.org/documents/cce4a539d0c87d908cfd7a62e78584870d7080c3
595. Ratnavelu, Nithya DG, Brown, Andrew P, Mallett, Susan, Scholten, Rob JPM, Patel, Amit, Founta, Christina, Galaal, Khadra, Cross, Paul, Naik, Raj. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. *Cochrane Database of Systematic Reviews*. 2016;3:CD010360.
www.epistemonikos.org/documents/cd7213ea55073ca4654a68d3e3152761298d3f25
596. Yuan C, Liu X, Yan S, Wang C, Kong B. Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk. *BioMed research international*. 2014;2014(no

- pagination):648137.
www.epistemonikos.org/documents/cdcb1b5e5dddeb5376505ed3b3700d98490bf319
597. Peng HL, He L, Zhao X. Association of reduced immunohistochemical expression of E-cadherin with a poor ovarian cancer prognosis--results of a meta-analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2012;13(5):2003-7.
www.epistemonikos.org/documents/cdfd967290ccf03c14909f3f1c4ac54dc323ae7e
598. Shen Z., Luo H., Li S., Sheng B., Zhao M., Zhu H., Zhu X.. Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: A meta-analysis. *Oncotarget*. 2017;8(37):62400-62413.
www.epistemonikos.org/documents/ce5b2a671bf9598894b6c0b6df0934239aefcdb7
599. Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Histologic distribution of borderline ovarian tumors worldwide: a systematic review. *Journal of gynecologic oncology*. 2013;24(1):44-51.
www.epistemonikos.org/documents/ce637d2db1ec369e598c726e1659fb854b86f179
600. Hua X., Yang Y., Li K., Zhang Q., Yu L.. Correction: An updated meta-analysis of the prognostic value of decreased E-cadherin expression in ovarian cancer [*Oncotarget*.,8, (2017) (81176-81185)] doi 10.18632/oncotarget.20885. *Oncotarget*. 2018;9(28):20220-20220.
www.epistemonikos.org/documents/ceecd1b937bbddb344da8a1f661197e2242e2146
601. Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, Vergote IB, Gonzalez-Martin A, Alberts DS, Plante M, Torri V, Ledermann JA. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2013;24(12):3028-34.
www.epistemonikos.org/documents/cfee3b1f1f87f1f0d806fc07d7ee86d5350dc5b4
602. Huang YW. Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. *Medicine*. 2018;97(2):e9380.
www.epistemonikos.org/documents/d0a3d8c3e694d30611e4928f980f26b4649e4136
603. Skrzypczyk-Ostaszewicz A, Rubach M. Gynaecological cancers coexisting with pregnancy - a literature review. *Contemporary oncology (Poznan, Poland)*. 2016;20(3):193-8.
www.epistemonikos.org/documents/d0d60a74a53e753a244d8245d2b6d9cbc1d15291
604. Nelson HD, Huffman LH, Fu R, Harris EL, Walker M, Bougatsos C. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. 2005;
www.epistemonikos.org/documents/d163a6775908ef332856923485986fd1d2c3e924
605. Pang Y, Wang W. Dietary protein intake and risk of ovarian cancer: Evidence from a meta-analysis of observational studies. *Bioscience reports*. 2018;38(6).
www.epistemonikos.org/documents/d1b5a7f769b67dface79f286dc68efef43202da1
606. Arden-Close E, Gidron Y, Moss-Morris R, School of Psychology, University of Southampton, Highfield, Southampton, UK, ejac103@soton.ac.uk. Psychological distress and its correlates in ovarian cancer: a systematic review. *Psycho-Oncology*. 2008;17(11):1061-1072.
www.epistemonikos.org/documents/d1ee6a9625aeff82e74ec2440ce65c01c5029ab5
607. Callesen AK, Mogensen O, Jensen AK, Kruse TA, Martinussen T, Jensen ON, Madsen JS. Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. *Journal of proteomics*. 2012;75(10):2758-72.
www.epistemonikos.org/documents/d2555455391085e6bd151c96ac50e0932ac703a6
608. Braem MG, Schouten LJ, Peeters PH, van den Brandt PA, Onland-Moret NC. Genetic susceptibility to sporadic ovarian cancer: a systematic review. *Biochimica et biophysica acta*. 2011;1816(2):132-46.
www.epistemonikos.org/documents/d2b11fec8cf2e29806f818258fa0310e1f3a66be

609. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. *Gynecologic oncology*. 2009;112(1):265-74. www.epistemonikos.org/documents/d2e5c293fd5c1eed8d0c49a2faa684a9d2d3cbc2
610. Ling Mei, Hui Chen, Dong Mei Wei, Fang Fang, Guan J Liu, Huan Yu Xie, Xun Wang, Juan Zou, Xu Han, Dan Feng. Maintenance chemotherapy for ovarian cancer. *Cochrane Database of Systematic Reviews*. 2013;6(6):CD007414. www.epistemonikos.org/documents/d2fe11f0e3b748f404729cf8e6d231ce63978c54
611. Kim J.H., Jang H.J., Kim H.S., Kim B.J., Park S.H.. Prognostic impact of high c-Met expression in ovarian cancer: A meta-analysis. *Journal of Cancer*. 2018;9(19):3427-3434. www.epistemonikos.org/documents/d2feaf1e00b3d12e709690da4be8497c7420c414
612. Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. *Cochrane database of systematic reviews (Online)*. 2010;(6):CD007822. www.epistemonikos.org/documents/d321960067f678a009f66ca75dcb9aeb881ddd84
613. Di Donato V, Kontopantelis E, Aletti G, Casorelli A, Piacenti I, Bogani G, Lecce F, Benedetti Panici P. Trends in Mortality After Primary Cytoreductive Surgery for Ovarian Cancer: A Systematic Review and Metaregression of Randomized Clinical Trials and Observational Studies. *Annals of surgical oncology*. 2017;24(6):1-10. www.epistemonikos.org/documents/d44978f92a9b5c99f34e9a3746b5de50d90257f6
614. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2002;20(5):1248-59. www.epistemonikos.org/documents/d4febe9458217f31448c963ac55a918011b7c443
615. Li J, Jiao X, Yuan Z, Qiu H, Guo R. C-reactive protein and risk of ovarian cancer: A systematic review and meta-analysis. *Medicine*. 2017;96(34):e7822. www.epistemonikos.org/documents/d55fe6410079005425ae55cecbe4e13efa978d49
616. Yang B, Wang D, Chen H, Yang F. The association between endometriosis and survival outcomes of ovarian cancer: Evidence-based on a meta-analysis. *Nigerian journal of clinical practice*. 2015;18(5):577-83. www.epistemonikos.org/documents/d57ca419bed77d0fb4ae532defafc677479c236e
617. Iavazzo C, Papakirtsis M, Gkegkes ID. Hypodontia and ovarian cancer: A systematic review. *Journal of the Turkish German Gynecological Association*. 2016;17(1):41-4. www.epistemonikos.org/documents/d5c4f7168c2414a3ed5b90a26e799bfba455c25e
618. Jégu M, Some Der A, Morcel K, Abadie C, Fritel X, Levêque J. [Breast and ovarian cancer due to BRCA1&2 hereditary cancer predisposition syndrome and reproduction: literature review]. *Journal de gynécologie, obstétrique et biologie de la reproduction*. 2015;44(1):10-7. www.epistemonikos.org/documents/d63d2e1a57c050f9b84a691cd7fbcc83e30248d6
619. Cheng A., Li M., Kanis M.J., Xu Y., Zhang Q., Cui B., Jiang J., Zhang Y., Yang X., Kong B.. Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis. *Gynecologic Oncology*. 2017;144(1):215-222. www.epistemonikos.org/documents/d6a6502fe1e99f02284c2b2aa7df6a7cf80dfe51
620. Svahn MF, Faber MT, Christensen J, Norrild B, Kjaer SK. Prevalence of human papillomavirus in epithelial ovarian cancer tissue. A meta-analysis of observational studies. *Acta obstetrica et gynecologica Scandinavica*. 2014;93(1):6-19. www.epistemonikos.org/documents/d72866bf1405dbd24a624170cab804fdb2a7ed3
621. Lawrie TA, Rabbie R, Thoma C, Morrison J. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. *Cochrane Database of Systematic Reviews*. 2013;10(10):CD010482. www.epistemonikos.org/documents/d72b7bce8d6487c9bab9cbb42d34f740f166eb27

622. Wang Q., Bian C., Peng H., He L., Zhao X.. Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: A systematic review and meta-analysis. *Molecular and Clinical Oncology*. 2015;3(3):623-628.www.epistemonikos.org/documents/d73e8a3e8ba18eae649a15214d447680ca4815b9
623. Murphy M.A., Wentzensen N.. Mismatch repair deficiency in the etiology of ovarian cancer: A systematic review of microsatellite instability, mismatch repair staining, and hMLH1 methylation. *Cancer Research*. 2010;
www.epistemonikos.org/documents/d790e380df34759feb62610774edb4e575d09e5b
624. Kim Y.T., Kim J.W., Yim G.W., Park H.J., Kim S., Nam E.J.. A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. *International Journal of Gynecological Cancer*. 2012;;E388.
www.epistemonikos.org/documents/d7da6ebc0060cac1766e0f0d1357afac77efc7cd
625. Shi C, Zhang Z. The prognostic value of the miR-200 family in ovarian cancer: a meta-analysis. *Acta obstetrica et gynecologica Scandinavica*. 2016;95(5):505-12.www.epistemonikos.org/documents/d873ca2388afa566b30d125c0cf9cab81cef5d84
626. Han S, Kim H, Kim YJ, Suh CH, Woo S. Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in ovarian cancer: a systematic review and meta-analysis. *Annals of nuclear medicine*. 2018;32(10):669-677.
www.epistemonikos.org/documents/d90f9aadcefe4008a6a53ed77a6c530b2d997b15
627. Huang Z, Li L, Li C, Ngaujah S, Yao S, Chu R, Xie L, Yang X, Zhang X, Liu P, Jiang J, Zhang Y, Cui B, Song K, Kong B. Diagnostic accuracy of frozen section analysis of borderline ovarian tumors: a meta-analysis with emphasis on misdiagnosis factors. *Journal of Cancer*. 2018;9(16):2817-2824.www.epistemonikos.org/documents/d90fb23763830135d75dfb3f0efc73b5b7a600b4
628. Johannesen EJ, Williams T, Miller DC, Tuller E. Synchronous ovarian and endometrial carcinomas in a patient with Rubinstein-Taybi syndrome: a case report and literature review. *International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists*. 2015;34(2):132-5.www.epistemonikos.org/documents/d98bf243a5790917ad9376140aa6388d116d3379
629. Dai L., Xie L., Liu Y., Qiu L., Di W.. Clinicopathological and prognostic significance of serum interleukin-8 in ovarian cancer: A meta-analysis. *International Journal of Clinical and Experimental Medicine*. 2017;10(1):97-105.
www.epistemonikos.org/documents/d9c56969a3524c79edb814bdf2eeec4df800579c
630. Lu M, Wang Y, Xu F, Xiang J, Chen D. The prognostic of p27(kip1) in ovarian cancer: a meta-analysis. *Archives of gynecology and obstetrics*. 2016;293(1):169-76.www.epistemonikos.org/documents/db217ff7220a71b1f5ffd309d8dfd33a5bb32433
631. Gianuzzi-Gaviria X., Palma-Ardiles G., Hernandez-Fernandez W., Pasupuleti V., Hernandez A., Perez-Lopez F.. Insulin growth factor (IGF) 1, IGF-binding proteins and ovarian cancer risk: A systematic review and meta-analysis. *Climacteric*. 2016;;70.
www.epistemonikos.org/documents/db3d5f2ab05e58e9790c9ca5eb93923ba6c56bd9
632. Wopen H, Richter R, Chekerov R, Siepmann T, Ismaeel F, Sehoul J. The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO). *Gynecologic oncology*. 2015;138(3):735-40.
www.epistemonikos.org/documents/db8350e4d39c1ee66e375afd2fa2d804f0cf331f
633. Bogani G, Borghi C, Leone Roberti Maggiore U, Ditto A, Signorelli M, Martinelli F, Chiappa V, Lopez C, Sabatucci I, Scaffa C, Indini A, Ferrero S, Lorusso D, Raspagliesi F. Minimally invasive surgical staging in early stage ovarian carcinoma: a systematic review and meta-analysis. *Journal of minimally invasive gynecology*. 2017;24(4):552-562.www.epistemonikos.org/documents/dbd183402da2e5016b9cbe154d0a3b3faafbe943
634. Jia H, Zhang Q, Liu F, Zhou D. Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis. *Archives of gynecology and*

- obstetrics. 2017;295(3):689-696.
www.epistemonikos.org/documents/dbe35f652dd77ee588c9caf34a9d4bddcae5cf4f
635. Weng L., Wang L., Zhang J., Wang B., Liu H.. Association between diabetes mellitus and subsequent ovarian cancer in women: A systematic review and meta-analysis of cohort studies. *Medicine (United States)*. 2017;96(16):e6396.
www.epistemonikos.org/documents/dbf64fea24f417ade9da808ff23cd9a4260e2f41
636. Liang Y., Liu J.-L., Zhang Z.-Y., Wu R.. Systemic review of efficacy and safety of chemotherapy in refractory and relapsed ovarian cancer. *Chinese Journal of Cancer Prevention and Treatment*. 2011;18(6):453-456.
www.epistemonikos.org/documents/dc0cc24fe284a7bca13f9708f1595eadc6032b05
637. Zuo S., Yang G., Hu F., Tang T., Wang Y., Peng X., Zeng X.. Combined detection of CA125, CA19-9, and CEA in the diagnosis of ovarian cancer: A meta analysis. *Chinese Journal of Clinical Oncology*. 2012;39(5):263-268.
www.epistemonikos.org/documents/dc8a80cd6307385e689054d9117a78f5f87bc83b
638. Aune D, Navarro Rosenblatt DA, Chan DS, Abar L, Vingeliene S, Vieira AR, Greenwood DC, Norat T. Anthropometric factors and ovarian cancer risk: A systematic review and nonlinear dose-response meta-analysis of prospective studies. *International journal of cancer. Journal international du cancer*. 2015;136(8):1888-1898.
www.epistemonikos.org/documents/dd09b6b527b4c272da1a6c26b7dc45fd8c8ad994
639. Cherbal F, Bakour R, Adane S, Boualga K. BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghreb countries. *Breast disease*. 2012;34(1):1-8.
www.epistemonikos.org/documents/ddc57bdb2e44e5b3e3e82642614ffc19c6ad29eb
640. Wu L, Dai ZY, Qian YH, Shi Y, Liu FJ, Yang C. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2012;22(7):1106-12.
www.epistemonikos.org/documents/ddef6aad1eadbe9e1974752569dbe969d2b1d25a
641. Crane TE, Khulpateea BR, Alberts DS, Basen-Engquist K, Thomson CA. Dietary intake and ovarian cancer risk: a systematic review. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2014;23(2):255-73.
www.epistemonikos.org/documents/de3c89ce62000a1f5b1b6c2847e4093219cfd399
642. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Human reproduction update*. 2014;20(5):748-58.
www.epistemonikos.org/documents/df8cc6197437989f74bb9990c1ccd2dbd5afa768
643. Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A. Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. *ISRN obstetrics and gynecology*. 2012;2012:245756.
www.epistemonikos.org/documents/dfdf245fdbf46288b49a927ebe21f82260e6f921
644. Cao H, You D, Lan Z, Ye H, Hou M, Xi M. Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies. *Expert review of molecular diagnostics*. 2018;18(4):1-13.
www.epistemonikos.org/documents/dfdff30474fb278d26561468dae97b3c94b15bf7
645. Waldron L., Riestler M., Birrer M., Parmigiani G.. A comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. *Cancer Research*. 2014;74(19).
www.epistemonikos.org/documents/e08148846684332ccb203eb3948840086ca11fc5
646. Sun S, Cai J, Yang Q, Zhu Y, Zhao S, Wang Z. Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis. *PloS one*.

- 2016;11(11):e0166058.
www.epistemonikos.org/documents/e089db9cda965fb712067f08cfa003529a3131be
647. Bae HS, Kim HJ, Hong JH, Lee JK, Lee NW, Song JY. Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis. *Journal of ovarian research*. 2014;7(1):41.
www.epistemonikos.org/documents/e09f5d267720f20ddb1e0d75ef9fac073cab7b
648. Li J.N., Pan L., Qin X., Chu H.Y., Mu H.Y., Wan G.X.. Association between ERCC2 rs13181 polymorphism and ovarian cancer risk: an updated meta-analysis with 4024 subjects. *Archives of Gynecology and Obstetrics*. 2017;296(3):551-558.
www.epistemonikos.org/documents/e0ad2f98de557818045b24129379c1b3a9497635
649. Nelson HD, Huffman LH, Fu R, Harris EL, U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. *Annals of internal medicine*. 2005;143(5):362-79.
www.epistemonikos.org/documents/e0f931a9705ec3f151d691b98cb46739b75ff351
650. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systematic review. *British Journal of Obstetrics & Gynaecology*. 1998;105(11):1136-1147. www.epistemonikos.org/documents/e143c117de28862b915184c31c5451cdcd104076
651. Yin Y, Feng L, Sun J. Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2013;34(6):4059-63.
www.epistemonikos.org/documents/e1f3499a909736901eb0748b583def261272b2a0
652. Han X., Wang A., He Y., Wang X.. Prognostic value of circulating and disseminated tumor cells in ovarian cancer: A meta-analysis. *International Journal of Clinical and Experimental Medicine*. 2018;11(1):43-58.
www.epistemonikos.org/documents/e28cadee558035594edd806df00cecf308029161
653. Kim, H, Ju, W, Jee, B, Kim, J, Song, Y, Lee, H. The efficacy of systemic lymphadenectomy for overall survival in epithelial ovarian cancer: A systematic review and meta-analysis by KOGYMAG. *Journal of Clinical Oncology*. 2009;27:16509-16509.
www.epistemonikos.org/documents/e291d69a48e259d330629e6effe963e02dc2a765
654. Miao H, Miao CX, Han J, Li N. Does the age affect the efficacy of angiogenesis inhibitors in ovarian cancer? A meta-analysis of randomized controlled trials. *European review for medical and pharmacological sciences*. 2017;21(13):3047-3053.
www.epistemonikos.org/documents/e2bf35dbbe6044b629308c83046b555f9a1c47c0
655. Jin Y, Wang H, Liang X, Ma J, Wang Y. Pathological and prognostic significance of hypoxia-inducible factor 1 α expression in epithelial ovarian cancer: a meta-analysis. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(8):8149-59.
www.epistemonikos.org/documents/e2c649e98f5a38cd8376f81451c150f8e86f7b71
656. Lan Z, Wang F, Yu X, Zeng X, Xi M. Diagnostic Accuracy of Serum Kallikrein-Related Peptidases for Ovarian Cancer: A Systematic Review and Meta-Analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2016;26(8):1366-74.
www.epistemonikos.org/documents/e2e8b40ecf92c5d29d813a6f348f9914abcf1e7a
657. Vlahos NF, Economopoulos KP, Creatsas G. Fertility drugs and ovarian cancer risk: a critical review of the literature. *Annals of the New York Academy of Sciences*. 2010;1205:214-9.
www.epistemonikos.org/documents/e3c63a84ac71a1d66bd187397fcfc171c0d384a6
658. Zeng Y, Zhang Q, Wang H, Lu M, Kong H, Zhang Y, Shi H. Prognostic significance of interleukin-17 in solid tumors: a meta-analysis. *International journal of clinical and experimental medicine*. 2015;8(7):10515-36.
www.epistemonikos.org/documents/e431baaeffddec63b5c13872d194064b0ee7ee9b1

659. Kim JH, Jang HJ, Kim HS, Kim BJ, Park SH. Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis. *Journal of Cancer*. 2018;9(19):3427-3434. www.epistemonikos.org/documents/e45f7b7e01d9f9d9e0d95b1e21246689d4db0c14
660. Helder-Woolderink J.M., Blok E.A.W., Vasen H.F.A., Hollema H., Mourits M.J.E., Bock De G.H.. Ovarian cancer in lynch syndrome: A systematic review. *International Journal of Gynecological Cancer*. 2015;:449. www.epistemonikos.org/documents/e474b59c99172c1b5a92d4a85ff9fce6fb756be7
661. Liang H, Li Y, Luo RY, Shen FJ. An increased risk of ovarian cancer associated with polymorphism in BRCC5 gene in Caucasian populations. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2014;35(9):9179-84. www.epistemonikos.org/documents/e4eca2e57322c4d38a4f07e18fed83ed7c5b7beb
662. Ge L.-N., Wang F.. Prognostic significance of preoperative serum albumin in epithelial ovarian cancer patients: A systematic review and dose-response meta-analysis of observational studies. *Cancer Management and Research*. 2018;10:815-825. www.epistemonikos.org/documents/e71752a9b7203178d7bad635d8aeb937c8b32166
663. Kim HS, Ahn JH, Chung HH, Kim JW, Park NH, Song YS, Lee HP, Kim YB. Impact of intraoperative rupture of the ovarian capsule on prognosis in patients with early-stage epithelial ovarian cancer: a meta-analysis. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. 2013;39(3):279-89. www.epistemonikos.org/documents/e791b77c05599c5774524c9de0af1eb8e7b09109
664. Simons M, Massuger L, Bruls J, Bulten J, Teerenstra S, Nagtegaal I. Relatively Poor Survival of Mucinous Ovarian Carcinoma in Advanced Stage: A Systematic Review and Meta-analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2017;27(4):651-658. www.epistemonikos.org/documents/e7920e0c5a4aea32893b1f6dc7e924a95f439f83
665. Kodama M, Grubbs BH, Blake EA, Cahoon SS, Murakami R, Kimura T, Matsuo K. Feto-maternal outcomes of pregnancy complicated by ovarian malignant germ cell tumor: a systematic review of literature. *European journal of obstetrics, gynecology, and reproductive biology*. 2014;181C:145-156. www.epistemonikos.org/documents/e84bf81be30138a6c896886b5d5d5032b09aa0be
666. Huang J, Chen J, Huang Q. Diagnostic value of HE4 in ovarian cancer: A meta-analysis. *European journal of obstetrics, gynecology, and reproductive biology*. 2018;231:35-42. www.epistemonikos.org/documents/e909994eddb3286ae5e2dbcc1d451aed7281ad11
667. He L, Wang Q, Zhao X. Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2015;16(3):869-74. www.epistemonikos.org/documents/e9d6bdd7ca9ae665f14758b47ddf52067526899a
668. Ye Q, Chen HL. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. *Archives of gynecology and obstetrics*. 2013;288(3):655-66. www.epistemonikos.org/documents/ea35590533e025792a91df23491aab9a3448ee
669. Park HJ, Nam EJ, Rha SY, Kim S, Kim SW, Kim JW, Kim YT. A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. *Gynecologic oncology*. 2012;126(3):357-63. www.epistemonikos.org/documents/ea6483115c41517ec9ba8344f16a9daa2ca2e576
670. Diniz Gomes D.B., Uson P.L.S., Franca M.S., Antunes Y.P., Taranto P., Guendelmann R.K., Del Giglio A.. Does time-to-chemotherapy (TTC) impact the outcomes of resected ovarian cancer? Meta-analysis of randomized and observational data. *Journal of Clinical Oncology*. 2016; www.epistemonikos.org/documents/ea8ec6b567eb0a9ff6327b0f6706b9fe1e3f0e63
671. ZHANG Meng-ting, TIAN Jin-hui, WANG Zi-jing, YANG Yong-xiu. Correlation between Physical Activities and Risk of Ovarian Cancer: A Meta-Analysis. *中国循证医学杂志*

- (Chinese Journal of Evidence-Based Medicine). 2014;10(2014):1194-1200.
www.epistemonikos.org/documents/ea99efd4c8a226e606e0d97e4f8357fe3aaa1558
672. Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. *Gynecologic oncology*. 2013;130(3):674-81.
www.epistemonikos.org/documents/eab6e50803daabfcb52c629c4b7e5fc39694e541
673. Hua X., Yang Y., Li K., Zhang Q., Yu L.. An updated meta-analysis of the prognostic value of decreased E-cadherin expression in ovarian cancer. *Oncotarget*. 2017;8(46):81176-81185.
www.epistemonikos.org/documents/eadcecd031b0c65513e0ebb26eb19b058e190ea
674. Huang Z., Li L., Li C., Ngaujah S., Yao S., Chu R., Xie L., Yang X., Zhang X., Liu P., Jiang J., Zhang Y., Cui B., Song K., Kong B.. Diagnostic accuracy of frozen section analysis of borderline ovarian tumors: A meta-analysis with emphasis on misdiagnosis factors. *Journal of Cancer*. 2018;9(16):2817-2824.
www.epistemonikos.org/documents/eb44bc7280a159f0d19c3513480a435990115caa
675. Ruan J, Xu P, Fan W, Deng Q, Yu M. Quantitative assessment of aberrant P16INK4a methylation in ovarian cancer: a meta-analysis based on literature and TCGA datasets. *Cancer management and research*. 2018;10:3033-3046.
www.epistemonikos.org/documents/eb672d5396c380a7273ac8e8e5f5f3898962fc14
676. Westwood M, Ramaekers B, Lang S, Grimm S, Deshpande S, de Kock S, Armstrong N, Joore M, Kleijnen J. Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. *Health technology assessment (Winchester, England)*. 2018;22(44):1-264.
www.epistemonikos.org/documents/eb7bd3e9e76dc75db48f987d116bdf9b1a3c4003
677. T S Shylasree, Andrew Bryant, Ram Athavale. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. *Cochrane Database of Systematic Reviews*. 2013;2(2):CD006246.
www.epistemonikos.org/documents/ebb4885474e348415ac119650c033c29267a19a7
678. Jiao YS, Gong TT, Wang YL, Wu QJ. Comorbidity and survival among women with ovarian cancer: evidence from prospective studies. *Scientific reports*. 2015;5:11720.
www.epistemonikos.org/documents/ebf5b3aa13ec65140ab1aeee13b97125a8452d63
679. Zhong Q., Peng H.-L., Zhao X., Zhang L., Hwang W.-T.. Effects of BRCA1- And BRCA2-related mutations on ovarian and breast cancer survival: A meta-analysis. *Clinical Cancer Research*. 2015;21(1):211-220.
www.epistemonikos.org/documents/ec81f76aaa07eb4531f55670c659d4f86d3a3346
680. Jiao X, Hu J, Zhu L. Prognostic Factors for Recurrence After Fertility-Preserving Surgery in Patients With Borderline Ovarian Tumors: A Systematic Review and Meta-analysis of Observational Studies. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2017;27(9):1833-1841.
www.epistemonikos.org/documents/ed28b900c6ddc0f455a18448973e0d414f131ff2
681. Rezaianzadeh, Abbas, Mokhtari, Ali Mohammad, Hassanipour, Soheil, Maghsoudi, Ahmad, Dehghani, Seyedeh Leila, Nazarzadeh, Milad, Maharlouei, Najmeh. The Age-standardized Incidence Rate of Ovarian Cancer in Iranian Women: A Systematic Review and Meta-analysis. *Middle East Journal of Cancer*. 2018;9(3):171-178.
www.epistemonikos.org/documents/ed5404733615f59663aa97a25d957f015a9ae787
682. Smits A, Lopes A, Das N, Bekkers R, Massuger L, Galaal K. The effect of lifestyle interventions on the quality of life of gynaecological cancer survivors: A systematic review and meta-analysis. *Gynecologic oncology*. 2015;139(3):546-552.
www.epistemonikos.org/documents/eda4b50288da1bcac4be8eabaaa1dfffc61dcc91
683. Chan DL, Morris DL, Rao A, Chua TC. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. *Cancer management and research*. 2012;4:413-22.
www.epistemonikos.org/documents/ee068d3028cbff35503432cfe0601e11ae8aa18c

684. Zafrakas M, Grimbizis G, Timologou A, Tarlatzis BC. Endometriosis and ovarian cancer risk: a systematic review of epidemiological studies. *Frontiers in surgery*. 2014;1:14. www.epistemonikos.org/documents/ee1b6547f9cd67239a8d7af23b305313434015ea
685. Ebell MH, Culp M, Lastinger K, Dasigi T. A Systematic Review of the Bimanual Examination as a Test for Ovarian Cancer. *American journal of preventive medicine*. 2015;48((Ebell M.H.; Culp M., ebell@uga.edu; Lastinger K.; Dasigi T.) Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, Georgia):350-6. www.epistemonikos.org/documents/eed7dcf61c9e8c85c66c7a9f55204fbec236d950
686. Parente, Raphael Câmara Medeiros, Silva, Juliana Murteira Esteves, Alves, Daniele Babosa Lemos, Boas, Gabriela Vieira Vilas, Felício, Flávia Luz, Berardo, Plínio Tostes, Miyahira, Hugo. When to do prophylactic oophorectomy based on scientific evidence, not beliefs. *Femina*. 2010;37(10). www.epistemonikos.org/documents/ef2e9c0992effd5ff4bab327e862db78ba3f0ae8
687. Dellinger T.H., Smith D.D., Ballard E., Mikhael E., Morgan R.J., Lee B., Wakabayashi M.T., Han E.S.. HIPEC treatment in advanced and recurrent ovarian cancer: A meta-analysis of observational studies. *European Journal of Gynaecological Oncology*. 2018;39(3):353-360. www.epistemonikos.org/documents/ef5ec01a7645f3834fb190c566cfdb291d748db5
688. Han LY, Liu K, Lin XL, Zou BB, Zhao JS. Lack of any association of GST genetic polymorphisms with susceptibility to ovarian cancer—a meta-analysis. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(15):6131-6. www.epistemonikos.org/documents/efdaa48a414efebbb240980a3961d04d6ba3a3bfd
689. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. *International journal of cancer. Journal international du cancer*. 2013;132(12):2894-900. www.epistemonikos.org/documents/efe52bdfc1053961489f497b6956353a9ca072f8
690. Rezaianzadeh A., Mokhtari A.M., Hassanipour S., Maghsoudi A., Dehghani S.L., Nazarzadeh M., Maharlouei N.. The age-standardized incidence rate of ovarian cancer in Iranian women: A systematic review and meta-analysis. *Middle East Journal of Cancer*. 2018;9(3):171-178. www.epistemonikos.org/documents/f0110d5a95c71c57dd78df516abf251d4ebcd536
691. Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B, Cancer Care Ontario Practice Guidelines Initiative Gynecology Disease Site Group. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum—a systematic review of the evidence from randomized trials. *European journal of gynaecological oncology*. 2002;23(2):104-10. www.epistemonikos.org/documents/f05f1709a7452adf41f977e7cb760a6ce61d08da
692. Liu L, Liao SG, Wang YJ. MTHFR polymorphisms and ovarian cancer risk: a meta-analysis. *Molecular biology reports*. 2012;39(11):9863-8. www.epistemonikos.org/documents/f0939578970e207e403674e3cf211224b225d4b08
693. Lee J. Physical activity, sitting time, and the risk of ovarian cancer: A brief research report employing a meta-analysis of existing. *Health care for women international*. 2019;40(4):1-26. www.epistemonikos.org/documents/f19bff5c58f928de50ae6bf15312e2e4f42e6518
694. Rossella D.L., Renato V., Valentina C., Patrizia D., Domenico B., Giuseppe C.. Impact of combination chemotherapy on toxicity in ovarian cancer: Systematic revision of literature and meta-analysis. *Acta Medica Mediterranea*. 2016;32(6):1835-1842. www.epistemonikos.org/documents/f1edc772dd06f70eb1ee912240d1d6b6f55ecef8
695. Li J, Zhou L, Chen X, Ba Y. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*. 2015;17(9):673-83. www.epistemonikos.org/documents/f1f424a12cbe8cfa57b486ec9241a9ff90c1f214
696. Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. *Critical reviews in oncology/hematology*.

- 2018;131:83-
89.www.epistemonikos.org/documents/f227791754985996d960c2c44b16ca0bbb25aef
697. Lu Y., Yao D., Xu J.. Evaluation of comprehensive laparoscopic surgical staging in early-stage ovarian cancer: A meta-analysis. *Chinese Journal of Clinical Oncology*. 2013;40(19):1174-1178. www.epistemonikos.org/documents/f272db4fd9d62e339efa3a2613efcd2a1b98bb3d
698. Terplan M, Smith EJ, Temkin SM. Race in ovarian cancer treatment and survival: a systematic review with meta-analysis. *Cancer causes & control : CCC*. 2009;20(7):1139-50. www.epistemonikos.org/documents/f27dd8eb53510ea8fb7c1b4a9cdab790d8c17d32
699. Pergialiotis V, Doumouchtsis SK, Perrea D, Vlachos GD. The Impact of Underweight Status on the Prognosis of Ovarian Cancer Patients: A Meta-Analysis. *Nutrition and cancer*. 2016;68(6):1-8. www.epistemonikos.org/documents/f284cc05c8a9e256fd60ee44a5c5b26cbbf9a790
700. Foong KW, Bolton H. Obesity and ovarian cancer risk: A systematic review. *Post reproductive health*. 2017;23(4):2053369117709225. www.epistemonikos.org/documents/f2a30d7daff29e04c4cd6434c59dcd28e1c1bb61
701. Parvaresh A, Razavi R, Rafie N, Ghiasvand R, Pourmasoumi M, Miraghajani M. Quercetin and ovarian cancer: An evaluation based on a systematic review. *Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences*. 2016;21:34. www.epistemonikos.org/documents/f310d0cec85afae9bdbff07436ecdaefe5fdb0ef
702. Tanyi JL, Chu CS. Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. *Immunotherapy*. 2012;4(10):995-1009. www.epistemonikos.org/documents/f3166fa1d1940318c26f810e101a7ab2545391b0
703. Husseinzadeh N, Husseinzadeh HD. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. *Gynecologic oncology*. 2014;133(2):375-81. www.epistemonikos.org/documents/f31674c52f0c87192fe43143bdb317c8222d5d20
704. Riester M., Wei W., Culhane A.C., Trippa L., Michor F., Huttenhower C., Parmigiani G., Birrer M.. Risk prediction for late-stage ovarian cancer by meta-analysis of 1,525 patient samples. *Cancer Research*. 2014;74(19). www.epistemonikos.org/documents/f32adf911799a34975ac06b5f4892c6ff75c4e50
705. Liu W., Li Y., Li R., Han X., Ma Y., Liu B., Kong X.. Association of MTHFR A1298C polymorphism with breast cancer and/or ovarian cancer risk: An updated meta-analysis. *African Journal of Traditional, Complementary and Alternative Medicines*. 2016;13(5):72-86. www.epistemonikos.org/documents/f333826b203d52c3e6233fa3e6db82b3dd33009b
706. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. *Gynecologic oncology*. 2007;105(3):801-12. www.epistemonikos.org/documents/f385f57e82016c7d23e2155d347a896cfac3e01f
707. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. *Lancet*. 2008;371(9609):303-14. www.epistemonikos.org/documents/f3d6533033aa593ea7c9844d66725225996f7d07
708. Yafei ZHU, Guolan GAO, Qingshui HUANG, Jun TANG. Diagnostic value of serum human epididymis protein 4 in human epithelial ovarian cancer: a meta-analysis. *中国肿瘤临床 (Chinese Journal of Clinical Oncology)*. 2011;38(24):1559-1564. www.epistemonikos.org/documents/f3de04a589a36881f5049640d4c64ebef66eea13
709. Lee JY, Myung SK, Song YS. Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. *Gynecologic oncology*. 2013;129(3):613-9. www.epistemonikos.org/documents/f3f2d7cea029790384b9e462a8f233790b31e2e6
710. Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525

- patient samples. *Journal of the National Cancer Institute*. 2014;106(5):48-48.
www.epistemonikos.org/documents/f41ddb0b135f740a9583986239c529e40776aee1
711. Möbus V, Kieback DG, Kaubitzsch SK. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis. *Anticancer research*. 2007;27(3B):1581-7.
www.epistemonikos.org/documents/f4bd9939b9d9ae56579bef350842967d7284d5d2
712. Xu L, Cai J, Yang Q, Ding H, Wu L, Li T, Wang Z. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. *Journal of cancer research and clinical oncology*. 2013;139(8):1257-77.
www.epistemonikos.org/documents/f5192178af5fc95436b2fec52a5d023f15ebb88e
713. Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T, Landoni F, Gadducci A, Sartori E, Gion M, Zola P. The role of HE4 in ovarian cancer follow-up: a review. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2014;24(8):1359-65.
www.epistemonikos.org/documents/f60c1dab5d5ad41f529b824ab2e67c6a66a52186
714. Alqumber MA, Akhter N, Haque S, Panda AK, Mandal RK. Evaluating the association between p53 codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysis. *PloS one*. 2014;9(4):e94874.
www.epistemonikos.org/documents/f6a0e566ddcb23613112d60786e910731b20adb1
715. Yuan Y, Gu ZX, Tao XF, Liu SY. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. *European journal of radiology*. 2012;81(5):1002-6.
www.epistemonikos.org/documents/f70679916b909e48085cf16dbddf74b6cf6ae95
716. Wu Y., Peng H., Zhao X.. Diagnostic Performance of Contrast-Enhanced Ultrasound for Ovarian Cancer: A Meta-Analysis. *Ultrasound in Medicine and Biology*. 2015;41((Wu Y., Wuyingxiongxiang@163.com; Peng H.; Zhao X.) Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, People's Republic of China):967-74.
www.epistemonikos.org/documents/f70b711ae3560cde19cf8824ee91e8a584af61e2
717. Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. *Drug design, development and therapy*. 2018;12:3013-3019.
www.epistemonikos.org/documents/f827be4c83eca01be1149daac0fd752d34d2dd4e
718. Garziera M, Montico M, Bidoli E, Scalone S, Sorio R, Giorda G, Lucia E, Toffoli G. Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis. *PloS one*. 2015;10(10):e0140351.
www.epistemonikos.org/documents/f8ccc4600b299aba9dc1e84bfebfd0dd36ba89d
719. Hu X, Sun S. RAD51 Gene 135G/C polymorphism and ovarian cancer risk: a meta-analysis. *International journal of clinical and experimental medicine*. 2015;8(12):22365-70.
www.epistemonikos.org/documents/f90633d8281bb5b0ef58fb7ccee4f8f64e46673c
720. Kucukmetin A, Naik R, Galaal K, Bryant A, Dickinson HO. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. *Cochrane database of systematic reviews (Online)*. 2010;(7):CD007792.
www.epistemonikos.org/documents/f916196dd18f70fadd13ca6f295556c2359c2539
721. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SE, Kjaer SK, Jensen A, Høgdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O,

- Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD, EMBRACE, kConFab Investigators, Cancer Genome Atlas Research Network. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA*. 2012;307(4):382-90. www.epistemonikos.org/documents/f91d45ae3124518e34c7b0c7ae1fd053160e4a31
722. Vasconcelos I, Olschewski J, Braicu I, Sehouli J. Ameta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants. *Oncologist*. 2015;20(2):151-158. www.epistemonikos.org/documents/fa205773bb1a52dd1b46fa36cb11a67f81d3ee52
723. Tempfer C.B., Schultheis B., Hilal Z., Dogan A., Rezniczek G.A.. Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature. *Oncology Letters*. 2017;14(3):3327-3336. www.epistemonikos.org/documents/fa38e1b1a098cea1a987f755f0ef95908e29623b
724. Meys EM, Kaijser J, Kruitwagen RF, Slangen BF, Van Calster B, Aertgeerts B, Verbakel JY, Timmerman D, Van Gorp T. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. *European journal of cancer (Oxford, England : 1990)*. 2016;58:17-29. www.epistemonikos.org/documents/fa45421d7431c613032f107b4a331f39788c115c
725. Xiao X., Cai F., Niu X., Shi H., Zhong Y.. Association between P16INK4a promoter methylation and ovarian cancer: A meta-analysis of 12 published studies. *PLoS ONE*. 2016;11(9):e0163257. www.epistemonikos.org/documents/fa50854ba0bac6751f69088e3832cf5bb5085986
726. Hess LM, Stehman FB. State of the science in ovarian cancer quality of life research: a systematic review. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2012;22(7):1273-80. www.epistemonikos.org/documents/fb3fea3b8afa3347e4afe3a6b78c219920884e54
727. Xu W., Wang W., Yang M., Song L., Xiong J., Lin J., Long J., Bai Y., Zheng Y., Zhao L., Sang X., Zhao H.. Prognostic significance of the platelet-to-lymphocyte ratio in ovarian cancer: A meta-analysis. *Translational Cancer Research*. 2018;7(3):552-560. www.epistemonikos.org/documents/fc0592872819f4a15e5e4252690f150a06a7fdbd
728. Gajjar K, Owens G, Sperrin M, Martin-Hirsch PL, Martin FL. Cytochrome P1B1 (CYP1B1) polymorphisms and ovarian cancer risk: a meta-analysis. *Toxicology*. 2012;302(2-3):157-62. www.epistemonikos.org/documents/fc090b34df3dfd405966411c96a97facb1ff53f9
729. Wang Q., Wang B., Zhang Y.-M., Wang W.. The association between CDH1 promoter methylation and patients with ovarian cancer: A systematic meta-analysis. *Journal of Ovarian Research*. 2016;9(1):23. www.epistemonikos.org/documents/fc670620dda7624d72ada88ad2aefdfb63bf63ae
730. Zhang X, Qin J, Qin A. Three Polymorphisms of Vascular Endothelial Growth Factor (+936C > T, -460C > T, and -2578C > A) and Their Susceptibility to Ovarian Cancer: A Meta-Analysis. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2015;25(5):779-85. www.epistemonikos.org/documents/fc8a3eae57de89b7757cd1c29c8ac985fd00e56d
731. Huncharek M, Geschwind JF, Kupelnick B. Perineal application of cosmetic talc and risk of invasive epithelial ovarian cancer: a meta-analysis of 11,933 subjects from sixteen observational studies. *Anticancer research*. 2003;23(2C):1955-60. www.epistemonikos.org/documents/fcac1090c46ec09e39b601c6bced988b3c6f8d16
732. Shen C., Sheng Q., Zhang X., Fu Y., Zhu K.. Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer. *Journal of Ovarian Research*. 2016;9(1):60. www.epistemonikos.org/documents/fcfede6a513637f177d754383cb4caadb948277a
733. Wang Z, Ji G, Wu Q, Feng S, Zhao Y, Cao Z, Tao C. Integrated microarray meta-analysis identifies miRNA-27a as an oncogene in ovarian cancer by inhibiting FOXO1. *Life sciences*. 2018;210:263-270. www.epistemonikos.org/documents/fd795d9eacfa9e54922a56510b0f10f250a1987c

734. Berretta M, Micek A, Lafranconi A, Rossetti S, Di Francia R, De Paoli P, Rossi P, Facchini G. Coffee consumption is not associated with ovarian cancer risk: a dose-response meta-analysis of prospective cohort studies. *Oncotarget*. 2018;9(29):20807-20815.
www.epistemonikos.org/documents/fdcb6e4b06b6a23df445fd0ae73d3bc2dd2bb7fa
735. Blieden M.B.. Body mass index and stage of diagnosis of ovarian cancer: A systematic review and meta-analysis. *Value in Health*. 2011;:A155.
www.epistemonikos.org/documents/fe9fd22ddc3afb451563203b30233f3ca7ea503b
736. Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D, Yeap BY. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. *British journal of cancer*. 1998;78(11):1479-87.
www.epistemonikos.org/documents/fec54db434d8b5baa4b1b10f214d75270dd65448
737. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. *Journal of clinical epidemiology*. 2000;53(4):367-75.
www.epistemonikos.org/documents/ff09454cdd0e13fe0f7cb23ae2e663a07144cdd3
738. Vos S, van Diest PJ, Moelans CB. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?. *Critical reviews in oncology/hematology*. 2018;127:29-41.
www.epistemonikos.org/documents/ffad2bab6e5aaa934dd7cba38c613d2ec28a1cee